

List of publications

- Univ.-Prof. em. Dr. med. Gerd Assmann, FRCP -

1. a. **Assmann, G.:** Der Einfluß der Serumeiweißbindung von Penicillin G und Ampicillin auf die Penetration in den intrazellulären Raum (Earle's strain L). *Dissertation* 1966
b. **Lange, A. and G. Assmann:** Penetration von Penicillin G und Ampicillin in Mäusefibroblasten (Earle's strain L) *Z. Med. Mikrobiol. Immunol.* 153: 60-67, 1966.
2. **Stoffel, W. and G. Assmann:** Metabolism of sphingosine bases. XV. Enzymatic degradation of 4t-sphingenine 1-phosphate (sphingosine 1-phosphate) to 2t-hexadecen-1-al and ethanolamine phosphate. *Hoppe Seylers. Z. Physiol. Chem.* 351: 1041-1049, 1970.
3. **Stoffel, W., G. Assmann and E. Binczek:** Metabolism of sphingosine bases. 13. Enzymatic synthesis of 1-phosphate esters of 4t-sphingenine (sphingosine), sphinganine (dihydrosphingosine), 4-hydroxysphinganine (phytosphingosine) and 3-dehydrosphinganine by erythrocytes. *Hoppe Seylers. Z. Physiol. Chem.* 351: 635-642, 1970.
4. **Stoffel, W., G. Assmann and K. Bister:** Metabolism of sphingosine bases. XVII. Stereospecificities in the introduction of the 4t-double bond into sphinganine yielding 4t-sphingenine (sphingosine). *Hoppe Seylers. Z. Physiol. Chem.* 352: 1531-1544, 1971.
5. **Assmann, G. and W. Stoffel:** Metabolism of sphingosine bases, XIX. On the origin of phytosphingosine (4d-hydroxysphinganine) in mammalian tissues. *Hoppe Seylers. Z. Physiol. Chem.* 353: 971-979, 1972.
6. **Stoffel, W. and G. Assmann:** Metabolism of sphingosine bases, 18. Degradation in vitro of phytosphingosine (4d-hydroxysphinganine). *Hoppe Seylers. Z. Physiol. Chem.* 353: 965-970, 1972.
7. **Stoffel, W. and G. Assmann:** On the metabolism of sphingenyl- and sphingenyl-1-phosphorylcholine. *Hoppe Seylers. Z. Physiol. Chem.* 353: 65-74, 1972.
8. **Assmann, G., R. M. Krauss, D. S. Fredrickson and R. I. Levy:** Positional specificity of triglyceride lipases in post-heparin plasma. *J. Biol. Chem.* 248: 7184-7190, 1973.
9. **Assmann, G., R. M. Krauss, D. S. Fredrickson and R. I. Levy:** Characterization, subcellular localization, and partial purification of a heparin-released triglyceride lipase from rat liver. *J. Biol. Chem.* 248: 1992-1999, 1973.
10. **Assmann, G., R. J. Highet, E. A. Sokoloski and H. B. Brewer, Jr.:** ¹³C nuclear magnetic resonance spectroscopy of native and recombined lipoproteins. *Proc. Nat. Acad. Sci. USA* 71: 3701-3705, 1974.
11. **Assmann, G., R. W. Mahley, B. Davis and K. S. Holcombe:** Cholesterol esterification by the rat liver Golgi apparatus. *Scand. J. Clin. Lab. Invest. Suppl.* 137: 23-28, 1974.
12. **Assmann, G. and D. S. Fredrickson:** Function and structure of lipoproteins. In: *Atherosclerosis III. Proc. III. Intern. Symp. Atheroscl.* edited by G. Schettler and G. Weizel. Springer-Verlag, 641-651, 1974.
13. **Assmann, G. and H. B. Brewer, Jr.:** A molecular model of high density lipoproteins. *Proc. Nat. Acad. Sci. USA* 71: 1534-1538, 1974.
14. **Assmann, G., R. M. Krauss, D. S. Fredrickson and R. I. Levy:** Lipolytic activities of hepatic plasma membrane origin in post-heparin plasma. In: *Atherosclerosis III. Proc. III. Intern. Symp. Atheroscl.* edited by G. Schettler and A. Weizel. Heidelberg: Springer-Verlag, 569-572, 1974.
15. **Assmann, G. and H. B. Brewer, Jr.:** Lipid-protein interactions in high density lipoproteins. *Proc. Nat. Acad. Sci. USA* 71: 989-993, 1974.
16. **Assmann, G., D. S. Fredrickson, H. R. Sloan, H. M. Fales and R. J. Highet:** Accumulation of oxygenated sterol esters in Wolman's disease. *J. Lipid Res.* 16: 28-38, 1975.

17. **Assmann, G.:** Hyperlipidemia or hyperlipoproteinemia? *Clin.Chem.* 21: 305-308, 1975.
18. **Assmann, G., B. G. Brown and R. W. Mahley:** Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured swine aortic smooth muscle cells by plasma lipoproteins. *Biochemistry* 14: 3996, 1975.
19. **Mahley, R. W., K. H. Weisgraber, T. Innerarity, H. B. Brewer, Jr. and G. Assmann:** Swine lipoproteins and atherosclerosis. Changes in the plasma lipoproteins and apoproteins induced by cholesterol feeding. *Biochemistry* 14: 2817-2823, 1975.
20. **Assmann, G.:** Tangier-Krankheit. In: *Handbuch der inneren Medizin, Fettstoffwechsel*, edited by G. Schettler, H. Greten, G. Schlierf, and D. Seidel. Berlin, Heidelberg, New York: Springer-Verlag, 1976.
21. **Assmann, G.:** Lecithin-cholesterol-acyl-transferase. Lipoprotein and phospholipid substrate specificity. pp. 34-46. In: *Peeters. H., ed. MEDLINE*, 1976.
22. **Assmann, G.:** Structure-function relationships of lipoproteins in Tangier disease. pp. 106-10. In: *Greten. H., ed.*, 1976.
23. **Brown, B. G., R. Mahley and G. Assmann:** Swine aortic smooth muscle in tissue culture. Some effects of purified swine lipoproteins on cell growth and morphology. *Circ. Res.* 39: 415-424, 1976.
24. **Gheorghiu, T., G. Assmann and H. E. Schaefer:** Endoscopic findings in Tangier disease. *Endoscopy* 8: 164-169, 1976.
25. **Levy, R. I. and G. Assmann:** Type III hyperlipoproteinemia. In: *Handbuch der Inneren Medizin, Band VII/4 Fettstoffwechsel*, edited by G. Schettler, H. Greten, G. Schlierf, and D. Seidel. Berlin, Heidelberg: Springer-Verlag, 301-316, 1976.
26. **Schaefer, H. E., G. Assmann and T. Gheorghiu:** Licht- und elektronenmikroskopische Untersuchungen zur Tangier-Krankheit (sog. An-alpha-lipoproteinämie). *Verh. Dt. Ges. Path.* 60: 473, 1976.
27. **Schaefer, H. E., G. Assmann and R. Fischer:** Morphologische und biochemische Untersuchungen bei Niemann-Pickscher Erkrankung. *Verh. Dt. Ges. Pathol.* 259-262, 1976.
28. **Assmann, G., O. Simantke, H. E. Schaefer and E. Smootz:** Characterization of high density lipoproteins in patients heterozygous for Tangier disease. *J. Clin. Invest.* 60: 1025-1035, 1977.
29. **Assmann, G., P. N. Herbert, D. S. Fredrickson and T. Forte:** Isolation and characterization of an abnormal high density lipoprotein in Tangier Disease. *J. Clin. Invest.* 60: 242-252, 1977.
30. **Assmann, G.:** Lipid-protein interactions in reconstituted lipoproteins. In: edited by H. Peeters and J. P. Massue. European Press 121, 1977.
31. **Assmann, G., E. Smootz, K. Adler, A. Capurso and K. Oette:** The lipoprotein abnormality in Tangier disease: quantitation of A apoproteins. *J. Clin. Invest.* 59: 565-575, 1977.
32. **Assmann, G.:** Zur Pathobiochemie der High Density Lipoproteine. In: *Merck Symposium: Aktuelle Probleme der Pathobiochemie*, Anonymous Berlin, Heidelberg: Springer-Verlag, 125, 1977.
33. **Assmann, G.:** [Diagnosis of hyperlipidemias]. *Med. Welt.* 28: 1356-1359, 1977.
34. **Assmann, G.:** High density lipoprotein abnormalities associated with disease. In: *Atherosclerosis IV, Proc. IV., Int. Symp. Atheroscl.* edited by G. Schettler, Y. Goto, Y. Haka, and G. Klose. Berlin, Heidelberg: Springer-Verlag, 238-242, 1977.

35. **Hanfland, P., G. Assmann and H. Egge:** Enzymatic determination of the anomeric structures of two blood group B active glycosphingolipids recombined with apolipoproteins. *Z. Naturforsch.* 33c: 73-78, 1978.
36. **Schaefer, H. E. and G. Assmann:** Die Manifestation der Tangier Krankheit an der portio uteri vaginalis. *Verh. Dt. Ges. Path.* 61: 401, 1977.
37. **Weisgraber, K. H., R. W. Mahley and G. Assmann:** The rat arginine-rich apoprotein and its redistribution following injection of iodinated lipoproteins into normal and hypercholesterolemic rats. *Atherosclerosis* 28: 121-140, 1977.
38. **Assmann, G., A. Capurso, E. Smootz and U. Wellner:** Apoprotein A metabolism in Tangier disease. *Atherosclerosis* 30: 321-332, 1978.
39. **Assmann, G., G. Schmitz and H. Heckers:** The role of high density lipoproteins in lecithin:cholesterol acyltransferase activity: Perspectives from Tangier disease. *Scand. J. Clin. Lab. Invest. Suppl.* 150: 98-102, 1978.
40. **Assmann, G.:** High Density Lipoproteins (Composition, Structure, Metabolism. Tangier Disease and Role in Atherogenesis). In: *II. Eur. Meeting on Metabolism*, Anonymous Academic Press, 263-271, 1978.
41. **Assmann, G.:** Familial lipoprotein deficiency. In: *NATO Advanced Study Institute: The Lipoprotein Molecule*, edited by H. Peeters. Plenum Press, 205, 1978.
42. **Assmann, G. and E. Smootz:** High density lipoprotein infusion and partial plasma exchange in Tangier disease. *Eur. J. Clin. Invest.* 8: 131-135, 1978.
43. **Assmann, G., G. Schmitz, N. Donath and D. Lekim:** Phosphatidylcholine substrate specificity of lecithin:cholesterol acyltransferase. *Scand. J. Clin. Lab. Invest. Suppl.* 150: 16-20, 1978.
44. **Gheorghiu, T., G. Assmann, R. Mies, and H. E. Schaefer:** [Gastroenterologic diagnosis of hypolipoproteinemias with special emphasis on Tangier disease]. *Verh. Dt. Ges. Inn. Med.* 1050-1053, 1978.
45. **Gheorghiu, T., G. Assmann, R. Mies and H. E. Schaefer:** Zur gastroenterologischen Diagnostik der Hypolipoproteinämien unter besonderer Berücksichtigung des Morbus Tangier. In: *Verhandlungen der Deutschen Gesellschaft für innere Medizin*, Anonymous München: J.F. Bergmann Verlag, 1049-1054, 1978.
46. **Stoffel, W., W. Darr and G. Assmann:** [Pleomorphic functions of highly unsaturated phospholipids in biological membranes and serum lipoproteins]. *Med. Welt.* 29: 124-131, 1978.
47. **Vaith, P., G. Assmann and G. Uhlenbruck:** Characterization of the oligosaccharide side chain of apolipoprotein C-III from human plasma very low density lipoproteins. *Biochim. Biophys. Acta* 541: 234-240, 1978.
48. **Assmann, G.:** Lipiddiagnostik heute. *Internist. Berl.* 20: 559-564, 1979.
49. **Assmann, G.:** [Tangier-disease (author's transl)]. *Klin. Wochenschr.* 57: 53-61, 1979
50. **Assmann, G. and K. Kladetzky:** Eine Doppelblindstudie mit Cholestyramin bei primärer Hypercholesterinämie. *Therapiewoche* 29: 2615-2625, 1979.
51. **Assmann, G.:** Tangier disease and the possible role of high density lipoproteins in atherosclerosis. In: *Atherosclerosis Reviews*, edited by A. M. Gotto and R. Paoletti. New York: Raven Press, 1-28, 1979.

52. **Assmann, G. and G. Schmitz:** The metabolism of plasma lipoproteins.
In: *Lipoprotein Metabolism and Endocrine Regulation*, edited by L. W. Hessel and H. M. J. Krans.
Amsterdam: Elsevier/North-Holland Biomedical Press, 3-11, 1979.
53. **Helb, H.-D. and G. Assmann:** Die integrierte Probenidentifikation.
GIT-Labor Medizin 4: 295-303, 1979.
54. **Hopf, U., G. Assmann, H. E. Schaefer and A. Capurso:** Demonstration of human apolipoprotein A in isolated mucosal cells from small intestine and isolated hepatocytes. *Gut* 20: 219-225, 1979.
55. **Schaefer, H. E. and G. Assmann:** Cholesteatosis naevi naevocellula—is - ein bisher unbekanntes Phänomen bei der Tangier Krankheit. *Verh. Dt. Ges. Path.* 63: 708, 1979.
56. **Assmann, G. and H. E. Schaefer:** Possible mechanisms of lipid storage in Tangier disease.
In: *Atherosclerosis V*, edited by A. M. Gotto, L. C. Smith, and B. Allen.
Berlin, Heidelberg: Springer-Verlag, 666-670, 1980.
57. **Assmann, G. and H. Schriewer:** High Density Lipoproteine: Analytik, Biochemie und Klinik.
Münch. Med. Wschr. 122, Suppl. 5: 197-208, 1980.
58. **Assmann, G.** Welche Maßnahmen in der Lipiddiagnostik sind heute Voraussetzung in der Beurteilung des Risikos einer Koronargefäßerkrankung? *Med. Welt* 31: 1079-1082, 1980.
59. **Assmann, G. and H. Schriewer:** Diagnostik der Hyperlipidämien.
Therapeutische Umschau 37: 965-972, 1980.
60. **Assmann, G.:** Polyensäurereiche Diät nur für Stoffwechselkranke. *Ärztl. Praxis* 28: 985-986, 1980.
61. **Assmann, G.:** Current laboratory diagnosis of lipid disorders.
In: *Lipoproteins and Coronary Heart Disease*, edited by H. Greten, P. O. Lang, and G. Schettler.
Baden-Baden: Witzstrock-Verlag, 29-32, 1980.
62. **Assmann, G., H. Schriewer, G. Schopohl and H. Funke:** Investigation of the specificity of the HDL-cholesterol test. In: *Lipoproteins and Coronary Heart Disease*, edited by H. Greten, P. O. Lang, and G. Schettler. Baden-Baden: Witzstrock-Verlag, 43-45, 1980.
63. **Assmann, G. and H. Schriewer:** Screening und Therapiekontrolle von Lipidstoffwechselstörungen in der Praxis. *Münch. Med. Wschr.* 122: 449-452, 1980.
64. **Assmann, G. and H. Schriewer:** Biochemie der High Density Lipoprotein. *Klin. Wschr.* 58: 749-756, 1980.
65. **Assmann, G., H. Schriewer and W. Oberwittler:** Klinik und Pathobiochemie der High Density Lipoproteine. *Klin. Wschr.* 58: 757-765, 1980.
66. **Assmann, G. and H. Schriewer:** Role of low-density and high-density lipoproteins in atherogenesis.
Nutr. Metab. 24, Suppl. 1: 19-25, 1980.
67. **Assmann, G., H. Schriewer, H. Schulte and W. Oberwittler:** Der Stellenwert des HDL-Cholesterins als Risikoindikator der koronaren Herzkrankheit. *Internist* 21: 202-212, 1980.
68. **Assmann, G., W. Oberwittler, H. Schulte, H. Schriewer, H. Funke, P. H. Epping and W. H. Hauss:** Prädiktion und Früherkennung der koronaren Herzkrankheit. Prospektive epidemiologische Studie bei Betriebsangehörigen im Raum Westfalen. *Internist* 21: 446-459, 1980.
69. **Dufaux, B., G. Assmann and W. Hollmann:** Biochemische Aspekte der Lipoproteinveränderungen bei Sportlern. *Münch. Med. Wschr.* 122, Suppl. 5: 244-250, 1980.

70. **Helb, H.-D. and G. Assmann:** Mechanisierte Probenverteilung im Zentrallaboratorium des Universitätsklinikums Münster. *GIT-Labormedizin* 6: 465-475, 1980.
71. **Hopf, U., G. Assmann, J. Voigt, H. E. Schaefer and H. G. Beger:** Nachweis von Apolipoproteinen in der Darmschleimhaut der Menschen. *Münch. Med. Wschr.* 122, Suppl. 5: 239-243, 1980.
72. **Kamanabroo, D., U. Harnest, H. Feldmann, G. Assmann and J. van den Loo:** Heredopathia atactia polyneuritiformis (Refsum's Disease) treated by diet and large-volume plasma exchange. In: *Plasma Exchange, Plasmapheresis-Plasmaseparation*, ed. by H. G. Sieberth. Stuttgart, New York: Schattauer-Verlag, 297-299, 1980.
73. **Karoff, C. and G. Assmann:** Diät, Lipoproteine und Arteriosklerose. *Münch. Med. Wschr.* 122, Suppl. 5: 251-262, 1980.
74. **Kladetzky, H. G., G. Assmann, S. Walgenbach, P. Tauchert and H.-D. Helb.:** Lipoprotein and apoprotein values in coronary angiography patients. *Artery* 7: 191-205, 1980.
75. **Rosseneu, M., H. Caster, M. J. Lievens and G. Assmann:** Displacement of the apo A-I by the apo A-II protein in lipid-apoprotein complexes. *Arch. Internat. Physiol. Biochim.* 88: BP14, 1980.
76. **Schaefer, H. E. and G. Assmann:** Bedeutung der Makrophagen für die Genese der Arteriosklerose. *Münch. Med. Wschr.* 122, Suppl. 5: 228-238, 1980.
77. **Schmitz, G. and G. Assmann:** Präparative Isolierung von Chylomikronen in der Mikro-Ultrazentrifuge "Airfuge". *Beckmann Report* 2: 14-16, 1980.
78. **Schriewer, H., G. Assmann and A. Holtwick:** Properties of 14-C HDL prepared by incorporation of labeled apoproteins into HDL. *Fresenius Z. Anal. Chem.* 301: 158-159, 1980.
79. **Sirowej, H., G. Assmann and R. Kattermann:** Lipoprotein and apolipoprotein patterns in rat plasma after liver injury induced bei D-galactosamine. *Hoppe Seyler's Z. Physiol. Chem.* 361: 1417-1425, 1980.
80. **Van Tornout, P., R. Vercaemst, M. J. Lievens, H. Costerm, M. Rosseneu and G. Assmann:** Reassembly of human apo A-I and apo A-II proteins with unilamellar phosphatidylcholine-cholesterol liposomes. Association kinetics and characterization of the complexes. *Biochem. Biophys. Acta* 601: 509-523, 1980.
81. **Assmann, G.:** Zur Therapie der Hyperlipidämien. *Arzneimittelbrief* 15: 9-13, 1981.
82. **Assmann, G.:** Primary dyslipoproteinemias. *J. Clin. Chem. Clin. Biochem.* 19: 558, 1981.
83. **Assmann, G., H. Schriewer and K. H. Juchem:** Zur Rolle des HDL Cholesterin in der Präventivmedizin. *Therapiewoche* 31: 5563-5574, 1981.
84. **Assmann, G. and G. Schmitz:** Interactions of lipoproteins with macrophages. In: *Haematology and Blood Transfusion, Disorders of the Monocyte Macrophage System*, edited by F. Schmalzl, D. Huhn, and H. E. Schaefer. Berlin, Heidelberg, New York: Springer-Verlag, 131-135, 1981.
85. **Assmann, G. and H. Schriewer:** Fettstoffwechselstörungen: Diagnostik der Hyperlipidämien. *Therapiewoche* 31: 1662-1669, 1981.
86. **Assmann, G., H. Schriewer and H. Funke:** Accuracy of HDL Cholesterol and HDL-apolipoprotein A-I determinations after phosphotungstate-MgCl₂ precipitation of apolipoprotein-B-containing lipoproteins. *J. Clin. Chem. Clin. Biochem.* 19: 273-278, 1981.

87. **Assmann, G. and H. Schriewer:** Möglichkeiten und Grenzen der Analytik des HDL-Cholesterins. *J. Clin. Chem. Clin. Biochem.* 19: 1-6, 1981.
88. **Assmann, G. and H. Schriewer:** Bedeutung der Hypertriglyceridämie als Risikofaktor der koronaren Herzkrankheit. *Intern. Welt* 12: 485-496, 1981.
89. **Dufaux, B., G. Assmann, U. Order, A. Hoederath and W. Hollmann:** Plasma-lipoproteins, hormones, and energy substrates during the 1st days after prolonged exercise. *Int. J. Sports Med.* 2: 256-260, 1981.
90. **Dufaux, B., A. Hoederath, I. Streitberger, W. Hollmann and G. Assmann:** Serum ferritin, transferrin, haptoglobin, and iron in middle-distance and long-distance runners, elite rowers, and professional racing cyclists. *Int. J. Sports Med.* 2: 43-46, 1981.
91. **Helb, H.-D. and G. Assmann:** Ein neues Konzept für Labordatenverarbeitung. *GIT-Labormedizin, Supplement Datenverarbeitung in Forschung und Medizin* 9-21, 1982.
92. **Hopf, U., W. Schwartzkopf, G. Assmann, H.-G. Beger, G. Ramadori and K. H. Meyer zum Büschenfelde:** Zum Nachweis der Apolipoproteine A-I und B in der Leber von Patienten mit und ohne Hyperlipoproteinämie. *Z. Gastroenterologie* 19: 284-292, 1981.
93. **Kladetzky, R. G., G. Assmann, S. Walgenbach, P. Tauchert and H. D. Helb:** Lipids and apoproteins in coronarographed patients. *Z. Kardiologie* 70: 638, 1981.
94. **Kuntz, H. D., B. May, V. Schejbal and G. Assmann:** Cholesteryl ester storage disease of the liver. *Leber. Magen. Darm.* 11: 258-263, 1981.
95. **Magour, S., V. Kristof, M. Baumann and G. Assmann:** Effect of acute treatment with cadmium on ethanol anesthesia, body-temperature, and synaptosomal Na^+K^+ -ATPase of rat brain. *Environ. Res.* 26: 381-391, 1981.
96. **Ramadori, G., U. Hopf, W. Schwartzkopff, G. Assmann, H. G. Beger and K. H. M. Zumbuschenfelde:** Evidence of apolipoprotein A-I and apolipoprotein B in the liver of patients with and without hyperlipoproteinemia. *Z. Kardiologie* 19: 601-602, 1981.
97. **Ramadori, G., U. Hopf, G. Assmann, C. Galanos and K. H. Meyer:** Localization of bacterial lipopolysaccharides (LPS) and high-density lipoproteins (HDL) in the liver after intravenous administration of LPS in mice. *Gastroenterology* 80: 1256, 1981.
98. **Rosseneu, M., P. Vantornout, M. J. Lievens and G. Assmann.** Dissociation of the apo A-I lipid binding in complexes in vitro and in native HDL by guanidine chloride. *Arch. Int. Physiol. Biochim.* 89: BP20-BP21, 1981.
99. **Rosseneu, M., P. Vantornout, M. J. Lievens and G. Assmann:** Displacement of the human apoprotein A-I by the human apoprotein A-II from complexes of (apoprotein A-I) phosphatidylcholine-cholesterol. *Eur. J. Biochem.* 117: 347-352, 1981.
100. **Schmitz, G., G. Assmann and B. Melnick:** The role of lecithin:cholesterol acyltransferase in high density lipoprotein-3/high density lipoprotein-2 interconversion. *Clin. Chim. Acta* 119: 225-236, 1981.

101. **Schriewer, H. and G. Assmann:** Aspects of familial hypercholesterolemia with regard to plasma exchange. In: *Plasma Exchange Therapy*, edited by H. Borgerg and P. Reuther. Stuttgart, New York: Thieme-Verlag, 104-110, 1981.
102. **Van Tornout, P., H. Caster, M. J. Lievens, M. Rosseneu and G. Assmann:** In vitro interaction of human HDL with human apolipoprotein A-II synthesis of apolipoprotein A-II-rich HDL. *Biochim. Biophys. Acta* 663: 630-6, 1981.
103. **Zierenberg, O., G. Assmann, G. Schmitz and M. Rosseneu:** Effect of polyenephosphatidylcholine on cholesterol uptake by human high-density lipoprotein. *Atherosclerosis* 39: 527-542, 1981.
104. **Assmann, G., H. Funke and H. Schriewer:** The relationship of HDL apolipoprotein A-I and HDL cholesterol to risk factors of coronary heart disease - initial results of the prospective epidemiological study in company employees in Westphalia. *J. Clin. Chem. Clin. Biochem.* 20: 287-289, 1982.
105. **Assmann, G.:** Normwerttabellen wichtiger Harn- und Blutuntersuchungen bei Nierenkranken. In: *Klinische Nephrologie, Band I*, edited by H. Losse and E. Renner. Stuttgart, New York: Thieme Verlag, 1-8, 1982.
106. **Assmann, G.:** Apolipoproteins and cardiovascular diseases. *Fette. Seifen. Anstrichmittel.* 84: 829, 1982.
107. **Assmann, G. and H. Schriewer:** The role of HDL cholesterol in preventive medicine. In: *Lipoproteins and Age*, edited by H. Schneider and H. Kaffarnick. Stuttgart, New York: Thieme Verlag, 8-19, 1982.
108. **Assmann, G.:** Zur Ätiologie der Atherosklerose. *Hämostasiologie* 4: 162-168, 1982.
109. **Assmann, G.:** Lipid Metabolism and Atherosclerosis. In: Anonymous Schattauer Verlag, 1982.
110. **Assmann, G.:** High density lipoproteins and atherogenesis. In: *Lipoprotein Metabolism and Therapy of Lipid Disorders*, edited by G. Crepaldi, H. Greten, G. Schettler, and G. Baggio. Excerpta Medica, 45, 1982.
111. **Assmann, G. and D. S. Fredrickson:** Acid lipase deficiency (Wolman's disease and Cholesteryl Ester Storage Disease). In: *The Metabolic Basis of Inherited Disease*, edited by Stanbury et al. McGraw-Hill, 803-819, 1982.
112. **Assmann, G.:** Step-by-step diagnosis of disturbances in lipid metabolism determination of HDL cholesterol. *Münch. Med. Wochenschr.* 124: A 12, 1982.
113. **Assmann, G. and H. J. Menzel:** Apolipoprotein disorders. *Ric Clin Lab.* 12: 63-81, 1982.
114. **Dufaux, B., G. Assmann and W. Hollmann:** Plasma lipoproteins and physical activity: review. *Int. J. Sports Med.* 3: 58-60, 1982.
115. **Dufaux, B., G. Assmann, H. Schachten and W. Hollmann:** The delayed effects of prolonged physical exercise and physical training on cholesterol level. *Eur. J. Appl. Physiol. Occupat. Physiol.* 48: 25-29, 1982.
116. **Funke, H. and G. Assmann:** Influence of triglyceride-rich lipoproteins on nephelometry of apolipoprotein A-I. *Clin. Chem.* 28: 1153-1158, 1982.

117. **Herbert, P. N., G. Assmann, A. M. J. Gotto and D. S. Fredrickson:** Familial lipoprotein deficiency: abetalipoproteinemia, hypobetalipoproteinemia, and Tangier disease. In: *The Metabolic Basis of Inherited Disease*, edited by Stanbury et al. McGraw-Hill, 589-621, 1982.
118. **Kladetzky, R. G., H. J. Menzel, G. Assmann and H. Kuhn:** Apo E polymorphism and coronary heart disease. *Z. Kardiol.* 71: 602, 1982.
119. **Menzel, H. J., P. M. Kovary and G. Assmann:** Apolipoprotein A-IV polymorphism in man. *Hum. Gen.* 62: 349-352, 1982.
120. **Menzel, H. J., R. G. Kladetzky and G. Assmann:** One-step screening method for the polymorphism of apolipoprotein A-I, apolipoprotein A-II, and apolipoprotein A-IV. *J. Lipid Res.* 23: 915-922, 1982.
121. **Rall, S. C., K. H. Weisgraber, T. L. Innerarity, R. W. Mahley and G. Assmann:** Identical structural and receptor-binding defects in apolipoprotein E2 from hypocholesterolemic, normocholesterolemic, and hypercholesterolemic subjects. *Circulation* 66: 11, 1982.
122. **Rosseneu, M., P. van Tornout, M. J. Lievens, G. Schmitz and G. Assmann:** Dissociation of apolipoprotein A-I from apoprotein-lipid complexes and from high density lipoproteins - a fluorescence study. *Eur. J. Biochem.* 128: 455-460, 1982.
123. **Schaefer, H. E. and G. Assmann:** Zur hämatopathologischen Diagnostik der Cholesterinesterspeicherkrankheit (CESK). *Pathologe.* 3: 114-115, 1982.
124. **Schmitz, G., G. Assmann, and B. Melnik:** The role of lecithin - cholesterol acyltransferase in high density lipoprotein-3 high density lipoprotein-2 interconversion. *Clin. Chim. Acta* 119: 225-236, 1982.
125. **Schmitz, G. and G. Assmann:** Isolation of human serum HDL1 by zonal ultra-centrifugation. *J. Lipid Res.* 23: 903-910, 1982.
126. **Schriewer, H., V. Gunnewig, K. Jung and G. Assmann:** The influence of a 100 km run on the composition of HDL. *J. Clin. Chem. Clin. Biochem.* 20: 533-536, 1982.
127. **Schriewer, H., K. Jung, V. Günnewig and G. Assmann:** Verhalten von Serumlipiden und Serumlipoproteinen während eines 20-tägigen Laufs über 1.100 Kilometer. *Österr. J. Sportmed.* 12: 24-29, 1982.
128. **Schriewer, H., H. U. Jabs, J. Schultze and G. Assmann:** Preparation of high density lipoproteins labeled exclusively at the cholesteryl ester moiety. *Clin. Chim. Acta* 123: 139-144, 1982.
129. **Schriewer, H., H. U. Jabs and G. Assmann:** The enzymatic analysis of sphingomyelin in HDL. *J. Clin. Chem. Clin. Biochem.* 20: 305-312, 1982.
130. **Ahrens, E. H., G. Assmann, F. H. Epstein, H. Greten, F. A. Gries, H. Sinclair and W. Stoffel:** Zur Bedeutung der Fette in der menschlichen Ernährung. In: *Wissenschaftliche Arbeitspapiere*, edited by Deutsche Forschungsgemeinschaft. Weinheim: Verlag Chemie, 1983.
131. **Assmann, G. and H. Schulte:** Prediction and early detection of coronary heart disease. In: *Proceedings of the Second Münster International Arteriosclerosis Symposium*, edited by W. Hauss. Westd. Verlag, 69-100, 1983.
132. **Assmann, G.:** Apolipoprotein disorders. *Klinische Wochenschrift.* 61: 169-182, 1983.

133. **Assmann, G., H.-D. Helb, K. H. Juchem and H. Gentz:** Herz-Kreislauf-Prävention in der Arbeitsmedizin. Ein interdisziplinäres Modell. *Deutsches Ärztebl.* 80: 37-44, 1983.
134. **Assmann, G.:** Apolipoprotein mutants and apolipoprotein disorders. In: *Atherosclerosis VI. Proceedings of the International Symposium on Atherosclerosis*, edited by G. Schettler and G. Schlierf. Berlin, Heidelberg: Springer Verlag, 511, 1983.
135. **Assmann, G.:** The physiology of lipoprotein metabolism. *Infusionsther. Klin. Ernährung* 10: 162-170, 1983.
136. **Assmann, G.:** Mutations of apolipoproteins. In: *Liver in Metabolic Diseases*, edited by L. E. Bianchi. 49, 1983.
137. **Assmann, G. and H.-J. Menzel:** Apolipoprotein Disorders. In: *Arterial Pollution, An Integrated View on Atherosclerosis*, edited by H. Peeters, G. A. Gresham, and R. Paoletti. New York: Plenum Press, 3, p. 213, 1983.
138. **Assmann, G., H. Schriewer and K. H. Juchem:** The role of HDL cholesterol in preventive medicine. In: *Proceedings of the Second Münster International Arteriosclerosis Symposium*, edited by W. Hauss. Westd. Verlag, 329-342, 1983.
139. **Assmann, G. and H. Schriewer:** Determination of High-Density Lipoprotein Phospholipids. In: *Phospholipids and Atherosclerosis*, edited by P. E. Avogaro. Raven Press, 81-86, 1983.
140. **Assmann, G. and H.-J. Menzel:** Lecithin-cholesterol acyltransferase. In: *Methods of Enzymatic Analysis*, edited by H. U. Bergmeyer. Weinheim: Verlag Chemie GmbH, 342-348, 1983.
141. **Assmann, G., H. Schriewer, G. Schmitz and E. O. Hagele:** Quantification of high density lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl₂. *Clin. Chem.* 29: 2026-2030, 1983.
142. **Assmann, G.:** Apolipoprotein disorders. *Internat. J. Sports Med.* 4: 291-292, 1983.
143. **Balleisen, L., J. Bailey, H. Schulte, G. Assmann, P. H. Ebbing and J. van de Loo:** Hemostatic variables in an epidemiological study and their correlations to risk factors for atherosclerosis. *Thromb. Haemost* 50: 135, 1983.
144. **Bartl, K., J. Ziegenhorn, I. Streitberger and G. Assmann:** Turbidimetric kinetic method for serum low density lipoprotein quantitation. *Clin. Chim. Acta* 128: 199-208, 1983.
145. **Dufaux, B., K. Ilsemann and G. Assmann:** Competitive enzyme immunoassay for apolipoprotein A-II. *J. Clin. Chem. Clin. Biochem.* 21: 39-43, 1983.
146. **Kattermann, R., I. R. Kupke, K. Borner, G. Assmann, M. Eggstein, P. Gambert, C. C. Heuck, F. H. Kreutz, D. Seidel, L. Siekmann, D. Stamm and H. Wieland:** Candidate selected method for the enzymatic determination of total cholesterol in serum. *J. Clin. Chem. Clin. Biochem.* 21: 347-355, 1983.
147. **Kladetzky, R. G., G. Schmitz, H. J. Menzel and G. Assmann:** Coronary heart disease in families with genetic apolipoprotein A-I variants. *Arteriosclerosis* 3: A480, 1983.
148. **Kladetzky, R. G., G. Schmitz, H. J. Menzel, I. Christoph, G. Assmann and H. Kuhn:** Apolipoprotein E polymorphism and coronary heart disease. *Circulation* 68: 188, 1983.
149. **H. J. Menzel, Kladetzky, R. G. and G. Assmann:** Apolipoprotein E polymorphism and coronary artery disease. *Arteriosclerosis* 3: 310-315, 1983.

150. **Rall, S. C., K. H. Weisgraber, T. L. Innerarity, R. W. Mahley and G. Assmann:** Identical structural and receptor binding defects in apolipoprotein E-2 from hypo-, normo- and hypercholesterolemic subjects. *J. Clin. Invest.* 71: 1023-1031, 1983.
151. **Rall, S. C., H. J. Menzel, G. Assmann, G. Utermann, J. Haas, R. J. Harris, K. H. Weisgraber, T. P. Bersot and R. W. Mahley:** Identification of amino-acid substitutions in 5 human apolipoprotein A-I variants. *Arteriosclerosis* 3: A515, 1983.
152. **Rosseneu, M., G. Schmitz and G. Assmann:** Association of the Tangier apolipoprotein A-I with lipids. *Arch. Internat. Physiol. Biochim.* 91: B 38-B 39, 1983.
153. **Schaefer, H. E. and G. Assmann:** The behavior of lymphocytary lysosomes in cholesteryl ester storage disease. *Acta Histochem.* 135-148, 1983.
154. **Schmitz, G., G. Assmann, S. C. Rall and R. W. Mahley:** Tangier disease - defective recombination of a specific Tangier apolipoprotein A-I isoform (pro-apo A-I) with high-density lipoproteins. *Proc. Natl. Acad. Sci. USA* 80: 6081-6085, 1983.
155. **Schmitz, G., K. Ilsemann, B. Melnik and G. Assmann:** Isoproteins of human apolipoprotein A-II - isolation and characterization. *J. Lipid Res.* 24: 1021-1029, 1983.
156. **Schmitz, G., H. U. Jabs and G. Assmann:** Densitometry of phosphatidylcholine and sphingomyelin in high density lipoproteins. *Clin. Chem.* 29: 1435-1437, 1983.
157. **Schriewer, H., V. Gunnewig and G. Assmann:** Effect of 10 weeks endurance training on the concentration of lipids and lipoproteins as well as on the composition of high density lipoproteins in blood serum. *Int. J. Sports Med.* 4: 109-115, 1983.
158. **Schriewer, H., H. U. Jabs, V. Gunnewig, and G. Assmann:** Determination of HDL phosphatidyl choline by an enzymatic method. *J. Clin. Chem. Clin. Biochem.* 21: 145-150, 1983.
159. **Schriewer, H., V. Gunnewig and G. Assmann:** HDL sphingomyelin determinations in normal individuals and patients with type IV hyperlipoproteinemia. *J. Clin. Chem. Clin. Biochem.* 21: 139-143, 1983.
160. **Schriewer, H., G. Jung, F. Emke and G. Assmann:** An economical assay for HDL phosphatidyl choline. *J. Clin. Chem. Clin. Biochem.* 21: 611-614, 1983.
161. **Seher, A., G. Assmann, G. Werner and H. J. Oslage:** Physiological effect of various mixtures of oleic, linoleic and linolenic acids on growing-pigs. 2. Influence on depot fats and blood-lipids. *Fette. Seifen. Anstrichmittel.* 85: 215-219, 1983.
162. **Assmann, G., G. Schmitz, H. J. Menzel and H. Schulte:** Apolipoprotein E polymorphism and hyperlipidemia. *Clin. Chem.* 30: 641-643, 1984.
163. **Assmann, G.:** Relationship of apolipoprotein E to coronary artery. In: *Treatment of hyperlipoproteinemia*, edited by L. A. Carlson and A. G. Olsson. Raven Press, 41, 1984.
164. **Assmann, G., H. Schulte and H. Schriewer:** The effects of cigarette smoking on serum levels of dHDL cholesterol and HDL apolipoprotein A-I - findings of a prospective epidemiological-study on employees of several companies in Westphalia, West-Germany. *J. Clin. Chem. Clin. Biochem.* 22: 397-402, 1984.
165. **Assmann, G.:** Apolipoprotein disorders. In: *Latent dyslipoproteinemias and atherosclerosis*, edited by J. L. de Gennes, J. Polonowski, and R. Paoletti. Raven Press, 123, 1984.

166. **Assmann, G., H. U. Jabs, U. Kohnert, W. Nolte and H. Schriewer:** LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate. *Clin. Chim. Acta* 140: 77-83, 1984.
167. **Assmann, G.:** Stoffwechselerkrankungen (Fettstoffwechselstörungen). In: *Taschenbuch der medizinisch-klinischen Diagnostik*, edited by Müller/Seifert. Berlin: Springer-Verlag, 499-533, 1984.
168. **Assmann, G., H. Schulte and H. Schriewer:** HDL phosphatidylcholine and cigarette smoking. *Klin. Wochenschr.* 62 (Suppl. II): 32-35, 1984.
169. **Assmann, G., H. J. Menzel, R. G. Kladetzky and G. Buttner:** Frequency of apolipoprotein A-I mutants in the German population. *J. Clin. Chem. Clin. Biochem.* 22: 585-589, 1984.
170. **Assmann, G. and H.-G. Kladetzky:** Lipoproteins: analysis and composition. In: *Handbook of Chromatography, Lipids, Vol. II*, edited by H. K. Mangold. CCR Press 241, 1984.
171. **Assmann, G. and H. U. Jabs:** Specificity of the heparin-LDL interaction. *Clin. Chim. Acta* 138: 119-123, 1984.
172. **Assmann, G. and H. Hackfort:** Experiments on xenon removal by freezing out from the gaseous effluent of reprocessing plants. *Atomwirtschaft-Atomtechnik* 29: 561-562, 1984.
173. **Assmann, G. and H. Schriewer:** High density lipoproteins and their role in preventing or retarding atherosclerosis. In: *Regression of Atherosclerotic Lesions*, edited by M. R. Malinow and V. H. Blaton. Plenum Press, 201-216, 1984.
174. **Assmann, G.:** Betablocker, Fettstoffwechsel und Atherosklerose. In: *Betablocker und Lipidstoffwechsel*, edited by G. Schettler, G. Assmann, C. Diehm, and H. Moerchel. Berlin, Heidelberg: Springer-Verlag, 3-26, 1984.
175. **Assmann, G. and H.-U. Jabs:** Lipoprotein lipase (post-heparin lipase). In: *Methods of enzymatic analysis*, edited by H. Bergmeyer. Weinheim: Verlag Chemie, 42-51, 1984.
176. **Assmann, G.:** What is the correct lecithin sphingomyelin ratio for human high density lipoprotein response. *Clin. Chem.* 30: 164, 1984.
177. **Assmann, G. and H. Schulte:** HDL-Cholesterin, HDL-apolipoprotein A-I und kardiovaskuläre Risikofaktoren. In: *Herz-Kreislauf-Prävention*, edited by K.-H. Ladwig. Urban & Schwarzenberg Verlag, 47-68, 1984.
178. **Assmann, G., H. U. Jabs, W. Nolte and H. Schriewer:** Precipitation of LDL with sulfopolyanions - a comparison of 2 methods for LDL cholesterol determination. *J. Clin. Chem. Clin. Biochem.* 22: 781-785, 1984.
179. **Assmann, G. and H. Schriewer:** Stoffwechselerkrankungen (Harnsäurestoffwechselstörungen). In: *Taschenbuch der medizinisch-klinischen Diagnostik*, edited by Müller/Seifert. Berlin: Springer-Verlag, 534-542, 1984.
180. **Assmann, G., H. Schriewer and U. Hopf:** Stoffwechselerkrankungen (Kohlenhydratstoffwechselstörungen). In: *Taschenbuch der medizinisch-klinischen Diagnostik*, edited by Müller/Seifert. Berlin: Springer-Verlag, 543-554, 1984.
181. **Bartl, K., J. Ziegenhorn, I. Streitberger and G. Assmann:** Eine turbidimetrische kinetische Methode zur Bestimmung von Low-Density-Lipoproteinen (LDL) im Serum. In: *Herz-Kreislauf-Prävention*, edited by K.-H. Ladwig. Urban & Schwarzenberg Verlag, 57, 1984.

182. **Menzel, H. J., G. Assmann, S. C. Rall, K. H. Weisgraber and R. W. Mahley:** Human apolipoprotein A-I polymorphism - identification of amino- acid substitutions in 3 electrophoretic variants of the munster-3 type. *J. Biol. Chem.* 259: 3070-3076, 1984.
183. **Rall, S. C., K. H. Weisgraber, R. W. Mahley, Y. Ogawa, C. J. Fielding, G. Utermann, J. Haas, A. Steinmetz, H. J. Menzel and G. Assmann:** Abnormal lecithin-cholesterol acyltransferase activation by a human apolipoprotein A-I variant in which a single lysine residue is deleted. *J. Biol. Chem.* 259: 63-70, 1984.
184. **Robenek, H., G. Schmitz and G. Assmann:** Topography and dynamics of receptors for acetylated and malondialdehyde-modified low-density lipoprotein in the plasma-membrane of mouse peritoneal-macrophages as visualized by colloidal gold in conjunction with surface replicas. *J. Histochem. Cytochem.* 32: 1017-1027, 1984.
185. **Rosseneu, M., G. Assmann, M. J. Taveirne and G. Schmitz:** Lipid binding properties of the Tangier apolipoprotein A-I and its isoproteins. *J. Lipid Res.* 25: 111-120, 1984.
186. **Schmitz, G., G. Assmann and D. E. Bowyer:** A quantitative densitometric method for the rapid separation and quantitation of the major tissue and lipoprotein lipids by high performance thin layer chromatography. I. Sample preparation, chromatography, and densitometry. *J. Chromatog.* 307: 65-79, 1984.
187. **Schmitz, G., M. Lenczyk, D. Ord, D. E. Bowyer and G. Assmann:** A quantitative densitometric method for the rapid separation and quantitation of the major lipids of tissues and lipoproteins by high performance thin layer chromatography. 2. Reduction of the densitometric data. *J. Chromatog.* 307: 81-89, 1984.
188. **Schriewer, H., K. Jung, F. Emke and G. Assmann:** Changes in HDL composition in female subjects following a 100-km run. *Int. J. Sports Med.* 5: 209-212, 1984.
189. **Schriewer, H., H. Schulte and G. Assmann:** HDL phosphatidylcholine and risk factors of coronary heart disease. *J. Clin. Chem. Clin. Biochem.* 22: 515-521, 1984.
190. **Schriewer, H., G. Assmann, M. Sandkamp and H. Schulte:** The relationship of lipoprotein (a) (lp(a)) to risk-factors of coronary heart-disease - initial results of the prospective epidemiological-study on company employees in Westphalia. *J. Clin. Chem. Clin. Biochem.* 22: 591-596, 1984.
191. **Schriewer, H., U. Kohnert and G. Assmann:** Determination of LDL cholesterol and LDL apolipoprotein B following precipitation of VLDL in blood serum with phosphotungstic acid $MgCl_2$. *J. Clin. Chem. Clin. Biochem.* 22: 35-40, 1984.
192. **Schwappe, K. W. and G. Assmann:** Changes of plasma lipids and lipoprotein levels during danazol treatment for endometriosis. *Horm. Metab. Res.* 16: 593-597, 1984.
193. **Zumkley, H., H. Losse, H. Vetter, G. Assmann, H. Raidt, C. Bohmann, C. Karoff and P. Baumgart:** Lipid metabolism in diuretics therapy. *Münch. Med. Wochenschr.* 126: 743-746, 1984.
194. **Assmann, G. and H. Schriewer:** Sphingomyelin. In: *Methods of enzymatic analysis*, edited by H. U. Bergmeyer. Weinheim: VCH Verlagsgesellschaft mbH, 105-112, 1985.
195. **Assmann, G.:** Die Bedeutung des Risikoquotienten in der Prädiktion der koronaren Herzkrankheit. In: *Effizienz und Effektivität medizinischer Diagnostik*, edited by H. R. Vogel. Stuttgart: Gustav Fischer Verlag, 67-74, 1985.
196. **Assmann, G. and H.-U. Jabs:** Enzymology of lecithin-cholesterol acyltransferase. *Biochem.Soc.Trans.* 13: 19-20, 1985.

197. **Assmann, G. and H. J. Lenzen:** Apolipoprotein E polymorphism, hyperlipidemia and coronary infarction risk. *Internist*. 26: 692-700, 1985.
198. **Assmann, G., H. Schulte and H. Schriewer:** Influence of cigarette smoking on HDL components in blood serum. *J. Clin. Chem. Clin. Biochem.* 23: 623-624, 1985.
199. **Assmann, G.:** Dyslipidemia screening in West Germany. In: *The treatment of dyslipidemia - an international perspective on the prevention of coronary heart disease (CHD)*, Anonymous The Journal of New Developments in Clinical Medicine, Suppl. 2, 15-21, 1985.
200. **Assmann, G., H. Schriewer and H. Schulte:** HDL cholesterol, apolipoprotein A-I and coronary risk-factors - intermediate results of a prospective cardiovascular study in Westphalia. *J. Clin. Chem. Clin. Biochem.* 23: 567-568, 1985.
201. **Assmann, G., H. U. Jabs and H. Funke:** Apolipoprotein mutants, dyslipoproteinemia, and coronary-artery disease - screening studies in coronary angiography patients. *J. Clin. Chem. Clin. Biochem.* 23: 563, 1985.
202. **Assmann, G and H. U. Jabs:** Enzymology of lecithin - cholesterol acetyltransferase. *Biochem. Soc. Trans.* 13: 19-20, 1985.
203. **Balleisen, L., G. Assmann, J. Bailey, P. H. Epping, H. Schulte and J. van de Loo.** Epidemiological-study on factor VII, factor VIII and fibrinogen in an industrial-population. 2. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. *Thromb. Haemost.* 54: 721-723, 1985.
204. **Dominick, H. C., D. Palm, G. Assmann, G. Schmitz and E. H. Schafer:** Vitamin E therapy in an abetalipoproteinemia variant. *Monatsschrift. Fur. Kinderheilkunde.* 133: 612, 1985.
205. **Dominick, H. C., G. Assmann, G. Schmitz and H. E. Schafer:** An abetalipoproteinemia variant with residual amounts of apo B 48 and apo B 100. *Eur. J. Pediatr.* 143: 243, 1985.
206. **Fischer, E. A., W. Winkler, H. Karwat, G. Assmann, D. Geithoff, P. Brockerhoff, H. Sobottka, M. Soll, E. Biurrun and H. Hollmann:** Nuclear-energy 1985 - nuclear-power as an economic factor of growing importance - reports on the technical sections of the Jahrestagung Kerntechnik 1985 In: Munich. *Atomwirtschaft-Atomtechnik* 30: 532-543, 1985.
207. **Gibbels, E., H. E. Schaefer, U. Runne, J. M. Schroder, W. F. Haupt and G. Assmann:** Severe polyneuropathy in Tangier disease mimicking syringomyelia or leprosy - clinical, biochemical, electrophysiological, and morphological evaluation, including electron microscopy of nerve, muscle, and skin biopsies. *J. Neurol.* 232: 283-294, 1985.
208. **Jabs, H. U. and G. Assmann:** Characterization of an apolipoprotein-C-III mutant associated with hypertriglyceridemia. *Circulation* 72: 199, 1985.
209. **Pusch, W., G. Assmann, E. Fritschka, A. Kribben and T. Philipp:** Antihypertensive effect and metabolic side-effects of a combination therapy including propranolol, bendroflumethiazide and hydralazine. *J. Hypertens.* 3: 413, 1985.
210. **Schmitz, G., H. Robenek U. Lohmann, and G. Assmann:** Interaction of high density lipoproteins with cholesteryl ester-laden macrophages - biochemical and morphological characterization of cell surface receptor-binding, endocytosis and resecretion of high density lipoproteins by macrophages. *EMBO J.* 4: 613-622, 1985.
211. **Schmitz, G., G. Assmann, J. Augustin, A. Dirkeskersting, B. Brennhäusen and C. Karoff:** Characterization of very low density lipoproteins and intermediate density lipoproteins of normolipidemic and hyperlipidemic apolipoprotein E2 homozygotes. *J. Lipid Res.* 26: 316-326, 1985.

212. **Schmitz, G. and G. Assmann:** Role of HDL receptor activity for cholesterol efflux from macrophages and endothelial-cells. *Arteriosclerosis* 5: A540, 1985.
213. **Schmitz, G. and G. Assmann:** Analytical isotachopheresis - a new routine method for the rapid analysis of whole serum lipoproteins and atherogenic lipoprotein subfractions. *J. Clin. Chem. Clin. Biochem.* 23: 621-622, 1985.
214. **Schmitz, G., G. Assmann, H. Robenek and B. Brennhausen:** Tangier disease - a disorder of intracellular membrane traffic. *Proc. Natl. Acad. Sci. USA* 82: 6305-6309, 1985.
215. **Schmitz, G. and G. Assmann:** The role of high-density lipoprotein (HDL)-receptor activity for cholesterol efflux from macrophages and endothelial cells. *Circulation* 72: 377, 1985.
216. **Schmitz, G., R. Niemann, B. Brennhausen, R. Krause and G. Assmann:** Regulation of high-density lipoprotein receptors in cultured macrophages - role of acyl-CoA cholesterol acyltransferase. *EMBO J.* 4: 2773-2779, 1985.
217. **Schmitz, G., U. Borgmann and G. Assmann:** Analytical capillary isotachopheresis - a routine technique for the analysis of lipoproteins and lipoprotein subfractions in whole serum. *J. Chromatog.* 320: 253-262, 1985.
218. **Schmitz, G. and G. Assmann:** Analytical isotachopheresis - a new routine method for the rapid analysis of whole serum lipoproteins and atherogenic lipoprotein subfractions. *J. Clin. Chem. Clin. Biochem.* 23: 621-622, 1985.
219. **Schriewer, H., F. Emke and G. Assmann:** Turbidimetric assay of apolipoprotein A-I. *J. Clin. Chem. Clin. Biochem.* 23: 355-359, 1985.
220. **Schriewer, H., W. Nolte and G. Assmann:** VLDL apolipoprotein B determination in blood-serum following precipitation of LDL with polyvinylsulfate. *J. Clin. Chem. Clin. Biochem.* 23: 349-353, 1985.
221. **Schriewer, H., K. Jung, F. Emke and G. Assmann:** Observations of HDL components in female probands following an ultra-long distance run of 100 miles. *J. Clin. Chem. Clin. Biochem.* 23: 21-25, 1985.
222. **Schriewer, H., W. Nolte, H. Robenek and G. Assmann:** Apolipoprotein-b determination in the infranatant obtained after precipitation of Idl with polyvinylsulfate. *J. Clin. Chem. Clin. Biochem.* 24: 620-621, 1985.
223. **Schriewer, H., G. Assmann, G. Hüttenbrink and H. Schulte:** Pseudocholinesterase im Blutserum als Indikator des koronaren Risikos. *Laboratoriumsmedizin* 9: 200-202, 1985.
224. **Strobl, W., K. Widhalm, M. Hayde, T. Holzinger H.-U. Jabs, and G. Assmann:** Studies on a kindred with a genetic variant of apolipoprotein A-I. In: *Diabetes, obesity and hyperlipidemias - III*, edited by G. Crepaldi. Elsevier Science Publishers B.V. 43-48, 1985.
225. **Assmann, G.:** European consensus on primary prevention of coronary heart disease. In: *Lipid regulation in the prevention of coronary heart disease. 6th International Meeting on Atherosclerosis and Cardiovascular Disease, Bologna*, Anonymous Morris Plains, New Jersey: Communications Media for Education, 21-28, 1986.
226. **Assmann, G.:** Lipoproteins and risk of myocardial infarction. *Fette. Seifen. Anstrichmittel.* 88: 433, 1986.

227. **Assmann, G.:** Pharmacological treatment of atherosclerosis. In: *The treatment of atherosclerosis. Current clinical considerations and future trends*, edited by G. Assmann and D. Steinberg. Princeton Junction: Communications Media for Education, Inc. 13-16, 1986.
228. **Assmann, G. and H. Schriewer.:** Verbesserte Hyperlipidämie Diagnostik unter Einbeziehung von HDL-Cholesterin. *Lebensversicherungsmedizin* 38: 47-51, 1986.
229. **Assmann, G.:** Neue Aspekte zur Diagnostik und Therapie der Fettstoffwechselkrankheiten. *JAMA*, 492-503, 1986.
230. **Assmann, G. and H. Schulte:** Die Westfalen-Studie. Koronare Herzkrankheit in der Bundesrepublik. *Der Kassenarzt* 26: 40-46, 1986.
231. **Assmann, G. and H. Schulte:** *PROCAM-Studie*. Zürich: Panscientia Verlag, 7-74, 1986.
232. **Assmann, G., P. Bicsan, G. Glöckner, B. Hegerfel, and H.-D. Helb:** Das Labordatenverarbeitungssystem LDV 2000. *GIT Labor-Medizin* 417-426, 1986.
233. **Assmann, G. and G. Schmitz:** Cholesterol metabolism of macrophages and its possible impact on atherosclerosis. In: *Lipoproteins and coronary heart disease*, edited by J. E. Shepherd, Blantyre Printing Ltd. 69, 1986.
234. **Assmann, G. and H. Schulte:** Pathophysiologie des Fettstoffwechsels unter Berücksichtigung der Ovulationshemmer und des Infarktrisikos. In: *Hormonale Kontrazeption und Herzkreislauf*, edited by F. K. Beller, M. Giesing, and H. Graeff. Gräfelfing: SMV-Verlagsgesellschaft mbH, 12-20, 1986.
235. **Assmann, G. and G. Schmitz:** Effect of antihypertensive drugs on cellular cholesterol metabolism - a challenge for further research. *J. Cardiovasc. Pharmacol.* 8: 72-75, 1986.
236. **Assmann, G.:** The function of human serum apolipoproteins: Clues from inborn errors of lipoprotein metabolism. In: *Human apolipoprotein mutants. Impact on atherosclerosis and longevity*, edited by C. R. E. Sirtori. Plenum Press, 1-16, 1986.
237. **G. Assmann, Coleman, R.T., Funke, H. and Frossard, P.M.:** Lack of association between RFLPs of the human apolipoprotein CII gene locus and clinical manifestations of atherosclerosis. *Am. J. Hum. Genet.* 39 (Suppl.): A89, 1986.
238. **Assmann, G.:** Lipoproteins and apolipoproteins in the prediction of coronary artery disease. *Fette. Seifen. Anstrichmittel.* 88: 549-555, 1986.
239. **Assmann, G. and H. Schulte:** Neue Aspekte zur Prädiktion und Früherkennung der koronaren Herzkrankheit. In: *Wege der Gesundheitsforschung*, edited by R. Gross. Berlin, Heidelberg: Springer-Verlag, 1-8, 1986.
240. **Coleman, R. T., P. A. Gonzalez, H. Funke, G. Assmann, B. Levywilson and P. M. Frossard:** Polymorphisms in the apolipoprotein AI-CIII gene complex. *Mol. Biol. Med.* 3: 21, 1986.
241. **Frossard, P. M., R. T. Coleman, H. Funke and G. Assmann:** Apal RFLP 5.4 KB 5' to the human apolipoprotein A-I (apoA-I) gene. *Nucl. Acids. Res.* 14: 1922, 1986.
242. **Frossard, P. M., P. A. Gonzalez, A. A. Protter, R. T. Coleman, H. Funke and G. Assmann:** Pvu-II RFLP in the 5' of the human apolipoprotein-B gene. *Nucl. Acids. Res.* 14: 4373, 1986.
243. **Frossard, P. M., R. T. Coleman, A. A. Protter, J. H. Seilhammer, H. Funke and G. Assmann:** Isolation of a genomic clone which detects a deletion polymorphism 5 to the human apolipoprotein A-I gene. *Nucl. Acids. Res.* 14: 8694, 1986.

244. **Frossard, P. M., R. T. Coleman, A. A. Protter, J. J. Seilhamer, H. Funke and G. Assmann:** Deletion polymorphism 5' to the human apolipoprotein A-I (apo A-I) gene. *Nucl. Acids. Res.* 14: 8695, 1986.
245. **P.M. Frossard, Funke, H., Coleman, R.T. and Assmann, G.:** Genetic markers for coronary atherosclerosis in the human apolipoprotein AI-CIII-AIV gene complex. *Am. J. Hum. Genet.* 39 (Suppl.): A199, 1986.
246. **Frossard, P. M., R. T. Coleman and G. Assmann:** NcoI RFLP at the human apolipoprotein CII gene locus. *Nucl. Acids. Res.* 14: 5120, 1986.
247. **Frossard, P. M., R. T. Coleman, N. A. Dillan, D. W. Lim, M. J. Malloy, J. P. Kane, H. Funke and G. Assmann:** DraI RFLP in the human apolipoprotein A-I-C-III-AIV gene complex. *Nucl. Acids. Res.* 14: 8699, 1986.
248. **Funke, H., S. Rus, and G. Assmann:** Detection of apolipoprotein E variants by an oligonucleotide melting procedure. *Clin. Chem.* 32: 1285-1289, 1986.
249. **Funke, H., J. Klug, P. M. Frossard, R. Coleman and G. Assmann:** PstI RFLP close to the LDL receptor gene. *Nucl. Acids. Res.* 14: 7820, 1986.
250. **H. Funke, Frossard, P.M., Coleman, R.T. and Assmann, G.:** Genetic marker for atherosclerosis at the human insulin gene locus. *Am. J. Hum. Genet.* 39 (Suppl.): A199, 1986.(Abstract)
251. **Jabs, H., G. Assmann, D. Greifendorf, and A. Benninghoven.** High performance liquid-chromatography and time-of-flight secondary ion mass spectrometry - a new dimension in structural-analysis of apolipoproteins. *J. Lipid Res.* 27: 613-621, 1986.
252. **Jabs, H.-U., M. Walter, G. Assmann and A. Benninghoven:** The application of time-of-flight secondary ion mass spectrometry in the characterization of apolipoprotein mutants. In: *Ion formation from organic solids (IFOS III) Mass spectrometry of involatile materials*, edited by A. Benninghoven. Berlin, Heidelberg, New York, Tokyo: Springer Verlag, 79-83, 1986.
253. **Konig, V., U. Hopf, B. Moller, G. Assmann, M. Freudenberg and C. Galanos:** The significance of high density lipoproteins (HDL) in the clearance of intravenously administered bacterial lipopolysaccharides (LPS) in mice. *Eos-Rivista. di Immunologia. e Immunofarmacologia.* 6: 184, 1986. (auch in: *Hepatogastroenterology* 35: 111-5, 1988)
254. **Konig, V., U. Hopf, B. Moller, G. Assmann, and C. Galanos:** The significance of high density lipoproteins (HDL) in hepatic clearance of bacterial lipopolysaccharide (LPS) in the mouse. *Z. Kardiol.* 24: 27-28, 1986.
255. **Lenzen, H. J., G. Assmann, R. Buchwalsky and H. Schulte:** Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. *Clin. Chem.* 32: 778-781, 1986.
256. **Schmitz, G., H. Robenek and G. Assmann:** Role of the high density lipoprotein receptor cycle in macrophage cholesterol metabolism. *Klin. Wochenschrift.* 64: 979-985, 1986.
257. **Schriewer, H., W. Nolte, H. Robenek and G. Assmann:** Apolipoprotein B determination in the dissolved precipitate obtained after precipitation of LDL with polyvinylsulfate - an alternative method for the determination of LDL apolipoprotein B without using ultracentrifugation. *J. Clin. Chem. Clin. Biochem.* 24: 347-352, 1986.

258. **Schriewer, H., F. Emke, H. Funke, H. Schulte and G. Assmann:** HDL apolipoprotein A-I and HDL apolipoprotein A-II concentrations in male company employees in Westphalia aged 40 years and older. *J. Clin. Chem. Clin. Biochem.* 24: 627-635, 1986.
259. **H. Schulte, Funke, H., Frossard, P.M., Coleman, R.T. and Assmann, G.:** The Msp I RFLP 3 to the human apolipoprotein AII gene is neutral with respect to atherosclerosis in Germans. *Am. J. Hum. Genet.* 39 (Suppl.): A100, 1986.(Abstract)
260. **Assmann, G., B. Lewis, M. Mancini, R. Paoletti and G. Schettler:** Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society. *Eur. Heart J.* 8: 77-88, 1987.
261. **Assmann, G.:** Identification of patients at high risk for myocardial infarction - screening procedures and their implementation. In: *Current views on prevention, diagnosis and treatment of hyperlipidaemia*, edited by B. Lewis and G. Assmann. Royal Society of Medical Services, 19-25, 1987.
262. **Assmann, G. and H. Schulte:** New strategies for the early detection of risk of myocardial infarction. In: *4th Münster International Arteriosclerosis Symposium Abhandlungen der Rhein. Westf. Akad. der Wissenschaften*, edited by W. H. Hauss, R. W. Wissler, and J. Grünwald. Westdeutscher Verlag, 29-32, 1987
263. **Assmann, G.:** Jeder 4. Herzinfarkt vor dem 65. Lebensjahr ist vermeidbar. *Herz & Gefäße* 12: 627, 1987.
264. **Assmann, G.:** Lipoproteins and apolipoproteins in the prediction of coronary artery disease. In: *Acta Medica Scandinavica Symposium Series No. 3, Suppl. 715, Biology of Fascular Disease*, edited by G. Holm and M. Björkholm. Stockholm: Almqvist & Wiksell International, 67-77, 1987.
265. **Assmann, G. and H. Schriewer:** Lipidstoffwechsel. In: *Qualitätssicherung in der Laboratoriumsmedizin*, edited by G. Boroviczeny. Berlin, Heidelberg: Springer Verlag, 298, 1987.
266. **Assmann, G. and G. Schettler:** Die Prävention der koronaren Herzkrankheit. Ein Strategie-Konzept der Europäischen Atherosklerose-Gesellschaft. *Deutsches Ärztebl.* 84: 45-48, 1987.
267. **Assmann, G. and U. Wahrburg:** Zur Therapie der Hyperlipidämie. *Der Arzneimittelbrief* 21: 59-61, 1987.
268. **Assmann, G.:** Erkennen und Behandeln von Risikopatienten - Diagnostik und Strategie. In: *Lipid-Workshop: Hyperlipoproteinämie und Atherosklerose*, edited by G. Assmann, F. A. Gries, P. D. Lang, and G. Wolfram. Mannheim: Studienreihe Boehringer, 19-38, 1986.
269. **Assmann, G. and H. Schulte:** The Prospective Cardiovascular Munster Study - prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. *Am. J. Cardiol.* 59: G 9-G 17, 1987.
270. **Assmann, G. and H. Schulte:** Orale Antikonzeptiva und Fettstoffwechsel: Zwischenergebnisse des PROCAM-Trial. In: *Hormonale Kontrazeption und Herzkreislauf*, ed. by F. K. Beller, M. Giesing, and H. Graeff. Gräfelfing: SMV Verlagsgesellschaft mbH, 27, 1987.
271. **Assmann, G. and H. Schulte:** Neue Strategien zur Früherkennung des Herzinfarkttrisikos. In: *Stoffwechsel-Endokrinologie. Diagnose und Therapie in Klinik und Praxis*, edited by P. Schwandt. München: Verlag Medical Concept, 31-35, 1987.
272. **Assmann, G.:** Lipoproteins and apolipoproteins in the prediction of coronary artery disease. *Acta Med. Scand.* 715: 67-77, 1987.

273. **Assmann, G., H. Funke and H. U. Jabs:** Analytical procedures for the detection and characterization of apolipoprotein E mutants. *Am. Heart J.* 113: 598-603, 1987.
274. **Balleisen, L., H. Schulte, G. Assmann, P. H. Epping and J. van de Loo:** Coagulation factors and the progress of coronary heart disease. *Lancet* 2: 461, 1987.
275. **Carlson, L. A., L. Holmquist and G. Assmann:** Different substrate specificities of plasma lecithin - cholesterol acyl transferase in fish eye disease and Tangier disease. *Acta Med. Scand.* 222: 345-350, 1987.
276. **Domke, W. and G. Assmann:** Experience from use of metabolism kit of Eberswalde institute of applied livestock hygiene. *Monatshefte. Fur. Veterinarmedizin.* 42: 702-704, 1987.
277. **Frossard, P. M., R. Coleman, H. Funke and G. Assmann:** Molecular genetics of the human apo AI/CIII/AIV gene complex application to detection of susceptibility to atherosclerosis. In: *4th Münster International Arteriosclerosis Symposium Abhandlungen der Rhein. Westf. Akad. der Wissenschaften*, edited by W. H. Hauss, R. W. Wissler, and J. Grünwald. Opladen: Westdeutscher Verlag, 53-62, 1987.
278. **Frossard, P. M., D. W. Lim, R. T. Coleman, H. Funke, G. Assmann, M. J. Malloy and J. P. Kane:** Human apolipoprotein CI (apoCI) gene locus: BgLI dimorphic site. *Nucl. Acids. Res.* 15: 1344, 1987.
279. **Frossard, P. M., R. T. Coleman, H. Funke and G. Assmann:** Dimorphic markers for the human apolipoprotein C-II gene locus. *Gene* 51: 103-106, 1987.
280. **Funke, H., G. Assmann and P. Frossard:** Genetic markers in the prediction of atherosclerosis. *J. Clin. Chem. Clin. Biochem.* 25: 145-146, 1987.
281. **Funke, H., J. Klug and G. Assmann:** Hind III RFLP in the lipoprotein-lipase gene, (lpl). *Nucl. Acids. Res.* 15: 9102, 1987.
282. **Funke, H., J. Klug, A. Reckwerth and G. Assmann:** RFLP in lipoprotein lipase gene (lpl). *Nucl. Acids. Res.* 15: 9102, 1987.
283. **Funke, H., J. Klug, P. Frossard, J. Kowalski, A. Reckwerth and G. Assmann:** Detection of a new msp I restriction fragment length polymorphism in the apolipoprotein A-I gene. *J. Clin. Chem. Clin. Biochem.* 25: 131-134, 1987.
284. **Jabs, H. U. and G. Assmann:** Characterization of an apolipoprotein C-III mutant by high performance liquid chromatography and time-of-flight secondary ion mass spectrometry. *J. Chromatog.* 414: 323-333, 1987.
285. **Roessner, A., G. Schmitz and C. Sorg:** What's new in the pathology of atherosclerosis? *Pathology, Research and Practice* 182: 694, 1987.
> Prof. Assmann als Autor nicht aufgeführt!
286. **Rust, S., H. Funke and G. Assmann:** Mineral oil enhances the autoradiographic detection of P-32 labeled nucleic-acids bound to nitrocellulose membranes. *Anal. Biochem.* 163: 196-199, 1987.
287. **Schmitz, G., H. Robenek and G. Assmann:** Role of the high density lipoprotein-receptor cycle in macrophage-cholesterol metabolism. In: *4th Münster International Arteriosclerosis Symposium Abhandlungen der Rhein. Westf. Akad. der Wissenschaften*, edited by W. H. Hauss, R. W. Wissler, and J. Grünwald. Opladen: Westdeutscher Verlag, 33-43, 1987.
288. **Schmitz, G., G. Wulf, T. Bruning and G. Assmann:** Flow-cytometric determination of high-density-lipoprotein binding sites on human leukocytes. *Clin. Chem.* 33: 2195-2203, 1987.

289. **Schmitz, G., G. Assmann, B. Brennhäuser and H. J. Schaefer:** Interaction of Tangier lipoproteins with cholesteryl ester-laden mouse peritoneal macrophages. *J. Lipid Res.* 28: 87-99, 1987.
290. **Schriewer, H., W. Nolte, H. Schulte and G. Assmann:** VLDL cholesterol and VLDL apolipoprotein B preliminary cross-sectional data of the prospective epidemiological-study of company employees in Westphalia. *J. Clin. Chem. Clin. Biochem.* 25: 293-297, 1987.
291. **Smith, S. J., G. R. Cooper, L. O. Henderson, W. H. Hannon, P. Alaupovic, G. Assmann, P. S. Bachorik, G. D. Calvert and P. W. E. Connelly:** An international collaborative study on standardization of apolipoproteins A-I and B. Part I. Evaluation of a lyophilized candidate reference and calibration material. *Clin. Chem.* 33: 2240-2249, 1987.
292. **Assmann, G.:** Lipoproteins and apolipoproteins in the prediction of coronary artery disease. In: *Expanding horizons in atherosclerosis research*, edited by G. Schlierf and H. Mörl. Berlin, Heidelberg: Springer Verlag, 1988.
293. **Assmann, G. and G. Schettler:** Diagnostik und Therapie der Hyperlipidämien. *Deutsches Ärztebl.* 85: A 2209-A 2212, 1988.
294. **Assmann, G.:** LDL und seine Rezeptoren. *Deutsches Ärztebl.* 85: 2213-2214, 1988.
295. **Assmann, G.:** Fettstoffwechselerkrankungen. In: *Arzneimitteltherapie in Klinik und Praxis*, edited by K. H. Rahn and K. H. Meyer zum Büschenfelde. Stuttgart, New York: Georg Thieme Verlag, 259-268, 1988.
296. **Assmann, G.:** Triglycerides and atherosclerosis. *Lipid Reviews* 2: 89, 1988.
297. **Assmann, G. and H. Schulte:** Ergebnisse und Folgerungen aus der Prospektiven Cardiovasculären Münster (PROCAM)-Studie. In: *Fettstoffwechselstörungen und koronare Herzkrankheit. Primärprävention, Diagnostik und Therapie-Leitlinien für die Praxis*, ed. by G. Assmann. München: MMV Medizin Verlag, 97, 1988.
298. **Assmann, G., J. Davignon, A. Fernandezcruz, A. M. Gotto, B. Jacotot, B. Lewis and R. Paoletti:** Recognition and management of lipid disorders. *Revista. Clinica. Espanola.* 183: 433-441, 1988.
299. **Assmann, G. and H. Schulte:** The prospective cardiovascular munster (PROCAM) study prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. *Am. Heart J.* 116: 1713-1724, 1988.
300. **Assmann, G.:** European consensus on primary prevention of coronary heart disease. *Canad. J. Cardiol.* 4: A 21-A 23, 1988.
301. **Assmann, G.:** Disorders of lipid metabolism and coronary heart disease. *Münch. Med. Wochenschr.* 130: 502-503, 1988.
302. **Assmann, G., H. Schulte and U. Wahrburg:** Konzepte zur Atherosklerose-Prävention (Concepts for the prevention of atherosclerosis.) *Münch. Med. Wochenschr.* 130: 260-267, 1988.
303. **Assmann, G. and H. Schriewer:** Lipidsenkende Pharmaka. In: *Schriftenreihe "Kardiologie", kardiovaskulärwirksame Pharmaka*, edited by Hombach et al. Stuttgart: Schattauer Verlag, 291-302, 1988.
304. **Assmann, G.:** Maßnahmenkatalog zur Senkung des koronaren Risikos. Richtlinien zur lipidsenkenden Therapie. Ergebnisse der 2. Konsensus-Konferenz der Europäischen Atherosklerose Gesellschaft. *Fortschritte der Medizin* 106 (Suppl. 46): 4-22, 1988.

305. **Assmann, G.:** Identification of patients at high risk for myocardial infarction - screening procedures and their implementation. In: *Royal Society of Medicine Services International Congress and Symposium Series*, Anonymous, 1988.
306. **Assmann, G., B. Lewis, M. Mancini and Y. Stein:** The recognition and management of hyperlipidemia in adults. A policy statement of the European Atherosclerosis Society. *Eur. Heart J.* 9: 571-600, 1988.
307. **Assmann, G., G. Schmitz and H. Funke:** Spezielle Laboruntersuchungen zur Differentialdiagnostik von Stoffwechselstörungen. In: *Fettstoffwechselstörungen und koronare Herzkrankheit: Prävention, Diagnostik und Therapie-Leitlinien für die Praxis*, edited by G. Assmann. München: MMV Medizin Verlag, 133, 1988.
308. **Assmann, G.:** Diagnostische Verfahren zur Differenzierung der Hyperlipidämien. *Ärzte-Zeitung, Wissenschafts-Journal Forschung und Praxis* 7: 4-6, 1988.
309. **Assmann, G. and H. Schulte:** Oral Contraceptives and Lipid Metabolism: Interim Analysis of the PROCAM Trial. In: *Female Contraception*, edited by B. Runnebaum, T. Rabe, and L. Kiesel. Berlin, Heidelberg: Springer Verlag, 91-96, 1988.
310. **Assmann, G.:** Fettstoffwechselstörungen und koronare Herzkrankheit. *Münch. Med. Wochenschr.* 130: 502-503, 1988.
311. **Assmann, G. and U. Wahrburg:** Diätverhalten bei Hyperlipidämie. Was ist gesichert? *Kolloquium* 6: Nr. 16, 1988.
312. **Assmann, G. and U. Wahrburg:** Fischöl - Was ist gesichert? *Kolloquium* 6: Nr. 18, 1988.
313. **Frossard, P. M., R. T. Coleman, A. A. Protter, J. J. Seilhammer, H. Funke and G. Assmann:** Deletion polymorphism 5 to the human apolipoprotein A-I (apo A-I) gene. *Nucl. Acids Res.* 14: 8694, 1986.
314. **Frossard, P. M., R. T. Coleman, N. A. Dillan, D. W. Lim, M. J. Malloy, J. P. Kane, H. Funke and G. Assmann:** Dral RFLP in the human apolipoprotein AI-CIII-AIV gene complex. *Nucl. Acids Res.* 14:8699, 1986.
315. **Funke, H., S. Rust and G. Assmann:** DNA analysis in the diagnosis of the polygenic disease hypercholesterolemia. *J.Clin. Chem. Clin. Biochem.* 26: 302, 1988.
316. **Funke, H., A. Reckwerth, D. Stapenhorst, M. S. Beiering, M. Jansen and G. Assmann:** Bst NI (Eco RII) RFLP in the lipoprotein lipase gene (LPL). *Nucl. Acids Res.* 16: 2741, 1988.
317. **Knedel, M., G. Assmann, A. Courbe, L. Vanimpe, R. Kattermann, H. Keller, M. Oellerich, R. Kuppers, H. D. Meyer and P. Willnow:** Investigation of the performance of the ES-600 Enzymun-Test system - a multicenter study. *J. Clin. Chem. Clin. Biochem.* 26: 149-162, 1988.
318. **König, V., U. Hopf, B. Moller, H. Lobeck, G. Assmann, M. Freudenberg and C. Galanos:** The significance of high density lipoproteins (HDL) in the clearance of intravenously administered bacterial lipopolysaccharides (lps) in mice. *Hepato-Gastroenterol.* 35: 111-115, 1988.
319. **Sandkamp, M., B. Tambyrajah, H. Schriewer and G. Assmann:** Simplified turbidimetric determination of apolipoprotein A-I, apolipoprotein A-I and apolipoprotein B using a microtitre method. *J. Clin. Chem. Clin. Biochem.* 26: 685-688, 1988.
320. **Schulte, H. and G. Assmann:** Results of the Prospective Cardiovascular Munster (PROCAM) study. *Sozial und Präventivmedizin.* 33: 32-36, 1988.

321. **Seitzer, D., B. Brandt, F. K. Beller and G. Assmann:** The tumor marker CA 15-3 in carcinoma of the breast in the serum and cell compartments as an additional prognostic criterion. *Geburtshilfe und Frauenheilkunde*. 48: 305-308, 1988.
322. **A. Steinmetz, Assefbarkhi, N., Eitze, C., Funke, H., Assmann, G. and Kaffarnik, H.:** Homozygosity for a rare apolipoprotein E (Apo E-1) mutant in a patient with type III hyperlipoproteinemia and a normolipemic subject with dysbetalipoproteinemia. *Eur. J. Clin. Invest.* 18 part II: A 12, 1988. (Abstract)
323. **Strobl, W., H. U. Jabs, M. Hayde, T. Holzinger, G. Assmann and K. Widhalm:** Apolipoprotein A-I (Glu 198 → Lys) - a mutant of the major apolipoprotein of high density lipoproteins occurring in a family with dyslipoproteinemia. *Pediatr. Res.* 24: 222-228, 1988.
324. **Witt, W., G. Wozny, L. Jeromin and G. Assmann:** Safety analyses in process-development and in the optimization of existing production processes. *Chemie. Ingenieur. Technik.* 60: 310-311, 1988.
325. **Assmann, G., G. Schmitz and H. Funke:** Analytical procedures for the differential diagnosis of the disorders of lipid metabolism. In: *Lipid metabolism disorders and coronary heart disease*, ed. by G. Assmann. MMV Medizin Verlag and Vieweg Verlag, 1989.
326. **Assmann, G., J. Davignon, A. Fernandezcruz, A. M. Gotto, B. Jacotot, B. Lewis and R. Paoletti:** Focus on women and CHD. *Revista. Clinica. Espanola.* 185: 308-315, 1989.
327. **Assmann, G.:** Indikationen zur LDL-Apherese. *Deutsches Ärztebl.* 86: B 1812, 1989.
328. **Assmann, G.** Dietary and genetic effects on plasma lipid concentrations. *Acta Cardiol.* 44: 463-464, 1989.
329. **Assmann, G. and U. Gleichmann:** Stufenmodell zur Erkennung von Hochrisikopatienten für den Herzinfarkt. *Deutsches Ärztebl.* 86: A 2663-A 2664, 1989.
330. **Assmann, G., H. Brinkers, H. Schulte and C. A. Carstensen:** Comparison of the reflectance method (reflotron reflectance photometer) with the absorbance method (automatic analyzers) for the determination of cholesterol. *J.Clin. Chem. Clin. Biochem.* 27: 961-966, 1989.
331. **Assmann, G., H. Schulte, H. Funke, A. Von Eckardstein, G. Schmitz and H. Robenek:** High density lipoprotein and atherosclerosis. In: *Atherosclerosis VIII*, edited by G. Crepaldi, A. H. Gotto, E. Manzato, and G. Baggio. Elsevier Science Publishers, 341, 1989.
332. **Assmann, G., G. Schmitz and H. B. Brewer, Jr.:** Familial high density lipoprotein deficiency: Tangier Disease. In: *The Metabolic Basis of Inherited Disease*, edited by C. H. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle. McGraw-Hill, 1267, 1989.
333. **Assmann, G., H. Schulte, H. Funke, A. Von Eckardstein and U. Seedorf:** The Prospective Cardiovascular Münster (PROCAM) study: Identification of high risk individuals for myocardial infarction and the role of HDL. In: *High density lipoproteins and atherosclerosis II*, edited by N. E. Miller. Amsterdam: Elsevier Science Publishers, 51-65, 1989.
334. **Assmann, G., H. Funke and G. Schmitz:** Low density lipoproteins and hypercholesterolemia. *Arzneimittel Forsch. /Drug Res.* 39-2: 996-1003, 1989.
335. **Assmann, G., J. Davignon, A. Fernandezcruz, A. M. Gotto, B. Jacotot, B. Lewis and R. Paoletti:** Nonpharmacological approaches to the management of hyperlipidemia. *Revista. Clinica. Espanola.* 185: 153-161, 1989.
336. **Assmann, G. and H. Schulte:** European lipid guidelines - therapeutic recommendations. *Am. J. Cardiol.* 63: H 53-H 55, 1989.

337. **Assmann, G. and H. Schulte:** Diabetes-mellitus and hypertension in the elderly - concomitant hyperlipidemia and coronary heart disease risk. *Am. J. Cardiol.* 63: H 33-H 37, 1989.
338. **Assmann, G., G. Schmitz and H. Funke:** Special investigations on the differential diagnosis of fat metabolism disorders. *Pol.Soc.Lab.Diag.*, 1989.
339. **Assmann, G., H. Funke and A. von Eckardstein:** Genetic defects in HDL metabolism. *Clin. Invest. Arteriosclerosis* 1: 175-178, 1989.
340. **Benninghoven, A., B. Hagenhoff, R. Kock, G. Assmann and M. Walter:** Peptide analysis by time-of-flight secondary ion mass spectrometry. In: *Methods in protein sequence analysis*, edited by Wittmann-Liebold. Berlin, Heidelberg: Springer Verlag, 199-205, 1989.
341. **Heinrich, J., R. Kokott, P. H. Epping, H. Schulte and G. Assmann:** Baseline data from an epidemiological study on PAI1, protein C, ATIII, factor VIIc and fibrinogen - with regard to an acute phase effect. *Thromb. Haemost.* 62: 572, 1989.
342. **Hoffmeister, F., G. Assmann, G. V. R. Born, F. R. Buhler, W. F. Caspary, R. J. Feldmann and W. Siegenthaler:** Panel discussion. 2. Objectives of basic research and predictive value preclinical testing. *Arzneimittel Forsch. /Drug Res.* 39-2: 1035-1040, 1989.
343. **Schmitz, G. and G. Assmann:** Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. In: *The Metabolic Basis of Inherited Disease*, edited by C. H. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle. McGraw-Hill, 1623, 1989.
344. **Schmitz, G., H. Robenek, B. Brennhause and G. Assmann:** Abnormal processing of HDL precursors in Tangier monocyte-derived macrophages. In: *NATO Advanced Res. Commun. Series*, edited by C. Sirtori. Plenum Press, 1989.
345. **Von Eckardstein, A., H. Funke, A. Henke, K. Altland, A. Benninghoven, and G. Assmann:** Apolipoprotein A-I variants – naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I. *J. Clin. Invest.* 84: 1722-1730, 1989.
346. **Wahrburg, U. and G. Assmann:** *Arteriosklerose; Risikofaktoren, Vorbeugung, Therapie; Richtige Ernährung bei erhöhtem Cholesterinspiegel.* Niedernhausen: Falken-Verlag GmbH, 1-192, 1989.
347. **Wahrburg, U., K. Hoeke, H. G. Becker and E. Köhler:** Beeinflussung von Körpergewicht und Stoffwechsellage durch eine energiereduzierte Mischkost mit hohem Anteil komplexer Kohlendhydrate bei Patienten in der kardialen Rehabilitation. *Akt. Ernährungsmed.* 14: 75, 1989.
348. **Assmann, G.:** Genes and dyslipoproteinaemias. *Eur. Heart. J.* 11: H4-H8, 1990.
349. **Hutchessen, A. C. Assmann, G.:** Is lipoprotein (a) an independent risk factor for myocardial infarction at a young age - reply. *Clin.Chem.* 36: 1258, 1990.
350. **Assmann, G.:** Apolipoproteins - structure, function and role in atherosclerosis. *Clin.Chem.* 36: 945-946, 1990.
351. **Assmann, G., A. Berg, G. Breithardt, U. Gleichmann, M. Halhuber, U. Keil, K. Kochsiek, J. Kruse-Jarres and P. U. A. Lichtlen:** Nationale Cholesterin-Initiative. Ein Strategie-Papier zur Erkennung und Behandlung von Hyperlipidämien. *Deutsches Ärztebl.* 87: A 1358-A 1382, 1990.
352. **Assmann, G., A. Berg, G. Breithardt, U. Gleichmann, M. Halhuber, U. Keil, K. Kochsiek, J.-D. Kruse-Jarres and P. U. A. Lichtlen:** Nationale Cholesterin-Initiative. Ein Strategie-Papier zur Erkennung und Behandlung von Hyperlipidämien. *Deutsche Apotheker Zeitung* 130: 1634-1646, 1990.

353. **Assmann, G., A. Berg, G. Breithardt, U. Gleichmann, M. Halhuber, U. Keil, K. Kochsiek, J.-D. Kruse-Jarres and P. U. A. Lichtlen:** Ein Strategie-Papier zur Erkennung und Behandlung von Hyperlipidämien (Teil 1). *Die Heilkunst* 7: 259-271, 1990.
354. **Assmann, G.:** Fettstoffwechsel und Schwangerschaft. In: *Erkrankungen während der Schwangerschaft*, edited by H. Kyank and F. K. Beller. Stuttgart: Georg Thieme Verlag, 85-89, 1990.
355. **Assmann, G. and H. Schulte:** Primary prevention of coronary heart disease in the Federal Republic of Germany: Analysis of cost-effectiveness. *Drugs* 40: 33-37, 1990.
356. **Assmann, G. and H. Schulte:** Modeling the Helsinki Heart-Study by means of risk equations obtained from the PROCAM Study and the Framingham Heart-Study. *Drugs* 40: 13-18, 1990.
357. **Assmann, G. and H. Schulte:** Diabetes mellitus and hyperlipidemia: Results from the Prospective Cardiovascular Muenster (PROCAM) Study. In: *Diabetes mellitus and its complications: Pathogenesis and treatment*, edited by M. Brownlee and L. M. Sherwood. Philadelphia: Hanley and Belfus, Inc. 253-268, 1990.
358. **Assmann, G. and H. Schulte:** Obesity and Hyperlipidemia: Results from the Prospective Cardiovascular Muenster (PROCAM) Study. In: *Obesity*, edited by P. Bjorntorp and B. Brodoff, 1990.
359. **Assmann, G., A. von Eckardstein, H. Funke and S. Rust:** Apolipoprotein mutants. In: *Atherosclerosis reviews 20: Biotechnology of dyslipoproteinemias. Applications in diagnosis and control*, edited by C. Lenfant, R. Paoletti, A. Albertini, and A. L. Catapano. Raven Press: 35-45, 1990.
360. **Assmann, G. and A. von Eckardstein:** Biochemie des Lipoprotein Stoffwechsels und klinische Bedeutung lipidsenkender Pharmaka. In: *Offizin und Praxis* 9, edited by Morck, Lieckfeld, and Schneider. Govi-Verlag, 92-110, 1990.
361. **Assmann, G., G. Schmitz, H. Funke and A. von Eckardstein:** Apolipoprotein A-I and HDL-deficiency. *Curr. Opin. Lipidol.* 1: 110-115, 1990.
362. **Assmann, G., A. von Eckardstein and H. Funke:** Apolipoprotein A-I mutants and their significance for HDL-metabolism. *J. Drug Dev.* 3 (Suppl. 1): 57-62, 1990.
363. **Assmann, G.:** At what levels of total, low density or high density lipoprotein cholesterol should diet or drug therapy be initiated? European guidelines. *Am. J. Cardiol.* 65: F 11-F 15, 1990.
364. **Assmann, G., A. Berg, G. Breithardt, U. Gleichmann, M. Halhuber, U. Keil, K. Kochsiek, J.-D. Kruse-Jarres and P. U. A. Lichtlen:** Ein Strategie-Papier zur Erkennung und Behandlung von Hyperlipidämien (Teil 2). *Die Heilkunst* 103: 287-294, 1990.
365. **Assmann, G. and H. Funke:** HDL metabolism and atherosclerosis. *J. Cardiovasc. Pharmacol.* 16: S 15 - S 20, 1990.
366. **Assmann, G., A. Von Eckardstein and H. Funke:** Clinical, biochemical and genetic heterogeneity of lecithin: cholesterol acyltransferase deficiency syndromes. In: *Disorders of HDL, proceedings of the international symposium held at the Karolinska Hospital, Stockholm*, edited by L. A. Carlson. Smith-Gordon and Company Ltd. 169-175, 1990.
367. **Assmann, G., J. Davignon, A. Fernandezcruz, A. M. Gotto, B. Jacotot, B. Lewis and R. Paoletti:** Children and dyslipidemia. *Revista. Clinica. Espanola.* 186: 178-186, 1990.
368. **Assmann, G.:** Apolipoproteins – structure, function and role in atherosclerosis. *Clin. Chem.* 36: 945-946, 1990.

369. **Brandt, B., D. Seitzer, H. Behling and G. Assmann:** Complementary prognostic relation of CA 15-3 and Kathepsin D in breast cancer tissue. *J. Cancer Res. Clin. Oncol.* 116, Suppl. I: 49, 1990.
370. **Castelli, W. P., G. Assmann, B. Lewis and S. Sarma:** Redefining risk factors for coronary heart disease – the benefit of regulating lipoproteins – Proceedings of a symposium supported by an educational grant from Parke-Davis, Division of Warner-Lambert company held in Nice on 13 september, 1989. *Drugs* 40: 53-56, 1990.
371. **Funke, H., A. Von Eckardstein, P. H. Pritchard, M. R. Hayden, J. J. Albers, B. Jacotot, U. Gerdes and G. Assmann:** Identification of several molecular defects responsible for familial lecithin -cholesterol acyltransferase (LCAT) deficiency. *Circulation* 82: 426, 1990.
372. **Funke, H., H. Wiebusch, B. Paulweber, and G. Assmann:** Identification of the molecular defect in a patient with type I hyperlipidemia. *Arteriosclerosis* 10: A 830, 1990.
373. **Grundy, S. H., L. Wilhelmsen, G. Rose, R. W. F. Campbell and G. Assmann:** Coronary heart disease in high risk populations: lessons from Finland. *Eur. Heart. J.* 11: 462-471, 1990.
374. **Heinrich, J., R. Kokott, P. H. Epping, H. Schulte and G. Assmann:** Das Verhalten des KHK-Risikoindicators Fibrinogen in Abhängigkeit von Entzündung und Fettstoffwechsel. In: *Neue Aspekte aus Zellbiologie und Molekulargenetik, Epidemiologie und Klinik*, edited by G. Assmann, E. Betz, H. Heinle, and H. Schulte. Vieweg Verlag, 111-119, 1990.
375. **Heinrich, J., U. Wahrburg, H. Martin and G. Assmann:** The effect of diets, rich in monosaturated or polyunsaturated fatty acids, on lipid metabolism and hemostasis. *Fibrinolysis* 4: 76-78, 1990.
376. **Jonas, A., A. von Eckardstein, K. E. Kezdy, A. Steinmetz and G. Assmann:** Structural and functional properties of reconstituted HDL prepared with six apolipoprotein A-I variants. *Circulation* 82: 330, 1990.
377. **H. Martin, Wahrburg, U., Sandkamp, M., Schulte, H. and Assmann, G.:** Vergleichende Untersuchungen zu den Auswirkungen einer monoensäure- und einer polyensäurereichen Kost auf Serumlipide und Lipoproteine. *Infusionstherapie* 17, Suppl. 1: 32, 1990. (Abstract)
378. **Roberts, W. C. and G. Assmann:** A symposium - Evolving issues in the treatment of hypercholesterolemia - Introduction. *Am. J. Cardiol.* 65: F 1- F 43, 1990.
379. **Sandkamp, M., H. Funke, H. Schulte, E. Kohler, and G. Assmann:** Lipoprotein(a) is an independent risk factor for myocardial-infarction at a young age. *Clin. Chem.* 36: 20-23, 1990.
380. **Sandkamp, M. and G. Assmann:** Lipoprotein (a) in PROCAM participants and young myocardial infarction survivors. In: *Lipoprotein (a)*, edited by A. M. Scanu. Academic Press, 205-209, 1990.
381. **Sandkamp, M., H. Schulte, A. Bentrup and G. Assmann:** Lipoprotein (a) und koronare Herzkrankheit. In: *Neue Aspekte aus Zellbiologie und Molekulargenetik, Epidemiologie und Klinik*, edited by G. Assmann, E. Betz, H. Heinle, and H. Schulte. Vieweg Verlag, 61-65, 1990.
382. **Schmitz, G., H. Fischer, M. Beuck, K. P. Hoecker, H. Robeneck and G. Assmann:** Dysregulation of phospholipid synthesis in Tangier monocyte-derived macrophages. *Arteriosclerosis* 10: 1010-1019, 1990.
383. **Schmitz, G., H. Robenek, B. Brennhäusen, and G. Assmann:** Abnormal processing of HDL precursors in Tangier monocyte-derived macrophages. In: *NATO Advanced Res. Commun. Series*, edited by C. Sirtori. New York: Plenum Press, 1990.

384. **Schulte, H. and G. Assmann:** Prevalence of cardiovascular risk factors and cholesterol reduction strategy in West Germany. *Maryland Medical Journal*, 1990.
385. **Schulte, H. and G. Assmann:** Epidemiologisches Modell für eine Kosten-Nutzen-Analyse zur Verminderung von Risikofaktoren der KHK. In: *Neue Aspekte aus Zellbiologie und Molekulargenetik, Epidemiologie und Klinik*, edited by G. Assmann, E. Betz, H. Heinle, and H. Schulte. Braunschweig: Vieweg Verlag, 75-84, 1990.
386. **Seedorf, U., K. Schrage, M. Walter, S. Scheek and G. Assmann:** Cloning, sequencing, and expression of rat and human sterol carrier protein 2 (SCP2) cDNAs. *Circulation* 82: 556, 1990.
387. **Seedorf, U., M. Walter and G. Assmann:** Nucleotide and derived amino acid sequence of a rat liver sterol carrier protein 2 (SCP2)-related cDNA. *Proc. Natl. Acad. Sci. USA*, 1990.
388. **Seedorf, U., K. Schrage, M. Walter, S. Scheek and G. Assmann:** Cloning, sequencing, and expression of rat and human sterol carrier protein-2 (SCP2) cDNAs - evolutionary relationship of the intracellular and extracellular lipid transport system. *Arteriosclerosis* 10: A 780, 1990.
389. **Steinmetz, A., N. Assefbarkhi, C. Eltze, K. Ehlenz, H. Funke, A. Pies, G. Assmann and H. Kaffarnik:** Normolipemic dysbetalipoproteinemia and hyperlipoproteinemia type III in subjects homozygous for a rare genetic apolipoprotein E variant (apoE1). *J. Lipid Res.* 31: 1005-1013, 1990.
390. **von Eckardstein, A., H. Funke, M. Walter, K. Altland, A. Benninghoven and G. Assmann:** Structural analysis of human apolipoprotein A-I variants - amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure. *J. Biol. Chem.* 265: 8610-8617, 1990.
391. **von Eckardstein, A., H. Funke, P. H. Pritchard, J. J. Albers, J. J. P. Kastelein, C. C. Droste and G. Assmann:** Fish-eye disease - characterization of the molecular defect. *Circulation* 82: 425, 1990.
392. **Assmann, G. and H. Schulte:** CHD risk equations obtained from the Framingham Heart Study, applied to PROCAM Study. *Cardiovasc. Risk Factors* 1: 126-133, 1991.
393. **Assmann, G., A. Von Eckardstein and H. Funke:** Lecithin: cholesterol acyltransferase deficiency and fish eye disease. *Curr. Opin. Lipidol.* 2: 110-117, 1991.
394. **Assmann, G. and R. Carmena:** Trastornos del metabolismo de los lipidos y cardiopatía coronaria. *München: MMV Medizin Verlag*, 1-190, 1991.
395. **Assmann, G., D. J. Betteridge, A. M. Gotto and G. Steiner:** Management of hypertriglyceridemic patients. A. Treatment classifications and goals. *Am. J. Cardiol.* 68: A 30-A 34, 1991.
396. **Assmann, G., M. Sandkamp and H. Schulte:** Lp (a) come fattore di rischio nelle donne in postmenopausa. *Giornale della Arteriosclerosi* 16 (Suppl.): 17-20, 1991.
397. **Assmann, G. and H. B. Brewer:** Genetic (primary) forms of hypertriglyceridemia. *Am. J. Cardiol.* 68: A 13 - A 16, 1991.
398. **Assmann, G., A. von Eckardstein and H. Funke:** HDL and reverse transport of cholesterol: insights from mutants. In: *DNA Polymorphisms as disease markers*, edited by D. J. Galton and G. Assmann. New York: Plenum Press, 61, 1991.
399. **Assmann, G., A. M. Gotto and R. Paoletti:** The hypertriglyceridemias: Risk and management Introduction. *Am. J. Cardiol.* 68: A 1-A 4, 1991.
400. **Assmann, G.:** Drugs affecting HDL cholesterol. *Cardiology* 78: 236-242, 1991.

401. **Assmann, G. and H. Schulte:** Triglycerides and atherosclerosis, results from the Prospective Cardiovascular Münster Study. In: *Atherosclerosis Reviews*, edited by A. M. J. Gotto and R. Paoletti. New York: Raven Press, 51-57, 1991.
402. **Assmann, G. and H.-D. Helb:** Chapter 8: Sample distribution. In: *Clinical Biochemistry 4: Laboratory Organization - Automation*, edited by D. J. Vonderschmitt. Berlin, New York: Walter de Gruyter, 165-205, 1991.
403. **Assmann, G., A. Von Eckardstein, H. Funke, S. Rust and M. Sandkamp:** Analysis of genetically determined structural variation in apolipoproteins E, B and (a). *Curr. Opin. Lipidol.* 2: 367-375, 1991.
404. **a. Assmann, G.:** Fettstoffwechselstörungen: Erkennung und Behandlung -FdM-Tabellen für die Praxis. *Fortschritte der Medizin* 109: 288-363 - 5 Folgen, 1991.
- b. Assmann, G.:** Hyperlipidämie: Triglyzeride stärker beachten. *Geriatric Praxis* 12: 33, 1991
405. **Brandt, B., D. Seitzer, C. Jackisch and G. Assmann:** Quantitative determination of the tumor marker CA 15-3 in breast cancer tissue compartments. *J. Tumor Marker Oncol.* 6: 173-182, 1991.
406. **Funke, H., A. von Eckardstein and G. Assmann:** Molecular genetics approach to polygenic disease – initial results from atherosclerosis research. In: *DNA Polymorphisms as Disease Markers*, edited by D. J. Galton and G. Assmann. New York: Plenum press, 15-25, 1991.
407. **Funke, H., A. von Eckardstein, P. H. Pritchard, J. J. Albers, J. J. P. Kastelein, C. Droste and G. Assmann:** A molecular defect causing fish eye disease – an amino-acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. *Proc. Natl. Acad. Sci. USA* 88: 4855-4859, 1991.
408. **Funke, H., A. von Eckardstein, P. H. Pritchard, M. Karas, J. J. Albers and G. Assmann:** A frameshift mutation in the human apolipoprotein A-I gene causes high-density lipoprotein deficiency, partial lecithin cholesterol acyltransferase deficiency, and corneal opacities. *J. Clin. Invest.* 87: 371-376, 1991.
409. **Heinrich, J., M. Sandkamp, R. Kokott, H. Schulte and G. Assmann:** Relationship of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population. *Clin. Chem.* 37: 1950-1954, 1991.
410. **Heinrich, J., H. Schulte, L. Balleisen, G. Assmann and J. van de Loo:** Predictive value of hemostatic variables in the PROCAM-study. *Thromb. Haemost.* 65: 815, 1991.
411. **Huskamp, B. and G. Assmann:** Treatment of equine laminitis in veterinary-medicine. *Prakt. Tierarzt* 72: 61-64, 1991.
412. **Jaroß, W., H. Schulte, S. Bergmann, G. Assmann and DRECAN-Team:** Differences in risk profile between people from "East" and "West" Germany (DRECAN-PROCAM comparison). In: *Advances in lipoprotein and atherosclerosis research, diagnostics and treatment*, edited by M. Hanefeld. Jena: Gustav Fischer Verlag, 171-177, 1991.
413. **Jonas, A., A. von Eckardstein, K. E. Kezdy, A. Steinmetz, and G. Assmann:** Structural and functional properties of reconstituted high density lipoprotein disks prepared with 6 apolipoprotein A-I variants. *J. Lipid Res.* 32: 97-106, 1991.
414. **Motti, C., H. Funke, S. Rust, A. Dergunov and G. Assmann:** Using mutagenic polymerase chain-reaction primers to detect carriers of familial defective apolipoprotein B-100. *Clin. Chem.* 37: 1762-1766, 1991.

415. **Paulweber, B., H. Wiebusch, G. Miesenboeck, H. Funke, G. Assmann, B. Hoelzl, M. J. Sippl, W. Friedl, J. R. Patsch and F. Sandhofer:** Molecular-basis of lipoprotein lipase deficiency in 2 Austrian families with type I hyperlipoproteinemia. *Atherosclerosis* 86: 239-250, 1991.
416. **Petersen, G., H. J. Bauch, U. Wahrburg and G. Assmann:** Simultane Bestimmung von freiem Cholesterin und Cholesterinestern im Serum mittels HPLC bei Patienten mit erhöhtem atherogenem Risiko. In: *Molekulargenetische Aspekte und zelluläre Mechanismen, Risikoprofile vor und nach invasiven Therapieverfahren*, edited by G. Assmann, E. Betz, H. Heinle, and H. Schulte. Braunschweig: Vieweg Verlag, 253, 1991.
417. **Petersen, G., H. J. Bauch, U. Wahrburg and G. Assmann:** Quantitative determination of total cholesterol, free cholesterol and different cholesteryl esters in serum samples using RP-HPLC and UV-detection. In: *Sixth Münster International Atherosclerosis Symposium: New aspects of metabolism and behaviour of mesenchymal cells during pathogenesis of arteriosclerosis*. edited by W. H. Hauss, R. W. Wissler, and H. J. Bauch. Rheinisch-Westfälische Akademie der Wissenschaften, 228, 1991.
418. **Schulte, H. and G. Assmann:** The PROCAM Study and consequences for a health promotion program. In: *Advances in lipoprotein and atherosclerosis research, diagnostics and treatment*, edited by M. Hanefeld. Jena: Gustav Fischer Verlag, 185-187, 1991.
419. **Schulte, H. and G. Assmann:** Kosten-Wirksamkeits-Analysen von Maßnahmen zur Reduktion von Cholesterin im Serum. In: *Koronare Herzkrankheit - Molekulargenetische Aspekte und zelluläre Mechanismen, Risikoprofile vor und nach invasiven Therapieverfahren*, edited by G. Assmann, E. Betz, H. Heinle, and H. Schulte. Vieweg Verlag, 51-60, 1991.
420. **Seedorf, U. and G. Assmann:** Cloning, expression, and nucleotide sequence of rat liver sterol carrier protein-2 cDNAs. *J. Biol. Chem.* 266: 630-636, 1991.
421. **Siebert, G., J. Heinrich, H. Schulte, S. Bergmann, G. Assmann, and W. Jaroß:** DREGAN: Relationship of plasminogen activator inhibitor; fibrinogen and antithrombin III to other risk of atherosclerosis. In: *Advances in lipoprotein and atherosclerosis research, diagnostics and treatment*, edited by M. Hanefeld. Jena: Gustav Fischer Verlag, 375-381, 1991.
422. **von Eckardstein, A., M. Walter, A. Roetrig and G. Assmann:** Methionine sulfoxidation of apo AI: impact of interactions of HDL with LDL and cells. In: *Advances in lipoprotein and atherosclerosis research*, edited by M. Hanefeld. Jena: Gustav Fischer Verlag, 272-274, 1991.
423. **von Eckardstein, A., M. Walter, H. Holz, A. Benninghoven, G. Assmann, A. Roetrig and R. Kock:** Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoprotein-A-I, apolipoprotein-C-II, and apolipoprotein-C-III. *J. Lipid Res.* 32: 1465-1476, 1991.
424. **von Eckardstein, A., H. Holz, M. Sandkamp, W. Weng, H. Funke and G. Assmann:** Apolipoprotein C-III (Lys58 → Glu) - identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. *J. Clin. Invest.* 87: 1724-1731, 1991.
425. **Wahrburg, U., H. Martin, H. Schulte, M. Sandkamp and G. Assmann:** Einfluß einer monoensäurereichen Kost auf Serumlipide und Lipoproteine bei gesunden Versuchspersonen im Vergleich zu polyensäurereicher Kost. In: *Molekulargenetische Aspekte und zelluläre Mechanismen, Risikoprofile vor und nach invasiven Therapieverfahren*, edited by G. Assmann, E. Betz, H. Heinle, and H. Schulte. Braunschweig: Vieweg Verlag, 43-50, 1991.
426. **Assmann, G.:** Risikofaktor Hypertriglyceridämie im Spiegel epidemiologischer Studien. In: *Atherogenität der Triglyceride - Symposium Mai 1991 Schloß Fuschl*, edited by P. Schwandt and W. Fuchs. Braunschweig: Vieweg Verlag, 16-21, 1992.

427. **Assmann, G. and H. Funke:** Genetische Diagnostik von Störungen des Lipoproteinstoffwechsels. *Laboratoriumsmedizin* 16: 369-374, 1992.
428. **Assmann, G. and H. Schulte:** Obesity and hyperlipidemia: Results from the Prospective Cardiovascular Munster (PROCAM) Study. In: *Obesity*, edited by P. Bjorntorp and B. N. Brodoff. Philadelphia: Lippincott, 502-511, 1992.
429. **Assmann, G. and H. Schulte:** The importance of triglycerides - results from the Prospective Cardiovascular Munster (PROCAM) Study. *Eur. J. Epidemiol.* 8: 99-103, 1992.
430. **Assmann, G. and H. Schulte:** Role of triglycerides in coronary artery disease - lessons from the Prospective Cardiovascular Munster Study. *Am. J. Cardiol.* 70: H 10-H 13, 1992.
431. **Assmann, G. and H. Schulte:** Ergebnisse der Prospektiven Cardiovaskulären Münster (PROCAM) Studie. In: *Erster Direktor Dr. med. h.c. Wilhelm Riehemann zum Abschied*, Anonymous 203-209, 1992.
432. **Assmann, G. and H. Schulte:** Hyperlipidemia according to age. In: *Excerpta Medica Newsletter*, Anonymous Tokyo: 1, 1992.
433. **Assmann, G. and H. Schulte:** Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). *Am. J. Cardiol.* 70: 733-737, 1992.
434. **Assmann, G., A. von Eckardstein and H. Funke:** Apolipoproteins, reverse cholesterol transport and coronary heart disease. In: *Cellular and molecular biology of atherosclerosis*, edited by A. M. Gotto. Berlin: Springer Verlag, 159, 1992.
435. **Assmann, G., A. von Eckardstein and H. Funke:** The role of apolipoprotein mutants in HDL metabolism. In: *CRC Reviews in Biochemistry*, Anonymous Boca Raton: CRC Press, 85, 1992.
436. **Brandt, B., C. Jackisch, D. Steinhoff, H. Rissing and G. Assmann:** Prognostic importance of Cathepsin D In: *Breast Cancer J. Tumor Marker Oncol.* 7: 79, 1992.
437. **Brandt, B., E. Liffers, W. Sasse and G. Assmann:** CA 72-4: The Tumormarker for Gastric Carcinoma. In: *Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the 90th*, Anonymous München: W. Zuckschwerdt Verlag, 10-13, 1992.
438. **Brandt, B., U. Vogt, F. Harms, C. Jackisch, K. S. Zänker and G. Assmann:** Differential polymerase chain reaction for the detection of erb B-2, erb B-3, c-Myc and Ha-Ras-Amplification in breast cancer tissue. *J. Tumor Marker Oncol.* 7: 32, 1992.
439. **Brandt, B., U. Vogt, F. Harms, C. Jackisch, K. S. Zänker and G. Assmann:** Detection of erb B-2, erb B-3 and c-Myc-Amplification in breast cancer tissue. *Breast Canc. Res. Treat.* 23: 176, 1992.
440. **Feussner, G., H. Funke, W. Weng, G. Assmann, K. J. Lackner and R. Ziegler:** Severe type-III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon-1 null genotype. *Eur. J. Clin. Invest.* 22: 599-608, 1992.
441. **Funke, H., S. Rust, U. Seedorf, B. Brennhäusen, A. Chirazi, C. Motti and G. Assmann:** Homozygosity for familial defective apolipoprotein B 100 (FDB) is associated with lower plasma-cholesterol concentrations than homozygosity for familial hypercholesterolemia (FH). *Circulation* 86: 691, 1992.
442. **Heinrich, J., A. Dirkeskersting, H. Schulte and G. Assmann:** Effects of age, menopause and human growth-hormone on variables of fibrinolysis. *Fibrinolysis* 6: 33-35, 1992.

443. **Heinrich, J., G. Assmann, H. J. Ulbrich and H. Schulte:** Plasmaviskosität und hämostasiologische Meßgrößen bei gesunden Probanden. In: *Arteriosklerotische Gefäßkrankungen: Prävention, Pathogenese und Therapieansätze der Arteriosklerose*, edited by H. Heinle, H. Schulte, and H. E. Schaefer. Braunschweig: Vieweg Verlag, 121-125, 1992.
444. **Heinrich, J. and G. Assmann:** Fibrinogen - a coronary risk marker. *Heartbeat* 4: 4, 1992.
445. **Heinrich, J., H. Schulte, R. Schönfeld, E. Köhler and G. Assmann:** Elevated fibrinogen, plasma viscosity, and coagulation inhibitors in survivors of myocardial infarction. In: *Fibrinogen: a "new" cardiovascular risk factor*, edited by E. Ernst, W. Koenig, G. D. O. Lowe, and T. W. Meade. Wien: Blackwell-MZV, 183, 1992.
446. **Köhler, E., A. Bentrup, H. Funke, M. Sandkamp, H. Schulte and G. Assmann:** Studies on the dependence between disorders of lipid metabolism and manifestation of coronary heart disease (CHD). *Z. Kardiol.* 81: 354-360, 1992.
447. **Lewis, B., G. Assmann, M. Tikkanen, M. Mancini and D. Pometta:** Prevention of coronary heart disease: Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society, prepared by the International Task Force for Prevention of Coronary Heart Disease. *Nutr. Metab. Cardiovasc. Dis* 2: 113-156, 1992.
448. **Niessen-Dietrich, U., H. Schulte, M. Sandkamp, G. Assmann and G. Simon:** Die Wirkungen eines Geh-, Lauf- und Krafttrainings auf Plasmalipide und die Lipoproteinspiegel bei gesunden Männern mittleren Alters. In: *Arteriosklerotische Gefäßkrankungen: Prävention, Pathogenese und Therapieansätze der Arteriosklerose*, edited by H. Heinle, H. Schulte, and H. E. Schaefer. Braunschweig: Vieweg Verlag, 57-65, 1992.
449. **Rust, S., H. Funke and G. Assmann:** Analysis of pooled samples from nearly 10000 individuals with mutagenically separated pcr (MS-PCR) shows a significant overrepresentation of familial defective apo B-100 in coronary-artery disease patients. *Circulation* 86: 420, 1992.
450. **Sandkamp, M., B. M. Tambyrajah, G. Assmann and H. Schriewer:** Determination of apolipoprotein B in apolipoprotein CII/CIII- containing lipoproteins by an immunoenzymetric assay. *Eur. J. Clin. Chem. Clin. Biochem.* 30: 223-228, 1992.
451. **Schulte, H., J. Heinrich and G. Assmann:** Fibrinogen und koronare Herzkrankheit, Ergebnisse der PROCAM Studie. In: *Arteriosklerotische Gefäßkrankungen: Prävention, Pathogenese und Therapieansätze der Arteriosklerose*, edited by H. Heinle, H. Schulte, and H. E. Schaefer. Braunschweig: Vieweg Verlag, 37-44, 1992.
452. **Schulte, H. and G. Assmann:** Triglycerides and atherosclerosis: The PROCAM experience. *Cardiovasc. Risk Factors* 2: 334-342, 1992.
453. **Seedorf, U., M. Fobker and G. Assmann:** Transport of newly synthesized cholesterol to the plasma-membrane. *Circulation* 86: 549, 1992.
454. **von Eckardstein, A., H. Funke, M. Schulte, M. Erren, H. Schulte and G. Assmann:** Nonsynonymous polymorphic sites in the apolipoprotein (apo) A-IV gene are associated with changes in the concentration of apo B- containing and apo A-I-containing lipoproteins in a normal population. *Am. J. Hum. Genet.* 50: 1115-1128, 1992.

455. **von Eckardstein, A., I. Wybranska, A. Jonas, K. E. Kezdy, G. Castro, J. C. Fruchart and G. Assmann:** Apolipoprotein A-I variants: Structure, function and metabolism. In: *Atherosclerosis IX. proceedings of the ninth international symposium on atherosclerosis, Rosemont-Chicago, IL, U.S.A.* edited by Y. Stein, S. Eisenberg, and O. Stein. Tel Aviv: R&L Creative Communications Ltd. 195, 1992.
456. **Wahrburg, U., H. Martin, M. Sandkamp, H. Schulte and G. Assmann:** Comparative effects of a recommended lipid-lowering diet vs a diet rich in monounsaturated fatty-acids on serum-lipid profiles in healthy young adults. *Am. J. Clin. Nutr.* 56: 678-683, 1992.
457. **Walter, M., J. R. Nofer, H. Reinecke, U. Seedorf and G. Assmann:** Influence of HDL subfractions on platelet aggregation. In: *Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease*, edited by A. M. Gotto, M. Mancini, and P. Schwandt, 69, 1992.
458. **Wiebusch, H., H. Funke, J. J. P. Kastelein, T. Bruin, D. Pometta, V. Armstrong and G. Assmann:** Mutations in the lipoprotein-lipase gene are not restricted to patients with type-I hyperlipidemia. *Circulation* 86: 609, 1992.
459. **Assmann, G.:** Review of the latest European and US guidelines. *Cardiovasc. J. S. Africa* 4, Nr. 5 Suppl. 11-16, 1993.
460. **Assmann, G.:** Aktualisierte Hinweise zur Primär- und Sekundärprävention der koronaren Herzkrankheit. Risikofaktoren als Ursachen der koronaren Herzkrankheit. *Deutsches Ärztebl.* 90: 3058-3070, 1993.
461. **Assmann, G., H. Schulte and A. von Eckardstein:** High density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience. *Cardiovasc. Risk Factors* 3: 297-304, 1993.
462. **Assmann, G. and B. J. Hunt:** Clinical chemistry and coagulation - Editorial overview. *Current Opinion in Lipidology* 4: 425-427, 1993.
463. **Assmann, G. and H. Schulte:** Results and conclusions of the Prospective Cardiovascular Münster (PROCAM) Study. In: *Lipid metabolism disorders and coronary heart disease*, edited by G. Assmann. München: MMV Medizin Verlag, 19: 1-34, 1993.
464. **Assmann, G. and H. Schulte:** Ergebnisse der Prospektiven Kardiovaskulären Münster (PROCAM) Studie. *Deutsches Ärztebl.* 90: 2764-2771, 1993.
465. **Assmann, G. and H. Schulte:** Cholesterol, coronary heart disease, and total mortality: the PROCAM experience. In: *Low blood cholesterol and health implications*, edited by B. Lewis, R. Paoletti, and M. J. Tikkanen. Current Medical Literature 10, 1993.
466. **Assmann, G., H. Schulte and A. von Eckardstein:** Hypertriglyceridemia/low high-density lipoprotein cholesterol syndrome. *Nutr Metab Cardiovasc Dis* 3: 1-4, 1993.
467. **Assmann, G., H. Schulte and A. von Eckardstein:** High density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience. In: *New Horizons in Coronary Heart Disease*, edited by G. R. Born and C. C. Schwartz. London: Science Press, 6.1, 1993.
468. **Assmann, G., A. von Eckardstein and H. Funke:** Disorders of the high-density lipoprotein metabolism. In: *Lipid Metabolism Disorders and Coronary Heart Disease. Primary Prevention, Diagnosis and Therapy Guidelines for General Practise*, edited by G. Assmann. München: MMV Medizin Verlag, 195, 1993.
469. **Assmann, G., A. von Eckardstein and H. Funke:** Mutant forms of apolipoproteins and enzymes involved in lipoprotein metabolism as risk markers. *Anal. Biol. Clin.* 51: 266, 1993.

470. **Assmann, G., A. von Eckardstein and H. Funke:** High density lipoproteins, reverse transport of cholesterol, and coronary-artery disease - insights from mutations. *Circulation* 87: Suppl. III 28-34, 1993.
471. **Bauch, H. J., H. Raidt, W. Raupp, H. Schulte and G. Assmann:** Einfluß von Lachsöl auf den Lipidstoffwechsel bei Dialysepatienten. In: *Diätetik und Arteriosklerose*, edited by H. Heinle, H. Schulte, and H. E. Schaefer. Braunschweig: Vieweg Verlag, 68-76, 1993.
472. **Bergmann, S., M. Sandkamp, G. Assmann, W. Jaroß and DRECAN-Team:** LP(a)-Verteilung in der Dresdener Bevölkerung – DRECAN-Studie. In: *Diätetik und Arteriosklerose*, edited by H. Heinle, H. Schulte, and H. E. Schaefer. Braunschweig: Vieweg Verlag, 199-207, 1993.
473. **Brandt, B., U. Vogt, F. Harms, C. Jackisch, K. S. Zänker and G. Assmann:** High-risk Mammakarzinome mit Amplifikationen der Onkogene erbB-2 und c-myc. *Laboratoriumsmedizin* 17: 199-200, 1993.
474. **Brandt, B., U. Vogt, F. Harms, C. Jackisch, G. Assmann, and K. S. Zänker:** Breast Cancer Prognosis: Identification of high-risk patients by erbB-2 and c-myc oncogene amplification. *Clin. Oncol.* 12: 237, 1993.
475. **Budde, T., E. Bösenberg, C. Fehtrup, C. Vielhauer, A. Enbergs, H. Schulte, G. Assmann and G. Breithardt:** Lipoprotein (a) correlates with number, severity and extension of coronary lesions in male patients with angiographically documented coronary artery disease. *Eur. Heart. J.* 14 (Suppl.): 425, 1993.
476. **Enbergs, A., A. Kleemann, A. Dorszewski, C. Vielhauer, H. Schulte, T. Budde, G. Breithardt and G. Assmann:** LDL/HDL-Quotient als Marker für das Ausmaß der koronaren Herzkrankheit. *Zeitschr. Kardiol.* 82 (Suppl.1): 89, 1993.
477. **Funke, H. and G. Assmann:** The rapid molecular diagnosis of genetic cardiovascular risk factors. *Current Opinion in Lipidology* 4: 453-460, 1993.
478. **Funke, H., A. von Eckardstein, P. H. Pritchard, A. E. Hornby, H. Wiebusch, C. Motti, M. R. Hayden, C. Dacet, B. Jacotot, U. Gerdes, O. Faergeman, J. J. Albers, N. Colleoni, A. Catapano, J. Frohlich, G. Assmann, M. Kleingunnewigk and A. Reckwerth:** Genetic and phenotypic heterogeneity in familial lecithin -cholesterol acyltransferase (LCAT) deficiency - 6 newly identified defective alleles further contribute to the structural heterogeneity in this disease. *J. Clin. Invest.* 91: 677-683, 1993.
479. **Goldbourt, U., S. Behar, H. Reicherreiss, J. Agmon, E. Kaplinsky, E. Graff, Y. Kishon, A. Caspi, J. Weisbort, L. Mandelzweig, E. Abinader, L. Aharon, S. Braun, D. David, M. Flich, Y. Friedman, N. Kristal, N. Leil, W. Markiewicz, A. Marmor, A. Palant, B. Pelled, B. Rabinowitz, L. Reisin, N. Roguin, T. Rosenfeld, Z. Schlesinger, S. Sclarovsky, L. Sherf, D. Tzivoni, I. Zahavi, M. Zion, D. Brunner, A. Fridensohn, J. Jafari, B. Ostfeld, S. Rochfleish, H. Schneider, S. Khalid, R. Narinsky, R. Rotzak, J. Vitrai, J. Pardu, S. Laniado, Y. Eshchar, A. Arditi, S. Botwin, M. Yahalom, A. Glusman, D. Motlak, J. Balkin, E. Barasch, J. Kellerman, M. Gueron, G. Assmann, P. Bauer, S. Eisenberg, L. H. Kuller, B. Modan, J. Schoenberger, H. Almog, A. Battler, Y. Baryehuda, S. Schwarz, S. Hiemstra, E. Heyman, K. Kehne, M. Snyder, M. Benderly and M. Goldberg:** Rationale and design of a secondary prevention trial of increasing serum high density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial). *Am. J. Cardiol.* 71: 909-915, 1993.
480. **Harms, F., U. Vogt, C. Griwatz, B. Brandt, G. Assmann and K. S. Zänker:** Is the differential polymerase chain reaction an adequate tool to evaluate prognostic parameters in breast cancer patients? *J. Cancer Res. Clin. Oncol.* 119 (2): 67, 1993.

481. **Heinrich, J., H. Funke, S. Rust, H. Schulte, R. Schonfeld, E. Kohler and G. Assmann:** Plasma-fibrinogen concentration and fibrinolysis are influenced by polymorphism at the beta-fibrinogen locus. *Thromb. Haemost.* 69: 970, 1993.
482. **Heinrich, J., H. Schulte and G. Assmann:** Oral contraceptives and variables of coagulation and fibrinolysis in an epidemiological study. *Gynecol. Endocrin.* 7, Suppl. 55-58, 1993.
483. **Heinrich, J., H. Schulte, R. Schonfeld, E. Kohler and G. Assmann:** Coagulation and fibrinolysis variables in myocardial infarction patients with and without changes on coronary angiography. *Thromb. Haemost.* 69: 801, 1993.
484. **Heinrich, J., A. von Eckardstein, H. Schulte, R. Schonfeld, E. Kohler and G. Assmann:** Changes in lipid-metabolism, hemostasis and fibrinolysis due to a low grade acute phase reaction in survivors of myocardial infarction. *Thromb. Haemost.* 69: 797, 1993.
485. **Huang, Y. D., A. von Eckardstein and G. Assmann:** Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma. *Arterioscler. Thromb.* 13: 445-458, 1993.
486. **Jaroß, W., H. Schulte, S. Bergmann, G. Assmann and DRECAN-Team:** KHK-Risikoprofil der arbeitenden Bevölkerung im Raum Dresden ein Jahr nach der "Wende" (DRECAN-Studie). In: *Diätetik und Arteriosklerose*, edited by H. Heinle, H. Schulte, and H. E. Schaefer. Braunschweig: Vieweg Verlag, 140-148, 1993.
487. **Jonas, A., A. von Eckardstein, L. Churgay, W. W. Mantulin and G. Assmann:** Structural and functional-properties of natural and chemical variants of apolipoprotein-A-I. *Biochim. Biophys. Acta* 1166: 202-210, 1993.
488. **Jonas, A., A. von Eckardstein, W. W. Mantulin and G. Assmann:** Structural and functional properties of apo A-I variants in reconstituted HDL. In: *Human Apolipoproteins Mutants III. Diagnosis and Treatment*, edited by C. R. Sirtori, G. Franceschini, and B. H. Brewer. Berlin, Heidelberg, New York: Springer Verlag, 53-56, 1993.
489. **Nofer, J. R., M. Walter, U. Seedorf and G. Assmann:** HDL3 modulates platelet aggregation by activation of protein kinase c. *Circulation* 88: 457, 1993.
490. **Petersen, G., H. J. Bauch, U. Wahrburg, H. Martin, H. Schulte and G. Assmann:** Untersuchungen zur Cholesterinsynthese und -absorption: Abhängigkeit der Parameter vom Apo E Polymorphismus sowie der alimentären Cholesterin- und Fettsäureaufnahme. In: *Diätetik und Arteriosklerose*, edited by H. Heinle, H. Schulte, and H. E. Schaefer. Braunschweig: Vieweg Verlag, 101, 1993.
491. **Rust, S., H. Funke and G. Assmann:** Mutagenically separated PCR (MS-PCR) - a highly specific one-step procedure for easy mutation detection. *Nucleic. Acids. Research.* 21: 3623-3629, 1993.
492. **Scheidemann, W., G. Assmann and H. J. Leps:** The unusual case - bronchial foreign-body in a trotting horse. *Prakt. Tierarzt* 74: 200, 1993.
493. **Schulte, H. and G. Assmann:** Primary prevention of coronary heart disease in the Federal Republic of Germany: Cost effectiveness analysis. In: *Lipid metabolism disorders and coronary heart disease*, edited by G. Assmann. München: MMV Medizin Verlag, 225-238, 1993. (auch in: *Drugs* 40, 33-37, 2012)
494. **Seedorf, U. and G. Assmann:** Methods for the diagnosis of disturbance in intracellular lipid metabolism. *Current Opinion in Lipidology* 4: 444-452, 1993.
495. **Seedorf, U., M. Raabe and G. Assmann:** Cloning, expression and sequences of mouse sterol-carrier protein-x-encoding cDNAs and a related pseudogene. *Gene* 123: 165-172, 1993.

496. **Seedorf, U., F. Skovby, V. Nickel, N. C. Christensen, M. Roskoss, L. Ose and G. Assmann:** A single homozygous missense mutation in the lipa gene causes cholesteryl ester storage disease. *Circulation* 88: 422, 1993.
497. **Szyperski, T., S. Scheek, J. Johansson, G. Assmann, U. Seedorf and K. Wüthrich:** NMR determination of the secondary structure and the 3-dimensional polypeptide backbone fold of the human sterol carrier protein-2. *FEBS Letters*. 335: 18-26, 1993.
498. **van den Maagdenberg, A. M. J. M., W. Wei, I. H. Debruijn, P. Deknijff, H. Funke, A. H. M. Smelt, J. A. G. Leuven, F. M. Vanthoof, G. Assmann, M. H. Hofker, L. M. Havekes and R. R. Frants:** Characterization of 5 new mutants in the carboxyl-terminal domain of human apolipoprotein-E - no cosegregation with severe hyperlipidemia. *Am. J. Hum. Genet.* 52: 937-946, 1993.
499. **Vogt, U., B. Brandt, F. Harms, C. Jackisch, G. Assmann and K. S. Zänker:** Gene amplification of the erbB family in breast cancer tissue. *Cancer Res.* 33: 1342, 1993.
500. **von Eckardstein, A., G. Castro, I. Wybranska, N. Theret, P. Duchateau, N. Duverger, J. C. Fruchart, G. Ailhaud and G. Assmann:** Interaction of reconstituted high density lipoprotein disks containing human apolipoprotein A-I (apoA-I) variants with murine adipocytes and macrophages - evidence for reduced cholesterol efflux promotion by apoA-I (Pro165 → Arg). *J. Biol. Chem.* 268: 2616-2622, 1993.
501. **von Eckardstein, A., J. Heinrich, H. Funke, H. Schulte, R. Schönfeld, E. Köhler, A. Steinmetz and G. Assmann:** Glutamine/Histidine polymorphism in Apo A-IV affects plasma concentrations of lipoprotein (a) and fibrin split products in coronary heart disease patients. *Arterioscler. Thromb. Vasc. Biol.* 13: 240-246, 1993.
502. **Y. D. Huang, von Eckardstein, A., S. L. Wu, N. Maeda and G. Assmann:** A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. *Proc Natl Acad Sci USA.* 91, 1834-1838, 1994
503. **von Eckardstein, A., A. Jonas, G. Castro, H. C. Fruchart, H. Funke and G. Assmann:** Structure-function relationships of apolipoprotein A-I variants. In: *Human apolipoprotein mutants III. Diagnosis and treatment*, edited by C. Sirtori, G. Franceschini, and H. B. Brewer. Berlin, Heidelberg: Springer Verlag, 257-266, 1993.
504. **von Eckardstein, A., M. Sandkamp, A. Dirkes-Kersting, J. Heinrich, D. Bänsch, H. Schulte and G. Assmann:** Coronary risk in women: potential role of age, lipoproteins, haemostasis, and hormones. In: *Hormones in Lipoprotein Metabolism*, edited by A. Steinmetz, J. Schneider, and H. Kaffarnik. Berlin: Springer Verlag, 115, 1993.
505. **Wahrburg, U., H. Martin, G. Petersen, M. Sandkamp, H. Schulte and G. Assmann:** Beeinflussbarkeit der Auswirkungen von Monoensäuren auf den Lipidstoffwechsel durch Nahrungscholesterin und Apolipoprotein E Polymorphismus. In: *Diätetik und Arteriosklerose*, edited by H. Heinle, H. Schulte, and H. E. Schaefer. Braunschweig: Vieweg Verlag, 54, 1993.
506. **Warnick, G. R., G. J. M. Boerma, G. Assmann, A. T. Endler, G. Gerique, A. M. Gotto, M. S. Graziani, U. Lippi, W. Patsch, W. F. Riesen, E. T. Leary, G. Hiller, R. Zerback and R. Leinberger:** Multicenter evaluation of reflotron(r) direct dry chemistry assay of high density lipoprotein cholesterol in venous and fingerstick specimens. *Clin. Chem.* 39: 271-277, 1993.
507. **Assmann, G. and B. J. Hunt:** Clinical chemistry and coagulation. *Current Opinion in Lipidology* 5: 391-394, 1994.
508. **Assmann, G. and U. Romberg:** Effekte von Celiprolol auf Blutdruck und Fettstoffwechsel. *Münchener Medizinische Wochenschrift* 136: 69-73, 1994.

509. **Assmann, G. and H. Schulte:** Prävention der KHK. *Medical Tribune, Koronare Herzkrankheit*, 34-38, 1994.
510. **Assmann, G. and H. Schulte:** Identification of individuals at high risk for myocardial infarction. *Atherosclerosis* 110: S11-S21, 1994.
511. **Assmann, G. and H. Schulte:** Ergebnisse der Prospektiven Cardiovasculären Münster (PROCAM) Studie. *Deutsches Ärzteblatt* 91A: 1963-1965, 1994.
512. **Assmann, G., H. Schulte and A. Von Eckardstein:** Epidemiological and clinical relevance of triglycerides and high density lipoprotein cholesterol. *Cardiovascular Risk Factors* 4: 101-110, 1994.
513. **Assmann, G., A. Von Eckardstein and P. Cullen:** The dyslipidemias in inborn errors of metabolism. *Springer Verlag* 1994.
514. **Berendes, E., M. Walter, T. Prien, G. Assmann and P. Lawin:** Digoxin like immunoreactive substance in critically ill patients. *Anesthesiology* 80: 1408-1409, 1994.
515. **Brandt, B., U. Vogt, F. Harms, U. Bosse, K. S. Zänker and G. Assmann:** Double-differential PCR for gene dosage estimation of erbB oncogenes in benign and cancer tissues, and comparison to cellular DNA content. *J. Exp. Clin. Cancer Res.* 13 (3): Suppl.1994.
516. **Brandt, B., U. Vogt and G. Assmann:** Prognostische Relevanz der Amplifikation der Onkogene c-erb B-2 und c-myc beim Mammakarzinom. *Laboratoriumsmedizin* 18: 255-259, 1994.
517. **Brandt, B., U. Vogt, A. Heinecke, U. Bosse, C. M. Schlotter, C. Jackisch, C. Griwatz, K. S. Zänker and G. Assmann:** Aberrations of the oncogenes erbB-1, erbB-2 and erbB-3 detected by differential polymerase chain reaction in breast cancer and benign breast disease. *Biol. Chem. Hoppe-Seyler* 375: 36, 1994.
518. **Brandt, B., U. Vogt, A. Heinecke, C. Jackisch, B. Bier, K. S. Zänker and G. Assmann:** Estimation of average gene copy number of erb B-1, erb B-2 and erb B-3 for prognosis in breast cancer. *Proc. Amer. Assoc. Cancer Res.* 1994.
519. **Brandt, B., U. Vogt, C. M. Schlotter, C. Jackisch, R. Werkmeister, M. Thomas, U. Bosse, G. Assmann and K. S. Zänker:** Prognostic relevance of aberrations of the erbB oncogenes in breast, ovarian, oral, and lung cancer: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. *J. Exp. Clin. Cancer Res.* 13 (3): Suppl.1994.
520. **Brüssel, T., A. Dirkes-Kersting and G. Assmann:** Laboranalytik in der Intensivmedizin. In: *Praxis der Intensivbehandlung*, edited by P. Lawin. Stuttgart, New York: Georg Thieme Verlag, 270-284, 1994.
521. **Budde, T., C. Fehtrup, E. Bösenberg, C. Vielhauer, A. Enbergs, H. Schulte, G. Assmann and G. Breithardt:** Plasma lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male-patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. *Arterioscler. Thromb.* 14: 1730-1736, 1994.
522. **Budde, T., C. Fehtrup, E. Bösenberg, C. Vielhauer, A. Enbergs, H. Schulte, G. Assmann and G. Breithardt:** Korrelation des Lipoprotein (a)-(Lp(a))-Serumspiegels mit Ausbreitung und Grad der Koronarläsionen bei Patienten mit koronarer Herzkrankheit. *Perfusion* 7, Supplement 1: 56-60, 1994.

523. **Enbergs, A., A. Kleemann, A. Dorszewski, C. Vielhauer, C. Fehtrup, T. Budde, H. Schulte, G. Assmann and G. Breithardt:** Bedeutung des LDL/HDL-Quotienten, der Triglyzeride und des Lipoprotein (a) in Bezug auf das Ausmaß der koronaren Herzkrankheit. *Perfusion* 7, Suppl. 1: 133-135, 1994.
524. **Funke, H., H. Wiebusch and G. Assmann:** Missense mutations in the human lipoprotein lipase gene appears to be frequently involved in the formation of common hypertriglyceridemia. *Eur. Heart J.* 15 Suppl: 419, 1994.
525. **Funke, H., H. Wiebusch, L. Fuer, S. Muntoni, H. Schulte and G. Assmann:** Identification of mutations in the cholesterol ester transfer protein in Europeans with elevated high density lipoprotein cholesterol. *Circulation* 90: 241, 1994.
526. **Gotto, A. M. G. Assmann, and R. Paoletti:** No deception in symposium supplement. *Brit. Med. J.* 308: 139, 1994.
527. **Greten, H., F. U. Beil, J. Schneider, P. Weisweiler, V. W. Armstrong, C. Keller, H. U. Klor, E. Vonhodenberg, G. Weidinger, H. Eskotter, L. Farber and G. Assmann:** Treatment of primary hypercholesterolemia - fluvastatin versus bezafibrate. *Am. J. Med.* 96: S 55-S 63, 1994.
528. **Griwatz, C., B. Brandt, G. Assmann and K. S. Zänker:** Detection of spreading carcinoma cells with oncogene erbB-2 expression by cytokeratin antibodies and RT-PCR in the peripheral blood. *J. Exp. Clin. Cancer Res.* 13 (3): Suppl.1994.
529. **Griwatz, C., B. Brandt, G. Assmann and K. S. Zänker:** An ultra sensitive technique for the enrichment of spreading carcinoma cells in peripheral blood. *Proc. Amer. Assoc. Cancer Res.* 1994.
530. **Heinrich, J., L. Balleisen, H. Schulte, G. Assmann and J. van de Loo:** Fibrinogen and factor VII in the prediction of coronary risk -results from the PROCAM study in healthy men. *Arterioscler. Thromb.* 14: 54-59, 1994.
531. **Heinrich, J., H. Schulte, R. Schönfeld, E. Köhler and G. Assmann:** Zusammenhang von Plasma-Viskosität und Schweregrad atherosklerotischer Veränderungen in koronaren, cerebralen und peripheren Gefäßen von KHK-Patienten. In: *Endothelfunktion und Arteriosklerose 8. Jahrestagung der Deutschen Gesellschaft für Arterioskleroseforschung*, edited by H. Heinle, H. Schulte, and H. K. Breddin. Stuttgart: W. Kohlhammer, 77-82, 1994.
532. **Heinrich, J., H. Schulte, A. Von Eckardstein, R. Schönfeld, E. Köhler and G. Assmann:** Assoziation von Fettstoffwechsel, Gerinnung und Fibrinolyse mit einer geringgradigen Akute-Phase-Reaktion bei Patienten mit koronarer Herzkrankheit. *Perfusion* 7: 13-16, 1994.
533. **Heyden, S., A. Von Eckardstein, H. Schulte, K. Schneider and G. Assmann:** Raised lipoprotein(a) in hypercholesterolemic black students compared to age-matched whites in North and South Carolina. *Internat. J. Epidemiol.* 23: 301-306, 1994.
534. **Huang, Y. D., A. Von Eckardstein, S. L. Wu, N. Maeda and G. Assmann:** A plasma lipoprotein containing only apolipoprotein E and with gamma-mobility on electrophoresis releases cholesterol from cells. *Proc. Natl. Acad. Sci. USA* 91: 1834-1838, 1994.
535. **Jaroß, W., G. Assmann, S. Bergmann, H. Schulte, P. H. Epping, T. Fraidt, J. Heinrich, H. Martin, S. Petersen, M. Sandkamp, B. Schottmann, B. Siegert, H. Thulin and U. Wahrburg:** Comparison of risk factors for coronary heart disease in Dresden and Munster - results of the DRECAN (Dresden cardiovascular risk and nutrition) study and the PROCAM (prospective cardiovascular Munster) study. *Eur. J. Epidemiol.* 10: 307-315, 1994.

536. **Lüttmann, S., A. Von Eckardstein, W. Wei, H. Funke, E. Kohler, R. W. Mahley and G. Assmann:** Electrophoretic screening for genetic variation in apolipoprotein C-III identification of a novel apo C-III variant, apo C-III (Asp 45 → Asn) in a Turkish patient. *J. Lipid Res.* 35: 1431-1440, 1994.
537. **Moennig, G., C. Vielhauer, H. Wiebusch, M. Luft, A. Enbergs, A. Dorszewski, S. Muntoni, H. Funke, H. Schulte, T. Budde, G. Assmann and G. Breithardt:** Genetische Variation der Lipoprotein Lipase und der hepatischen Triglyzeridlipase bei dyslipidmischen, koronarangiographierten Patienten. In: *Endothelfunktion und Arteriosklerose*, edited by H. Heinle, H. Schulte, and H. K. Breddin. Deutsche Gesellschaft für Arterioskleroseforschung, 144-148, 1994.
538. **Niessen-Dietrich, U., G. Simon, H. Blome, H. Schulte, A. Schmidt and G. Assmann:** Wirkungen eines Geh-, Lauf- und Krafttrainings auf Leistungsfähigkeit und Fettstoffwechselformparameter. *Sportmedizin* 45: 19-29, 1994.
539. **Raabe, M., U. Seedorf, G. Assmann and N. Maeda:** Development of a sterol carrier protein-2 gene targeting vector. *Futura* 2: 129-130, 1994.
540. **Ros, E., D. Zambon, C. Sanllehy, E. Casals, U. Seedorf and G. Assmann:** Enfermedad por depósito de colesterol (CESD) causada por la homocigosidad de una mutación en el ajuste del exón 8 del gen de la lipasa ácida lisosómica (LAL). *Clin. Invest. Arterioscler.* 6 (Suppl.) 68, 1994.
541. **Römling, R., A. Von Eckardstein, H. Funke, C. Motti, G. C. Fragiaco, G. Nosedá and G. Assmann :** A nonsense mutation in the apolipoprotein A-I gene is associated with high density lipoprotein deficiency and periorbital xanthelasmas. *Arterioscler. Thromb.* 14: 1915-1922, 1994.
542. **Schlotter, C. M., U. Bosse, U. Vogt, B. Brandt, G. Assmann and H. P. G. Schneider:** DNA image analysis and oncogene amplifications of EGFR, erbB-2, erbB-3 and c-myc in breast cancer. *J. Exp. Clin. Cancer Res.* 13 (3): Suppl.1994.
543. **Schulte, H. and G. Assmann:** 61 Prozent aller Infarkte bei ungünstigem Risikofaktorenprofil. *Ärzte-Zeitung, Forschung und Praxis* 181: 22, 1994.
544. **Seedorf, U., P. Brysch, T. Engel, K. Schrage and G. Assmann:** Sterol carrier protein-x is peroxisomal 3-oxoacyl Coenzyme-A thiolase with intrinsic sterol carrier and lipid transfer activity. *J. Biol. Chem.* 269: 21277-21283, 1994.
545. **Seedorf, U., S. Scheek, T. Engel, P. Brysch, T. Szyperski, K. Johansson, K. Wüthrich and G. Assmann:** Molecular analyses of sterol carrier protein 2: implications for intracellular sterol and phospholipid transport. *Eur. Heart. J.* 15 (Suppl.) 488, 1994.
546. **Seedorf, U., S. Scheek, T. Engel, C. Steif, H. J. Hinz and G. Assmann:** Structure-activity studies of human sterol carrier protein-2. *J. Biol. Chem.* 269: 2613-2618, 1994.
547. **Seedorf, U., F. Skovsky, V. Nickel, H. C. Christensen, M. Roskoss, P. Brysch, E. Ros, L. Ose and G. Assmann:** Molecular characterization of the underlying defects in two patients with cholesteryl ester storage disease. *Eur. Heart. J.* 15 (Suppl.) 419, 1994.
548. **Seedorf, U., M. Walter and G. Assmann:** Diagnosis of Smith-Lemli-Opitz syndrome. *New Engl. J. Med.* 330: 1686-1687, 1994.
549. **Thomas, M., B. Brandt, M. von Eiff, F. Klinke, U. Bosse and G. Assmann:** Detection of oncogene amplification of the erbB-/myc family in non-small cell lung cancer with differential PCR: Implications for further studies. *J. Exp. Clin. Cancer Res.* 13 (3): Suppl., 1994.
550. **Vogt, U., B. Brandt, F. Harms, C. Jackisch, B. Bier, G. Assmann and K. S. Zänker:** Is there a genomic crosstalk of erbB-2 and erbB-3 in breast cancer with prognostic relevance? *Breast Cancer Research and Treatment* 24: 141, 1994.

551. **von Eckardstein, A. and G. Assmann:** Neue Strategien bei der Diagnostik von Fettstoffwechselstörungen. *MTA* 9: 878-886, Teil 1, 1994.
552. **von Eckardstein, A. and G. Assmann:** Neue Strategien bei der Diagnostik von Fettstoffwechselstörungen. *MTA* 9: 978-983, Teil 2, 1994.
553. **von Eckardstein, A., H. Funke, A. Chirazi, C. T. Chenhaudenschild, H. Schulte, R. Schonfeld, E. Kohler, S. Schwarz, A. Steinmetz and G. Assmann:** Sex-specific effects of the glutamine/histidine polymorphism in apolipoprotein A-IV on high density lipoprotein metabolism. *Arterioscler. Thromb.* 14: 1114-1120, 1994.
554. **von Eckardstein, A., Y. Huang and G. Assmann:** Physiological role and clinical relevance of high density lipoprotein subclasses. *Curr. Opin. Lipidol.* 5: 404-416, 1994.
555. **von Eckardstein, A., M. R. Malinow, B. Upson, J. Heinrich, H. Schulte, R. Schonfeld, E. Kohler and G. Assmann:** Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. *Arterioscler. Thromb.* 14: 460-464, 1994.
556. **Wahrburg, U., H. Martin, S. Bergmann, H. Schulte, W. Jaroß, G. Assmann and DRECAN-Team:** Veränderungen der Ernährungsgewohnheiten und ihre möglichen Beziehungen zu KHK-Risikofaktoren bei berufstätigen Personen im Raum Dresden: Ergebnisse der DRECAN-Studie. *Perfusion* 7, Supplement 1: 99-101, 1994.
557. **Wahrburg, U., H. Martin, H. Schulte, T. Walek and G. Assmann:** Effects of 2 kinds of decaffeinated coffee on serum lipid profiles in healthy young adults. *Eur. J. Clin. Nutr.* 48: 172-179, 1994.
558. **Walter, M., U. Gerdes, U. Seedorf and G. Assmann:** The high density lipoprotein-induced and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. *Biochem. Biophys. Res. Comm.* 205: 850-856, 1994.
559. **Walter, M., S. Kerber, C. Fehtrup, U. Seedorf, G. Breithardt and G. Assmann:** Characterization of atherosclerosis in a patient with familial high density lipoprotein deficiency. *Atherosclerosis* 110: 203-208, 1994.
560. **Walter, M., S. Kerber, C. Fehtrup, U. Seedorf, G. Breithardt and G. Assmann:** Koronarangiographie und intravaskuläre Ultraschalluntersuchung bei einem 60jährigen Patienten mit familiärer HDL-Defizienz (Tangier-Krankheit). *Z. Kardiol.* 83: 381-385, 1994.
561. **Walter, M., H. Reinecke, U. Gerdes, J.-R. Nofer, U. Seedorf and G. Assmann:** Apolipoprotein A-I activates phospholipase D. *Eur. Heart. J.* 15: 49, 1994.
562. **Werkmeister, R., B. Brandt, U. Vogt, G. Assmann and U. Joos:** Oncogene amplification in oral squamous cell carcinoma (OSCC). *J. Exp. Clin. Cancer Res.* 13 (3): Suppl.1994.
563. **Assmann, G., A. Berg, F. Bidlingmaier, H. K. Breddin, G. Breithardt, H. D. Faulhaber, H. Von Frankenberg, U. Gleichmann, M. Halhuber, M. Hanefeld, W. Jaross, U. Keil, J. Kruse-Jarres, H. Oberritter, E. E. Pudiel, H. E. Schaefer, H. P. Schuster and H. Wieland:** Lipiddiagnostik zur Prävention der koronaren Herzkrankheit. *Deutsches Ärztebl.* 92: 749-750, 1995.
564. **Assmann, G., B. Brandt and K. S. Zänker:** Research in gene diagnostics of cancer disease. *Gene* 159: IX-X, 1995.
565. **Assmann, G., H. Schulte and K. D. Henke:** Kosten-Wirksamkeits-Analyse einer Interventionsstrategie zur Prävention der koronaren Herzkrankheit in der Bundesrepublik Deutschland. In: *Pathophysiologie, Diagnostik, Therapie und Prävention der Dyslipoproteinämien*, edited by P. Schwandt and W. O. Richter. Stuttgart: Schattauer Verlagsges. mbH, 738-745, 1995.

566. **Assmann, G., H. Schulte, W. Oberwittler and W. H. Hauss:** New aspects in the prediction of coronary heart disease. In: *Atherosclerosis VII, Proceedings of the 7th International Atherosclerosis Symposium, Melbourne*, edited by N. H. Fidge and P. J. Nestel. Elsevier Science Publishers, 19-24, 1995.
567. **Assmann, G., H. Schulte and A. von Eckardstein:** Epidemiological and clinical relevance of triglycerides and high density lipoprotein cholesterol. *Cardiovasc. Risk Factors* 5: 4-14, 1995.
568. **Assmann, G. and U. Seedorf:** Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. In: *The Metabolic and Molecular Basis of Inherited Disease*, edited by C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle. New York: McGraw-Hill, 2563-2587, 1995.
569. **Assmann, G., A. von Eckardstein and H. B. J. Brewer:** Familial high density lipoprotein deficiency: Tangier disease. In: *The Metabolic and Molecular Basis of Inherited Disease*, edited by C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle. New York: McGraw-Hill, 2053-2072, 1995.
570. **Assmann, G., A. von Eckardstein and H. Funke:** Role of apolipoprotein and lipid transfer enzyme mutants in high density lipoprotein metabolism. In: *Advances in lipoprotein and atherosclerosis research, diagnostics and treatment*, edited by M. Hanefeld. Jena: Gustav Fischer Verlag, 126-134, 1995.
571. **Assmann, G., A. von Eckardstein, and H. Funke:** Störungen im Stoffwechsel der high density lipoproteine. In: *Pathophysiologie, Diagnostik, Therapie und Prävention der Dyslipoproteinämien*, edited by P. Schwandt and W. O. Richter. Stuttgart: Schattauer Verlagsges. mbH, 227-249, 1995.
572. **Assmann, G., A. von Eckardstein and P. Cullen:** The Dyslipidemias. In: *Inborn Metabolic Diseases*, edited by J. Fernandes, J. M. Saudubray, and G. van de Berghe. Berlin Heidelberg New York London Paris Tokyo Hong Kong Barcelona Budapest: Springer Verlag, 261-268, 1995.
573. **Assmann, G., A. von Eckardstein, Y. Huang and S. Wu:** A lipoprotein containing only apoE is present in normal and HDL-deficient plasmas and releases cholesterol from cells. In: *Atherosclerosis X*, edited by F. P. Woodford, J. Davignon, and A. Sniederma. Amsterdam: Elsevier Science, 662-665, 1995.
574. **Bolibar, I., S. Thompson, A. von Eckardstein, M. Sandkamp, G. Assmann, on behalf of the ECAT Angina pectoris Study Group:** Dose-response relationships of serum lipid measurements with the extent of coronary stenosis: strong, independent, and comprehensive. *Arterioscler. Thromb. Vasc. Biol.* 15: 1035-1042, 1995.
575. **Brandt, B., F. Gebhardt, U. Vogt, D. Schuster, J. Beck, A. Möller, K. S. Zänker and G. Assmann:** Deletions at the exon 1/intron 1 boundary of the EGF-R gene and primary breast cancer progression. *J. Cancer Res. Clin. Oncol.* 119: 13, 1995.
576. **Brandt, B., U. Vogt, F. Harms, U. Bosse, K. S. Zänker and G. Assmann:** Double-differential PCR for gene dosage estimation of erbB oncogenes in benign and cancer tissues, and comparison to cellular DNA content. *Gene* 159: 29-34, 1995.
577. **Brandt, B., U. Vogt, C. M. Schlotter, C. Jackisch, R. Werkmeister, M. Thomas, U. Bosse, G. Assmann and K. S. Zänker:** Prognostic relevance of aberrations of the erbB oncogenes in breast, ovarian, lung cancer: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. *Gene* 159: 35-42, 1995.
578. **Deng, M. C., M. Erren, L. Kammerling, F. Gunther, A. Fahrenkamp, G. Assmann, G. Breithardt and H. H. Scheld:** The relation of interleukin-6, tumor necrosisfactor-alpha, IL-2, and IL-2 receptor levels to cellular rejection, allograft dysfunction, and clinical events early after cardiac transplantation. *Transplantation* 60: 1118-1124, 1995.

579. **Deng, M. C., M. Wiedner, M. Erren, T. Mollhoff, G. Assmann and H. H. Scheld:** Arterial and venous cytokine response to cardiopulmonary bypass for low-risk cabg and relation to hemodynamics. *Eur. J. Cardio-Thoracic Surg.* 9: 22-29, 1995.
580. **Funke, H. and G. Assmann:** The low down on lipoprotein lipase. *Nat. Gen.* 10: 6-7, 1995.
581. **Funke, H., H. Wiebusch, S. Rust and G. Assmann:** Molecular genetics approach to lipoprotein metabolism disorders. In: *HDL deficiency and atherosclerosis*, edited by G. Assmann. Dordrecht: Kluwer Academic Publishers, 1-15, 1995.
582. **Glomset, J. A., G. Assmann, E. Gjone and K. R. Norum:** Lecithin:Cholesterol acyltransferase deficiency and fish eye disease. In: *The Metabolic and Molecular Basis of Inherited Disease*, edited by C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle. New York: McGraw-Hill, 1933-1951, 1995.
583. **Griwatz, C., B. Brandt, G. Assmann and K. S. Zänker:** An immunological enrichment method for epithelial cells from peripheral blood. *J. Immunol. Meth.* 183: 251-265, 1995.
584. **Griwatz, C., B. Brandt, G. Assmann and K. S. Zänker:** Detection of rare oncogene mRNA transcripts with quantitative RT-PCR after combined density gradient immunomagnetic separation. *Proc. Amer. Assoc. Cancer Res.* 36: 78, 1995.
585. **Heinrich, J. and G. Assmann:** Fibrinogen and cardiovascular risk. *J. Cardiovasc. Risk* 2: 197-205, 1995.
586. **Heinrich, J., T. Budde and G. Assmann:** Mutation in the factor V gene and the risk of myocardial infarction (letter). *N. Engl. J. Med.* 333: 881, 1995.
587. **Heinrich, J., H. Funke, S. Rust, H. Schulte, R. Schönfeld, E. Köhler and G. Assmann:** Impact of polymorphisms in the alpha and beta-fibrinogen gene on plasma fibrinogen concentrations of coronary heart disease patients. *Thromb. Res.* 77: 209-215, 1995.
588. **Heinrich, J., H. Schulte, R. Schönfeld, E. Köhler and G. Assmann:** Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. *Thromb. Haemostasis* 73: 374-379, 1995.
589. **Huang, Y., A. Von Eckardstein, S. Wu and G. Assmann:** Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. *J. Clin. Invest.* 96: 2693-2701, 1995.
590. **Huang, Y., A. Von Eckardstein, S. W, and G. Assmann:** Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. *Arterioscler. Thromb. Vasc. Biol.* 15: 1412-1418, 1995.
591. **Huang, Y., A. Von Eckardstein, S. Wu, C. Langer and G. Assmann:** Generation of pre- β 1-hdl and conversion into α -hdl evidence for disturbed hdl conversion in tangier disease. *Arterioscler. Thromb. Vasc. Biol.* 15: 1746-1754, 1995.
592. **Junker, R., B. Brandt, A. Semjonow, C. Zechel and G. Assmann:** Vergleich von 12 verschiedenen Assays zur Messung von freiem PSA und Gesamt PSA. *Anticancer Res.* 15: 75, 1995.
593. **Kuivenhoven, J. A., E. J. G. M. Van Voorst tot Voorst, H. Wiebusch, S. Marcovina, H. Funke, G. Assmann, P. H. Pritchard and J. J. P. Kastelein:** A unique genetic and biochemical presentation of fish-eye disease. *J. Clin. Invest.* 96: 2783-2791, 1995.
594. **Langner, J., B. Brandt, S. Leibel and G. Assmann:** One-step separation of a hydrophilic and ipophilic isoform of the tumor-associated DF3-antigen with immobilized artificial membrane HPLC (IAM.PC HPLC). *J. Exp. Clin. Cancer Res.* 14: 293-300, 1995.

595. **Lüttmann, S., A. Von Eckardstein, W. Weng, H. Funke and G. Assmann:** Strukturdefekte des Apolipoproteins C-III: Häufigkeit und Bedeutung für den Lipidstoffwechsel. *Nieren- und Hochdruckkrankheiten* 24: 41-43, 1995.
596. **Modan, B., G. Assmann, P. Bauer, L. H. Kuller and J. Schoenberger:** Statement of the international review and advisory board of the bezafibrate infarction prevention study (letter). *Circulation* 92: 1675, 1995.
597. **Muntoni, S., H. Wiebusch, H. Funke, E. Ros, U. Seedorf and G. Assmann:** Homozygosity for a splice junction mutation in exon 8 of the gene encoding lysosomal acid lipase in a Spanish kindred with cholesterol ester storage disease (CESD). *Hum. Gen.* 95: 491-494, 1995.
598. **Navalesi, R., R. Miccoli, L. Odoguardi, H. Funke, A. von Eckardstein, H. Wiebusch and G. Assmann:** Genetically determined absence of HDL-cholesterol and coronary atherosclerosis. *Lancet* 346: 708-709, 1995.
599. **Nofer, J. R., A. von Eckardstein and G. Assmann:** Mannitol prevents methionine sulfoxidation-mediated electrophoretic heterogeneity of apolipoprotein A-I. *Biomed. Chromatog.* 9: 28-31, 1995.
600. **Nofer, J. R., A. von Eckardstein, H. Wiebusch, W. Weng, H. Funke, H. Schulte, E. Köhler, and G. Assmann:** Screening for naturally occurring apolipoprotein A-I variants: apo A-I(Lys107->0) ist associated with low HDL-cholesterol levels in men but not in women. *Hum. Gen.* 96: 177-182, 1995.
601. **Nofer, J. R., M. Walter, B. Kehrel, U. Seedorf and G. Assmann:** HDL(3) activates phospholipase D in normal but not in glycoprotein IIb/IIIa-deficient platelets. *Biochem. Biophys. Res. Commun.* 207: 148-154, 1995.
602. **Raabe, M., U. Seedorf, N. Maeda and G. Assmann:** The sterol carrier protein 2 / sterol carrier protein x-deficient mouse: a new transgenic mouse model for atherosclerosis research. *Eur. Heart. J.* 16: 27, 1995.
603. **Schulze-Bahr, E., W. Haverkamp, H. Wiebusch, H. Schulte, M. Hördt, M. Borggrefe, G. Breithardt, G. Assmann and H. Funke:** Molecular analysis at the Harvey Ras-1 gene in patients with long QT syndrome. *J. Mol. Med.* 73: 565-569, 1995.
604. **Seedorf, U., P. Brysch, T. Engel, S. Scheek, M. Raabe, M. Fobker, T. Szyperski, K. Wüthrich, N. Maeda and G. Assmann:** Intracellular cholesterol transport. In: *HDL Deficiency and Atherosclerosis*, edited by G. Assmann. Dordrecht, Boston, London: Kluwer Academic Publishers, 43-52, 1995.
605. **Seedorf, U., P. Brysch, T. Engel, S. Scheek, M. Raabe, T. Szyperski, K. Wüthrich, N. Maeda and G. Assmann:** Cholesterol transport mediated by sterol carrier protein 2. In: *Excerpta Medica, Atherosclerosis X*, edited by F. P. Woodford, J. Davignon, and A. Sniderman. Amsterdam: Elsevier Science B.V. 430-437, 1995.
606. **Seedorf, U., T. Engel, G. Assmann, F. Leenders and J. Adamski:** Intrinsic sterol and phosphatidylcholine transfer activities of 17 β -hydroxysteroid dehydrogenase type IV. *J. Steroid Biochem. Molec. Biol.* 55: 549-553, 1995.
607. **Seedorf, U., M. Fobker, R. Voss, K. Meyer, F. Kannenberg, D. Meschede, K. Ullrich, A. Benninghoven and G. Assmann:** Smith-Lemli-Opitz syndrome diagnoses by using time-of-flight secondary-ion mass spectrometry. *Clin.Chem.* 41: 548-552, 1995.
608. **Seedorf, U., M. Raabe, M. Fobker, F. Kannenberg, P. Brysch, T. Engel, N. Maeda and G. Assmann:** The asp pathway - evidence for a positive feedback loop in human adipocytes. *Circulation* 92: 2036, 1995.

609. **Seedorf, U., M. Raabe, M. Fobker, F. Kannenberg, P. Brysch, T. Engel, N. Maeda and G. Assmann:** Reduced absorption and hepatic esterification of dietary cholesterol in mice lacking sterol carrier protein-2 and sterol carrier protein-x. *Circulation* 92: 2037, 1995.
610. **Seedorf, U., H. Wiebusch, S. Muntoni, N. C. Christensen, F. Skovby, V. Nickel, M. Roskos, H. Funke and G. Assmann:** A novel variant of lysosomal acid lipase (Leu336->Pro) associated with acid lipase deficiency and cholesterol ester storage disease. *Arterioscler. Thromb. Vasc. Biol.* 15: 773-778, 1995.
611. **von Eckardstein, A., Y. Huang and G. Assmann:** Struktur, Funktion und Stoffwechsel von High Density Lipoprotein-Subklassen. In: *Arteriosklerose zerebraler Gefäße*. edited by H. Heinle, H. Schulte, and H. Kaffarnik. Deutsche Gesellschaft für Arterioskleroseforschung, 76-90, 1995.
612. **von Eckardstein, A., Y. Huang and G. Assmann:** Role of high density lipoprotein subclasses in reverse cholesterol transport. In: *HDL Deficiency and Atherosclerosis*, edited by G. Assmann. Dordrecht, Boston, London: Kluwer Academic Publishers, 17-25, 1995.
613. **von Eckardstein, A., Y. Huang, M. Raabe, C. Langer, S. Wu, U. Seedorf, N. Maeda and G. Assmann:** Reverse cholesterol transport in normal, apolipoprotein-AI and apolipoprotein E-deficient mice. *Circulation* 92: 2661, 1995.
614. **von Eckardstein, A., Y. Huang, S. Wu, H. Funke, G. Nosedá and G. Assmann:** Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency. *Arterioscler. Thromb. Vasc. Biol.* 15: 691-703, 1995.
615. **von Eckardstein, A., Y. Huang, S. Wu, A. S. Sarmadi, S. Schwarz, A. Steinmetz, and G. Assmann:** Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. *Arterioscler. Thromb. Vasc. Biol.* 15: 1755-1763, 1995.
616. **Wahrburg, U. and G. Assmann:** Fettstoffwechselstörungen, Herz und Kreislauf. In: *Ernährungsmedizin*, edited by H.-K. Biesalski, P. Fürst, H. Kasper, R. Kluthe, W. Pölerl, C. Puchstein, and H. B. Stähelin. Stuttgart, New York: Georg Thieme Verlag 270-288, 1995.
617. **Wahrburg, U., H. Martin, S. Bergmann, H. Schulte, W. Jaross, G. Assmann and DRECAN-Team:** Dietary habits in Eastern Germany. Changes due to German reunification and their relations to serum lipids: results of the DRECAN-Study. *Nutr. Metab. Cardiovasc. Dis.* 5: 201-210, 1995
618. **Walek, T., A. Von Eckardstein, H. Schulte and G. Assmann:** Effect of hypertriglyceridaemia on lipoprotein (a) serum concentrations. *Eur. J. Clin. Invest.* 25: 311-316, 1995.
619. **Walter, M., H. Reinecke, J. R. Nofer, U. Seedorf and G. Assmann:** HDL3 stimulates multiple signaling pathways in human skin fibroblasts. *Arterioscler. Thromb. Vasc. Biol.* 15: 1975-1986, 1995.
620. **Wiebusch, H., P. Cullen, J. S. Owen, D. Collins, P. S. Sharp, H. Funke and G. Assmann:** Deficiency of lecithin, cholesterol acyltransferase due to compound heterozygosity of 2 novel mutations (Gly33Arg and 30 bp Ins) in the *Icat* gene. *Hum. Molec. Genet.* 4: 143-145, 1995.
621. **Wiebusch, H., J.-R. Nofer, A. Von Eckardstein, H. Funke, U. Wahrburg, H. Martin, E. Köhler and G. Assmann.** Electrophoretic screening for human apolipoprotein C-II variants: repeated identification of apolipoprotein C-II (K19T). *J. Mol. Med.* 73: 373-378, 1995.
622. **Assmann, G. and P. Cullen:** Erkennung und Behandlung von Fettstoffwechselstörungen. *Deutsches Ärztebl.* 93: 1-12, 1996.
623. **Assmann, G., P. Cullen, J. Heinrich and H. Schulte:** Hemostatic variables in the prediction of coronary risk: results of the 8-year follow-up of healthy men in the Münster Heart Study (PROCAM). *Isr. J. Med. Sci* 32: 364-370, 1996.

624. **Assmann, G., P. Cullen and H. Schulte:** HRT, plasma risk factors and cardiovascular disease. *European Menopause Journal* 3: 203-208, 1996.
625. **Assmann, G., H. Schulte and A. von Eckardstein:** Hypertriglyceridemia and elevated levels of lipoprotein (a) are risk factors for major coronary events in middle-aged men. *Am. J. Cardiol.* 77: 1179-1184, 1996.
626. **Assmann, G., H. Schulte, A. von Eckardstein and Y. Huang:** High density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. *Atherosclerosis* 124: S11-S20, 1996.
627. **Bijvoet, S. M., H. Wiebusch, Y. Ma, P. W. A. Reymer, T. Bruin, H. D. Bakker, H. Funke, G. Assmann, M. R. Hayden and J. J. P. Kastelein:** Compound heterozygosity for a novel defect in the lipoprotein lipase gene (Asp250Asn, Ser251Cys) resulting in lipoprotein lipase deficiency. *Netherlands J. Med.* 49: 189-195, 1996.
628. **Brandt, B., C. Griwatz, S. Heidl, G. Assmann and K. S. Zänker:** Isolation of single cells and coherent cell sheets from peripheral blood of cancer patients with reference to shedded cytokeratin 8/18 and erbB-2-oncoprotein. *Proc. Amer. Assoc. Cancer Res.* 37: 80, 1996.
629. **Brandt, B., C. Griwatz, G. Assmann and K. S. Zänker:** Detection of the metastatic potential of blood-born and immuno-magnetically enriched epithelial cells by quantitative erbB-2RT-PCR. *Clin. Exp. Metastasis* 14: 399-408, 1996.
630. **Brandt, B., S. Heidl, C. Griwatz, R. Junker, C. Jackisch, G. Assmann and K. S. Zänker:** C-erbB-2 positive cells and cell clusters in breast cancer patients peripheral blood. *Breast Cancer Res. Treatm.* 37: 441, 1996.
631. **Brandt, B., R. Junker, C. Griwatz, S. Heidl, O. Brinkmann, A. Semjonow, G. Assmann, and K. S. Zänker:** Isolation of prostate-derived single cells and cell clusters from human peripheral blood. *Cancer Res.* 56: 4556-4561, 1996.
632. **Brandt, B., R. Junker, C. Griwatz, S. Heidl, O. Brinkmann, A. Semjonow, G. Assmann, and K. S. Zänker:** Enrichment of prostate cancer cells and cell clusters for single cell analysis from peripheral blood. *Clin. Exp. Metastasis* 14: 93, 1996.
633. **Brandt, B., M. Thomas, M. von Eiff and G. Assmann:** Immunophenotyping of lymphocytes obtained by bronchoalveolar lavage: description of an all-purpose tricolor flow cytometric application. *J. Immunol. Meth.* 194: 95-102, 1996.
634. **Brandt, B., U. Vogt, A. Heinecke, C. Jackisch, K. S. Zänker, and G. Assmann:** Relevance of aberrations of the erbB oncogenes in breast cancer diagnosis and therapy. *Clin. Exp. Metastasis* 14: 93, 1996.
635. **Contacos, C., D.R. Sullivan, K.A. Rye, H. Funke and G. Assmann:** A new molecular defect in the lecithin:cholesterol acyltransferase (LCAT) gene-associated with fish eye disease. *J. Lipid Res.* 37: 35-44, 1996.
636. **Cullen, P., A. Cignarella, A. Von Eckardstein, S. Mohr and G. Assmann:** Phenotype-dependent differences in apolipoprotein E gene expression and protein secretion in human monocyte-derived macrophages. *Circulation* 94: 1589, 1996.
637. **Cullen, P., H. Schulte and G. Assmann:** Lipidologie - Umfassendes Risikokonzept. *Münch. Med. Wschr.* 138: 447-450, 1996.
638. **Cullen, P., A. Von Eckardstein and G. Assmann:** Genetic and acquired abnormalities of lipoprotein metabolism. *Cardiovasc. Risk Factors* 6: 99-121, 1996.

639. **Deng, M.C., M. Erren, A. Lütgen, P.I. Zimmermann, B. Brisse, W. Schmitz, G. Assmann, G. Breithardt and H. Scheld:** Interleukin-6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure. *Int. J. of Cardiology* 57: 129-134, 1996.
640. **Junker, R., B. Brandt, A. Semjonow and G. Assmann:** Measurement of prostate specific antigen: No advantage by means of ultrasensitive assays. *J. Natl. Cancer Inst.* 88: 1594-1595, 1996.
641. **Kuivenhoven, J. A., H. Wiebusch, P. H. Pritchard, H. Funke, R. Benne, G. Assmann and J. J. P. Kastelein:** An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish eye disease). *J. Clin. Invest.* 98: 358-364, 1996.
642. **Meyer, K., M. Fobker, U. Christians, M. Erren, K. F. Sewing, G. Assmann and A. Benninghoven:** Characterization of glucuronidated phase II metabolites of the immunosuppressant cyclosporine in urine of transplant patients using time-of-flight secondary-ions mass spectrometry. *Drug Metab. and Dispos.* 24: 1151-1154, 1996.
643. **Miccoli, R., A. Bertolotto, N. Navalesi, L. Odoguardi, A. Boni, J. Wessling, H. Funke, H. Wiebusch, A. Von Eckardstein and G. Assmann:** Compound heterozygosity for a structural apolipoprotein A-I-variant - ApoA-I (L141R) Pisa - and an Apolipoprotein A-I null allele in patients with density lipoprotein deficiency, corneal opacifications, and coronary heart disease. *Circulation* 94: 1622-1628, 1996.
644. **Muntoni, S., H. Wiebusch, H. Funke, U. Seedorf, M. Roskos, H. Schulte, K. Saku, K. Arakawa and G. Assmann:** A missense mutation (Thr6Pro) in the lysosomal acid lipase (LAL) gene is present with a high frequency in three different ethnic populations: impact on serum lipoprotein concentrations. *Hum. Genet* 97: 265-267, 1996.
645. **Nofer, J. R., M. Tepel, B. Kehrel, M. Walter, U. Seedorf, G. Assmann and W. Zidek:** High density lipoproteins enhance the Na⁺/H⁺ antiport in human platelets. *Thromb. Haemost.* 75: 635-641, 1996.
646. **Owen, J. S., H. Wiebusch, P. Cullen, G. F. Watts, V. L. Lima, H. Funke and G. Assmann:** Complete deficiency of plasma lecithin:cholesterol acyltransferase (LCAT) activity due to a novel homozygous mutation (Gly30Ser) in the LCAT gene. *Hum. Mutation* 8: 79-82, 1996.
647. **Raabe, M., T. Engel, F. Kannenberg, N. Maeda, R. A. Wanders, G. Assmann and U. Seedorf:** Reduced absorption and hepatic esterification of dietary-cholesterol is secondary to a block in peroxisomal beta-oxidation in mice lacking sterol carrier protein-2 and sterol carrier protein-x. *Circulation* 94: 2717, 1996.
648. **Raabe, M., U. Seedorf, Hameister and G. Assmann:** Structure and chromosomal assignment of the murine sterol carrier protein 2 gene and two related pseudogenes by in situ hybridization. *Cytogenet. Cell Genet.* 73: 279-281, 1996.
649. **Raabe, M., R. A. Wanders, T. Engel, P. Brysch, M. Fobker, F. Kannenberg, G. Assmann and U. Seedorf:** Knockout of murine sterol carrier protein 2 gene causes a Refsum disease-like phenotype. *Molecular. Biology of the Cell* 7: 2886, 1996.
650. **Seedorf, U., H. Wiebusch, S. Muntoni, E. Mayatepek, H. Funke and G. Assmann:** Wolman disease due to homozygosity for a novel truncated variant of lysosomal acid lipase (351Insa) associated with complete in situ acid lipase deficiency. *Circulation* 94: 196, 1996.
651. **Semjonow, A., F. Oberpenning, B. Brandt, G. Assmann and L. Hertle:** Gefahren durch unterschiedliche Bestimmungsverfahren des prostataspezifischen Antigens. *Urologe (B)* 36: 35-43, 1996.

652. **Tepel, M., S. Heidenreich, H. Schlüter, A. Beinlich, J. R. Nofer, M. Walter, G. Assmann, and W. Zidek:** Diadenosine phosphates induce trans-plasma membrane Ca^{2+} influx in cultured glomerular mesangial cells. *Eur. J. Clin. Invest.* 26: 1077-1084, 1996.
653. **Tepel, M., S. Löwe, J. R. Nofer, G. Assmann, H. Schlüter and W. Zidek:** Diadenosine phosphates induce Ca^{2+} influx in human fibroblasts. *Biochim. Biophys. Acta* 1312: 145-150, 1996.
654. **von Eckardstein, A. and G. Assmann:** Role of ApoA-IV and its genetic polymorphisms for reverse cholesterol transport, hemostasis and coronary heart disease. In: *Nutrition, Genetics, and Heart Disease*, edited by G. A. Bray and D. H. Ryan. Baton Rouge, London: Louisiana State University Press, 198-211, 1996.
655. **von Eckardstein, A., Y. Huang and G. Assmann:** Uptake transfer and esterification of cell-derived cholesterol in plasma of patients with familial HDL deficiency. *Z. Gastroenterol* 36: 143-144, 1996.
656. **von Eckardstein, A., Y. Huang, S. Wu and G. Assmann:** Role of apoE for reverse cholesterol transport. In: *Nutrition, Genetics, and Heart Disease*, edited by G. A. Bray and D. H. Ryan. Baton Rouge, London: Louisiana State University Press, 189-197, 1996.
657. **von Eckardstein, A., M. Jauhiainen, Y. Huang, J. Metso, C. Langer, P. Pussinen, S. Wu, C. Ehnholm and G. Assmann:** Phospholipid transfer protein mediated conversion of high density lipoproteins (HDL) generates pre β 1-HDL. *Biochim. Biophys. Acta* 1301: 255-262, 1996.
658. **von Eckardstein, S., A. von Eckardstein, H. G. Bender, H. Schulte and G. Assmann:** Elevated low density lipoprotein-cholesterol in women with polycystic ovary syndrome. *J. Gynecol Endocrin* 10: 311-318, 1996.
659. **Walter, M., H. Reinecke, U. Gerdes, J. R. Nofer, G. Höbbel, U. Seedorf and G. Assmann:** Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease. Evidence for the involvement of phosphatidylcholine breakdown in HDL-mediated cholesterol efflux mechanisms. *J. Clin. Invest.* 98: 2315-2323, 1996.
660. **Wiebusch, H., H. Funke, T. Bruin, H. Bucher, A. Von Eckardstein, J. J. P. Kastelein and G. Assmann:** Compound heterozygosity for a known (D250N) and a novel (E410K) missense mutation in the c-terminal domain of lipoprotein lipase causes familial chylomicronemia. *Hum. Mutat.* 8: 381-383, 1996.
661. **Wiebusch, H., H. Funke, S. Santer, W. Richter and G. Assmann:** A novel missense (Glu163Gly) mutation in the catalytic subunit of lipoprotein lipase causes familial chylomicronemia. *Hum. Mut.* 8: 392-396, 1996.
662. **Wiebusch, H., S. Muntoni, F. Lu, H. Funke, U. Seedorf and G. Assmann:** A novel missense mutation (Gly2Arg) in the human lysosomal acid lipase gene is found in individuals with and without cholesterol ester storage disease (CESD). *J. Clin. Genet.* 50: 106-107, 1996.
663. **Wronska-Nofer, T., W. Laurmann, J. R. Nofer, U. Seedorf, M. Walter and G. Assmann:** Carbon disulfide-induced modification and cytotoxicity of low-density lipoproteins. *Toxicol. in Vitro* 10: 423-429, 1996.
664. **Young, P., H. Wiebusch, F. Stögbauer, B. Ringelstein, G. Assmann and H. Funke:** Four frequently observed polymorphisms in the 3'UTR of human peripheral myelin protein 22 (PMP22): Identification of different haplotypes. *Clin. Genet.* 49: 321-322, 1996.
665. **Assmann, G.:** Simvastatin in the secondary prevention of coronary heart disease. *Pharmacol. Res.* 35: Nr. 3, 1997.
666. **Assmann, G.:** Increased CK Levels in Lipid-Lowering Therapy. *Internist* 38: (11), 1114-1114, 1997.

667. **Assmann, G., P. Cullen and H. Schulte:** HRT, plasma factors, and cardiovascular disease. Proceedings of the 2nd International Symposium on Women's Health and Menopause: Risk Reduction Strategies, Florence, Italy, December 5-8, 1996, Kluwer Academic Publishers, Dordrecht, Boston, London, 91-98, 1997.
668. **Assmann, G., H. Schulte and P. Cullen:** Metabolic syndrome and dyslipidemia. In: *The Metabolic Syndrome*, edited by M. Hanefeld and W. Leonhardt. Jena: Gustav Fischer Verlag, 38-48, 1997.
669. **Assmann, G., H. Schulte and P. Cullen:** New and classical risk factors - The Münster Heart Study (PROCAM). *Eur.J.Med.Res.* 2: 237-242, 1997.
670. **Assmann, G., A. von Eckardstein and H. Schulte:** Relationship of high density lipoprotein cholesterol to the incidence of atherosclerotic coronary heart disease. The PROCAM experience. In: *Proceedings of The Congress on Drugs Affecting Lipid Metabolism*, edited by Paoletti, 1997.
671. **Bänsch, D., A. Dirkes-Kersting, H. Schulte, G. Assmann and A. von Eckardstein:** Basal growth hormone levels are positively correlated with high density lipoprotein cholesterol levels in women. *Metabolism* 1997, 46: 1039-1043, 1997.
672. **Bergmann, S., G. Siegert, U. Wahrburg, H. Schulte, G. Assmann, W. Jaroß and DRECAN-Team:** Influence of menopause and lifestyle factors on high density lipoproteins in middle-aged women. *Menopause: The Journal of the North American Menopause Society*, 4: 52-61, 1997.
673. **Brandt, B., A. Beckmann, F. Gebhardt, A. Rötger, C. Jackisch, G. Assmann and K. S. Zänker:** Translational research studies of erbB oncogenes: selection strategies for breast cancer treatment. *Cancer Lett.* 118: 143-151, 1997.
674. **Brandt, B., S. Heidi, C. Griwatz, R. Junker, G. Assmann and K. S. Zänker:** Separation of double-positive cytokeratin/ErbB-2 single and clustered cells from peripheral blood of breast cancer patients. *J. Cancer Res. Clin. Oncol. Suppl.* 1: S43, 1997.
675. **Bruckert, E., A. Von Eckardstein, H. Funke, I. Beucler, G. Turpin, and G. Assmann:** The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I_(Paris) causes a phenocopy of apolipoprotein A-I_(Milano). *Atherosclerosis* 128: 121-128, 1997.
676. **Bucher, H., S. Rampini, W. J. James, D. Pometta, H. Funke, H. Wiebusch and G. Assmann:** Marked changes of lipid levels during puberty in a patient with lipoprotein lipase deficiency. *Eur. J. Pediatr.* 156: 121-125, 1997.
677. **Cullen, P. and G. Assmann:** Treatment goals for low density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering? *Am. J. Cardiol.* 80: 1287-1294, 1997.
678. **Cullen, P., M. Fobker, K. Tegelkamp, K. Meyer, F. Kannenberg and A. Cignarella:** An improved method for quantification of cholesterol and cholesteryl esters in human monocyte-derived macrophages by high performance liquid chromatography with identification of unassigned cholesteryl ester species by means of secondary ion mass spectrometry. *J. Lipid Res.* 38: 401-409, 1997.
679. **Cullen, P., H. Funke, H. Schulte and G. Assmann:** Lipoproteins and cardiovascular risk – from genetics to CHD prevention. *J. Atheroscler. Thromb.* 4: 1-8, 1997.
680. **Cullen, P., S. Mohr, B. Brennhäusen, A. Cignarella and G. Assmann:** Downregulation of the Selectin Ligand-Producing Fucosyltransferase Fuc-TIV and Fuc-TVII During Foam Cell Formation in Monocyte-Derived Macrophages. *Arterioscler. Thromb. Vasc. Biol.* 17: 1591-1598, 1997.

681. **Cullen, P., H. Schulte and G. Assmann:** The Münster Heart Study (PROCAM) - Total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. *Circulation* 96: 2128-2136, 1997.
682. **Cullen, P., K. Tegelkamp, M. Fobker, F. Kannenberg and G. Assmann:** Measuring Cholesterol in Macrophages: Comparison of High-Performance Liquid Chromatography and Gas-Liquid Chromatography with Enzymatic Fluorometry. *Anal. Biochem.* 251: 39-44, 1997.
683. **Haverkamp, W., E. Schulze-Bahr, M. Hördt, H. Wedekind, H. Funke, M. Borggrefe, G. Assmann and G. Breithardt:** QT-Syndrome. Aspekte zur Pathogenese, molekularen Genetik, Diagnostik und Therapie. *Deutsches Ärztebl.* 94: A-667-672, 1997.
684. **Huang, Y., C. Langer, M. Raabe, B. Wiesenhütter, S. Wu, U. Seedorf, N. Maeda, G. Assmann and A. Von Eckardstein:** Effects of genotype and diet on cholesterol efflux into plasma and lipoproteins of normal, apolipoprotein A-I-, and apolipoprotein E-deficient mice. *Arterioscler. Thromb. Vasc. Biol.* 17: 2010-2019, 1997.
685. **Junker, R., B. Brandt, A. Semjonow and G. Assmann:** Clinical application of ultrasensitive prostate-specific antigen assays (response). *J. Natl. Cancer Inst.* 89: 1077-1078, 1997.
686. **Junker, R., B. Brandt, C. Zeche, and G. Assmann:** Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. *Clin.Chem.* 43: 1588-1594, 1997.
687. **Junker, R., J. Heinrich, J. van de Loo and G. Assmann:** Coagulation factor VII and the risk of coronary heart disease in healthy men. *Arterioscler.Thromb.Vasc.Biol.* 17: 1539-1544, 1997.
688. **Junker, R., M. Käse, M. Erren and G. Assmann:** No apparent restriction on measuring FVIIa in frozen plasma. *Thromb. Haemost.* 78: 1162-1163, 1997.
689. **Kuivenhoven, J.A., H. Pritchard, P. Haydn, J. Hill, J. Frohlich, G. Assmann and J. Kastelein:** The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. *J. Lipid Res.* 38: 191-205, 1997.
690. **Knudsen, P., M. Antikainen, M. Uusi-Oukari, S. Ehnholm, S. Lahdenpera, A. Bensatoun, H. Funke, H. Wiebusch, G. Assmann, M. R. Taskinen and C. Ehnholm:** Heterozygous hepatic lipase deficiency due to two missense mutations R186H and L334F in the HL gene. *Atherosclerosis* 128: 165-174, 1997.
691. **Leren, T. P., K. S. Bakken, U. Daum, L. Ose, K. Berg, G. Assmann and A. Von Eckardstein:** Heterozygosity for apolipoprotein A-I (R160L)_{Oslo} is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL-subclass LpA-I. *J. Lipid Res.* 38: 121-131, 1997.
692. **Meschede, D., U. Seedorf, M. Fobker, P. Miniy, U. Flotmann, H. G. Koch, K. Ullrich, G. Assmann and J. Horst:** A "new" heritable lipid abnormality in children with partial Smith-Lemli-Opitz syndrome phenotype. *Am. J. Med. Genet.* 68: 5, 1997.
693. **Miccoli, R., Y. Zhu, U. Daum, J. Wessling, Y. Huang, R. Navalesi, G. Assmann and A. von Eckardstein:** A natural apolipoprotein A-I variant – apoA-I (L141R)_{Pisa} – interferes with the formation of alpha-high density lipoproteins (HDL) but not with the formation of pre-beta1-HDL: effects on cholesterol efflux into plasma. *J. Lipid Res.* 38: 1242-1253, 1997.
694. **Mohr, S., P. Cullen, R. Schmidt, A. Cignarella and G. Assman:** Avoidance of false positives in PCR-based mRNA differential display during investigation of nonstandardized tissues or cells. *Clin. Chem.* 43: 182-184, 1997.

695. **Muntoni, S., H. Wiebusch, M. Jansen, S. Rust, F. Lu, U. Seedorf, H. Funke and G. Assmann:** The mutation commonly associated with the cholesterol ester storage disease seems to be absent in the Sardinian population. *Atherosclerosis* 133: 41, 1997.
696. **Nauck, M., W. März, J. Jarausch, C. Cobbaert, A. Sägers, D. Bernard, J. Delanghe, G. Honauer, P. Lehmann, E. Oestrich, A. Von Eckardstein, S. Walch, H. Wieland and G. Assmann:** Multicenter evaluation of a homogeneous assay for HDL-cholesterol without sample pretreatment. *Clin.Chem.* 43: 1622-1629, 1997.
697. **Nofer, J. R., M. Tepel, B. Kehrel, M. Walter, U. Seedorf, G. Assmann and W. Zidek:** Low density lipoproteins inhibit the Na⁺/H⁺ antiport in human platelets – A novel mechanism enhancing platelet activity in hypercholesterolemia. *Circulation* 95: 1370-1377, 1997.
698. **Nofer, J. R., M. Tepel, M. Walter, U. Seedorf, G. Assmann and W. Zidek:** Phosphatidylcholine-specific phospholipase C regulates thapsigargin-induced calcium influx in human lymphocytes. *J. Biol. Chem.* 272: 32861-32868, 1997.
699. **Schulze-Bahr, E., W. Haverkamp, G. Breithardt, H. Wiebusch, G. Assmann and H. Funke:** ECG repolarization anomalies in chromosome 7-linked QT syndrome (LQTS 2) [letter]. *Circulation* 94: 2318-2319, 1997.
700. **Schulze-Bahr, E., Q. Wang, H. Wedekind, W. Haverkamp, Q. Chen, Y. Sun, C. Rubie, M. Hördt, J. A. Towbin, M. Borggreffe, G. Assmann, X. Qu, J. C. Somberg, G. Breithardt, C. Obert and H. Funke:** KCNE1 mutations cause Jervell and Lange-Nielsen Syndrome. *Nat. Gen.* 17: 267-268, 1997.
701. **Schulze-Bahr, E., W. Haverkamp, H. Wedekind, sC. Rubie, M. Hördt, M. Borggreffe, G. Assmann, G. Breithardt and H. Funke:** Autosomal recessive long-QT syndrome (Jervell and Lange-Nielsen syndrome) is genetically heterogeneous. *Human Genet.*100: 573-576, 1997.
702. **von Eckardstein, A. and G. Assmann:** Plasma homocysteine levels and mortality in patients with coronary artery disease. *N. Engl. J. Med.* 337: 1632-1633, 1997.
703. **von Eckardstein, A., S. Kliesch, E. Nieschlag, A. Chirazi, G. Assmann and H. M. Behre:** Suppression of endogenous testosterone in young men increases serum levels of HDL-subclass LpA-I and lipoprotein (a). *J. Clin. Endocrinol. Metab.* 82: 3367-3372, 1997.
704. **Wiebusch, H., H. Funke, K. Saku, K. Arakawa and G. Assmann:** Mutational analysis of two frequently observed lipoprotein lipase gene variants in the Japanese population. *J. Inherit. Metab. Dis.* 20: 108-109, 1997.
705. **Young, P., H. Wiebusch, F. Stögbauer, B. Ringelstein, G. Assmann and H. Funke:** Eine neue Punktmutation im PMP22-Gen in einer Familie mit hereditärer Neuropathie mit Neigung zu Druckpareesen (HNPP). In: *Jahrbuch der neuromuskulären Erkrankungen 1996*, edited by T. Grimm, F. Hanefeld, H. C. Hopf, K. Kunze, W. Mortier, B. Neundörfer, D. Pongratz, and R. Rüdell. München: Arcis Verlag, 248-249, 1997.
706. **Young, P., H. Wiebusch, F. Stögbauer, B. Ringelstein, G. Assmann and H. Funke:** A novel frameshift mutation in PMP22 accounts for hereditary neuropathy with pressure palsies. *Neurology* 48: 450-452, 1997.
707. **Assmann, G.:** Primär- und Sekundärprophylaxe der koronaren Herzkrankheit (KHK). Neueste internationale Empfehlungen. *Notabene medici* 12: 610-611, 1998.
708. **Assmann, G., P. Cullen and H. Schulte:** The Münster Heart Study (PROCAM). Results of follow-up at 8 years. *Eur. Heart J.* 19 (Suppl.A): A2-A11, 1998.

709. **Assmann, G., P. Cullen and H. Schulte:** Comment on the West of Scotland Study. *Circulation* 97: 2033-2034, 1998.
710. **Assmann, G., H. Schulte and P. Cullen:** Pravastatin and Coronary Heart Disease. *Circulation* 98: 2932-2935, 1998.
711. **Assmann, G., R. Carmena, P. Cullen, J.-C. Fruchart, B. Lewis, M. Mancini, A. Olsson, R. Paoletti and M. Tikkanen:** for the International Task Force for Prevention of Coronary Heart Disease. Coronary heart disease: reducing the risk. The scientific background to primary and secondary prevention of coronary heart disease – a worldwide view. *Nutr. Metab. Cardiovasc. Dis.* 8: 205-271, 1998.
712. **Assmann, G., H. Schulte, H. Funke and A. von Eckardstein:** The emergence of triglycerides as a significant independent risk factor in coronary artery disease. *Eur. Heart J.* 19: M8-M14, 1998.
713. **Assmann, G., A. von Eckardstein, M. Walter and P. Cullen:** Genetic dissection of high-density lipoproteins metabolism and reverse cholesterol transport. Jacotot, B., Mathé, D., Fruchart, J.-C. (Eds.) Proceedings of the IXth International Symposium on Atherosclerosis. Elsevier Science B.V., 19-28, 1998.
714. **Bänsch, D., C. Chen-Haudenschild, A. Dirkes-Kersting, H. Schulte, G. Assmann and A. von Eckardstein:** Basal growth hormone levels in women are positively correlated with high density lipoprotein cholesterol and apolipoprotein A-I independently of insulin-like growth factor 1 or insulin. *Metabolism* 47: 339-344, 1998.
715. **Berger, K., H. Schulte, F. Stögbauer and G. Assmann:** Incidence and risk factors for stroke in an occupational cohort The PROCAM Study. *Stroke* 29: 1562-1566, 1998.
716. **Brandt, B., A. Roetger, S. Heidl, C. Jackisch, R.J. Lelle, G. Assmann and K.S. Zänker:** Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. *Int. J. Cancer* 76: 824-828, 1998.
717. **Cignarella, A., B. Brennhäusen, A. von Eckardstein, G. Assmann and P. Cullen:** Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages. *Arterioscler. Thromb. Vasc. Biol.* 18: 1322-1329, 1998.
718. **Cullen, P., A. Cignarella, B. Brennhäusen, S. Mohr, G. Assmann and A. von Eckardstein:** Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. *J. Clin. Invest.* 101: 1670-1677, 1998.
719. **Cullen, P. and G. Assmann:** Current goals for low density lipoprotein cholesterol. *Cardiol. Rev.* 15: 12-16, 1998.
720. **Cullen, P., H. Funke, H. Schulte and G. Assmann:** Lipoproteins and cardiovascular risk - from genetics to CHD prevention. *Eur. Heart J.* 19: Suppl. C, C5-C11, 1998.
721. **Cullen, P., H. Funke, H. Schulte and G. Assmann:** Lipoproteins and cardiovascular risk: From genetics to prevention of coronary heart disease. In: Gotto AM., Lenfant C., Paoletti R., Catapano, AL., Jackson AS. (eds.) Multiple Risk Factors in Cardiovascular Disease-Strategies of Prevention of Coronary Heart Disease, Cardiac Failure and Stroke. Kluwer Academic Publishers, Dordrecht, Boston, London, 217-228, 1998.
722. **Cullen, P., H. Schulte and G. Assmann:** Smoking, lipoproteins and coronary heart disease risk: Data from the Münster Heart Study (PROCAM). *Eur. Heart J.* 19: 1632-1641, 1998.
723. **Cullen, P., A. von Eckardstein and G. Assmann:** Diagnosis and management of new cardiovascular risk factors. *Eur. Heart J.*, 19: Suppl. O, O13-O19, 1998.

724. **Ehrhardt, V., G. Assmann, O. Bätz, Ch. Bieglmayer, Ch. Müller, D. Neumeier, H.-J. Roth, A. Veys and J.P. Yvert:** Results of the multicentre evaluation of an electrochemiluminescence immunoassay for HCG on Elecsys 2010. *Wiener Klin. Wochenschrift* 110: Suppl. 3, 61-67, 1998.
725. **Ellinghaus, P., U. Seedorf and G. Assmann:** Cloning and sequencing of a novel murine liver carboxylesterase cDNA. *Biochim. Biophys. Acta* 1397: 175-179, 1998.
726. **Enbergs, A., A. Dorszewski, M. Luft, G. Mönnig, A. Kleemann, H. Schulte, G. Assmann, G. Breithardt and S. Kerber:** Failure to confirm ferritin and caeruloplasmin as risk factors for the angiographic extent of coronary arteriosclerosis. *Coron. Artery Dis* 9: 119-124, 1998.
727. **Huang, Y., X.Q. Liu, S.C. Rall Jr., J.M. Taylor, A. von Eckardstein, G. Assmann and R.W. Mahley:** Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. *Biol. Chem.* 273: 26388-26393, 1998.
728. **James, R.W., M.C. Blatter Guerin, L. Calabresi, R. Miccoli, A. von Eckardstein, M. Tilly-Kiesi, M.R. Taskinen, G. Assmann and G. Franceschini:** Modulated serum activities and concentration of paroxonase in high density lipoprotein deficiency states. *Atherosclerosis* 139: 77-82, 1998.
729. **Jankowsky, J., J.R. Nofer, M. Tepel, B. Griewel, H. Schlüter, G. Assmann and W. Zidek:** Identification of oxidized low density lipoprotein in human serum by NMR spectroscopy. *Clin. Sci.* 95 (4): 489-495, 1998.
730. **Junker, R., B. Brandt, A. Semjonow, M. Erren, C. Zechel and G. Assmann:** The biological lower detection limit of six ultrasensitive PSA assays. *Anticancer Res.* 19: 2625-2628, 1998.
731. **Junker, R., J. Heinrich, H. Ulbrich, H. Schulte, R. Schönfeld, E. Köhler and G. Assmann:** Relationship between plasma viscosity and the severity of coronary heart disease. *Arterioscler. Thromb. Vasc. Biol.* 18: 870-875, 1998.
732. **Junker, R., J. Heinrich, H. Schulte, M. Erren and G. Assmann:** Hemostasis in normotensive and hypertensive men: results of the PROCAM Study. *J. Hypertens.* 16: 917-923, 1998.
733. **Junker, R., J. Heinrich, H. Schulte, R. Schönfeld, M. Tataru, E. Köhler, U. Nowak-Göttl and G. Assmann:** Plasminogen activator inhibitor-1 4G/5G-polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young men. *Blood Coagul. Fibrinol.* 9: 597-602, 1998.
734. **Junker, R., D. Nabavi, E. Wolff, P. Lüdemann, U. Nowak-Göttl, R. Bäumer, M. Käse, E.B. Ringelstein and G. Assmann:** Plasminogen activator inhibitor-1 4G/5G-polymorphism in sinus thrombosis. *Thromb. Haemost.* 80: 706-707, 1998.
735. **Lüdemann, P., D. Nabavi, R. Junker, E. Wolf, Buchner, H., Assmann, G. and E.B. Ringelstein:** Factor V-Leiden mutation is a risk factor for cerebral venous thrombosis – a case control study on 55 patients. *Stroke* 29: 2507-2510, 1998.
736. **Moennig, G., U. Seedorf, W. Haverkamp, P. Kirchhof, L. Eckardt, P. Pulawski, G. Assmann and G. Breithardt:** Arrhythmogenic effects of phytanic acid in sterol carrier protein-2 knockout mice and implication for sudden cardiac death. *Circulation* 98: SS 3907, 1998.
737. **Nabavi, D.G., R. Junker, E. Wolff, P. Lüdemann, C. Doherty, S. Evers, D.W. Droste, C. Kessler, G. Assmann and E.B. Ringelstein:** Prevalence of factor V Leiden mutation in young adults with cerebral ischaemia: a case-control study on 225 patients. *J. of Neurology*, 245: 653-658, 1998.

738. **Nofer, J.R., M. Walter, B. Kehrel, S. Wierwille, M. Tepel, U. Seedorf and G. Assmann:** HDL₃-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-trisphosphate. *Arterioscler. Thromb. Vasc. Biol.* 18: 861-869, 1998.
739. **Rust, S., M. Walter, H. Funke, A. von Eckardstein, P. Cullen, H.Y. Kroes, R. Hordijk, J. Geisel, J. Kastelein, H.O.F. Molhuizen, M. Schreiner, A. Mischke, H.W. Hahmann and G. Assmann:** Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. *Nat. Gen.* 20, 96-98, 1998.
740. **Saku, K., A. von Eckardstein, B. Zhang, R. Liu, S. Jimi, J. Ou, T. Ohta, G. Assmann and K. Arakawa:** In vivo kinetics of human apolipoprotein A-I variants in rabbits. *Eur. J. Clin. Invest.* 29: 196-203, 1998.
741. **Schlüter, H., I. Groß, J. Bachmann, R. Kaufmann, M. van der Giet, M. Tepel, J.R. Nofer, G. Assmann, M. Karas, J. Jankowski and W. Zidek:** Adenosine (5') oligophospho-(5') guanosines and guanosine (5') oligophospho-(5') guanosines in human platelets. *J. Clin. Invest.* 101: 682-688, 1998.
742. **Seedorf, U., M. Raabe, P. Ellinghaus, F. Kannenberg, M. Fobker, T. Engel, S. Denis, F. Wouters, K.W.A. Wirtz, R.J.A. Wanders, N. Maeda and G. Assmann:** Defective peroxisomal catabolism of branched fatty acyl coenzyme A in mice lacking the sterol carrier protein-2/sterol carrier protein-x gene function. *Genes Dev.* 12, 1189-1201, 1998.
743. **Stögbauer, F., P. Young, M. Kerschensteiner, E.B. Ringelstein, G. Assmann and H. Funke:** Recurrent brachial plexus palsies as the only clinical expression of hereditary neuropathy with liability to pressure palsies associated with a de novo deletion of the peripheral myelin protein-22 gene. *Muscle Nerve* 21: 1199-1201, 1998.
744. **Stögbauer, F., P. Young, H. Wiebusch, V. Timmermann, G. Kuhlenbaumer, E. Nelis, E.B. Ringelstein, G. Kurlemann, G. Assmann, C. Van Broeckhoven and H. Funke:** Absence of mutations in peripheral myelin protein-22, myelin protein zero, and connexin 32 in autosomal recessive Dejerine-Scottas syndrome. *Neurosci. Lett.* 240: 1-4, 1998.
745. **Uhl, W., D.W. Chan, K. Jones, C. Kelley, G. Assmann, A. von Eckardstein, A. Sägers, J.P. Yvert, A.M. Schneider, A. Torralba, X. Fuentes-Arderiu, B. Gonzalez de la Presa, M. Vives, H. Greiling, A. Eberle, C.H. Niederau, P. Cremer, W. Reiter, M. Vogeser, D. Neumaier, P. Lippa and U. Huber:** ElecsysR CEA, PSA, and AFP. Clinical results of a multicentre evaluation. *Wiener Klin. Wochenschr.* 110: Suppl. 3, 51-61, 1998.
746. **von Eckardstein, A. and G. Assmann:** Welchen Stellenwert hat Homocystein im Rahmen der Atherogenese. *Der Internist* 39: 214-215, 1998.
747. **von Eckardstein, A. and G. Assmann:** High density lipoproteins and reverse cholesterol transport: Lessons from mutations. *Atherosclerosis* 137: (Suppl.) S7-S11, 1998.
748. **von Eckardstein, A., A. Chirazi, S. Schuler-Lüttmann, M. Walter, J.J.P. Kastelein, J. Geisel, J. T. Real, R. Miccoli, G. Nosedo, G. Höbbel and G. Assmann:** Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I. *J. Lipid Res.* 39: 987-998, 1998.
749. **von Eckardstein, A., Y. Huang, J.J.P. Kastelein, J. Geisel, J.T. Real, J.A. Kuivenhoven, R. Miccoli, G. Nosedo and G. Assmann:** Lipid-free apolipoprotein (apo) A-I is converted into alpha-migrating high density lipoproteins by lipoprotein-depleted plasma of normolipidemic donors and apo A-I-deficient patients but not of Tangier disease patients. *Atherosclerosis* 138: 25-34, 1998.

750. **Walter, M., R. Reinecke, G. Breithardt G. Assmann and J. Heinrich:** Factor V Leiden and thromboembolism. *Circulation* 97: 14, 1426-1427, 1998.
751. **Young, P., F. Stögbauer, H. Wiebusch, A. Lofgren, V. Timmerman, C. van Broeckhoven, E.B. Ringelstein, G. Assmann and H. Funke:** PCR-based strategy for the diagnosis of hereditary neuropathy with liability to pressure palsies and Charcot-Marie-Tooth disease type 1A. *Neurology* 50: 760-763, 1998.
752. **Zhu, Y., St. Bellosta, C. Langer, F. Bernini, R.E. Pitas, R.W. Mahley, G. Assmann and A. von Eckardstein:** Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. *Proc. Natl. Acad. Sci.* 95: 7585-7590, 1998.
753. **Assmann, G.:** Secondary coronary heart disease prevention by Red Wine? *Internist* 40: (9), 982, 1999.
754. **Assmann, G., A. von Eckardstein, J. R. Nofer and M. Walter:** Role of HDL in reverse cholesterol transport. *Atherosclerosis* 146: Suppl. 1, S1, 1999.
755. **Assmann, G., P. Cullen, R. Carmena, J.C. Fruchart, B. Lewis and M. Mancini:** Recommendations of the 2nd Joint Task Force of the European Societies of Atherosclerosis, Cardiology and Hypertension. *Eur. Heart J.* 20: 841-843, 1999.
756. **Assmann, G., R. Carmena, P. Cullen, J.C. Fruchart, F. Jossa, B. Lewis, M. Mancini and R. Paoletti:** for the International Task Force for the Prevention of Coronary Heart Disease. Coronary Heart Disease: Reducing the Risk. *Circulation* 100: 1930-1938, 1999.
757. **Assmann, G., P. Cullen, F. Jossa, B. Lewis and M. Mancini:** Coronary Heart Disease: Reducing the Risk. The Scientific Background to Primary and Secondary Prevention of Coronary Heart Disease. A Worldwide View. *Arterioscler. Thromb. Vasc. Biol.* 19: 1819-1824, 1999.
758. **Assmann, G., P. Cullen, A. Von Eckardstein, H. Funke and H. Schulte:** The importance of triglycerides as a significant risk factor. *Eur. Heart J.*, 1: Suppl. J, J7-J11, 1999.
759. **Assmann, G., D. Hüwel, K.-M. Schussman, J.G. Smilde, M. Kösling, A.J.A.M. Withagen, J. Wunderlich, I. Stoel, J.J. van Dormaal, J. Neuss, C. Oldenbroek, M.C. Cüppers, A. von Eckardstein, H. Schulte, B. Wagner, R. McLain and D.M. Black:** Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia. *Eur. J. Intern. Med.* 10, 33-39, 1999.
760. **Assmann, G., H. Schulte and P. Cullen:** Update kardiovaskulärer Risikofaktoren die PROCAM-Studie. *Berliner Ärzte* 31-34, 1999.
761. **Assmann, G., H. Schulte, H. Funke and A. von Eckardstein:** The emergence of triglycerides as a significant independent risk factor in coronary artery disease. *Eur. Heart J.* 19: Suppl. M, M8-M14, 1998.
762. **Assmann, G. and A. von Eckardstein:** Tangier Disease. In: *Lipoproteins in Health and Disease*. Edited by Hodder & Stoughton Ltd. Kent, pp 767-781, 1999.
763. **Assmann, G. and A. von Eckardstein:** Menopause, koronare Herzkrankheit und koronare Risikofaktoren. *Notabene medici* 29: 560-561, 1999.
764. **Assmann, G. and U. Wahrburg:** Adipositas; *Fettstoffwechselstörungen*. Consilium Cedip Practicum; Handbuch für Diagnose und Therapie CEDIP Verlagsgesellschaft, 26. Auflage, München 71-73 und 354-361, 1999.

765. **Bobak, M., H.W. Hense, J. Kark, B. Kuch, P. Vojtisek, R. Sinnreich, J. Gostomzyk, M. Bui, A. von Eckardstein, R. Junker, H. Schulte, M. Fobker, G. Assmann and M. Marmot.** An ecological study of determinants of coronary heart disease rates: a comparison of Czech, Bavarian and Israeli men. *Int. J. Epidemiol.* 28: 437-444, 1999.
766. **Brandt, B., A. Roetger, T. Dittmar, G. Nikolai, M. Seeling, A. Merschjann, J.R. Nofer, G. Dehmer-Moller, R. Junker, G. Assmann and K.S. Zänker:** c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. *FASEB J.* 13: 1939-1949, 1999.
767. **Büchter, D., H.M. Behre, S. Kliesch, A. Chirazi, E. Nieschlag, G. Assmann and A. von Eckardstein:** Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin. *Exp. Clin. Endocrinol. Diabetes* 107: 522-529, 1999.
768. **Cullen P. and G. Assmann:** High risk strategies for atherosclerosis. *Clinica Chimica Acta* 286: 31-45, 1999.
769. **Cullen, P., H. Schulte, U. Wahrburg and G. Assmann:** Neue Methoden zur Identifizierung von koronaren Hochrisikopatienten in der täglichen Praxis. *Ärztliche Praxis* 16. Juni, S. 42, 1999
770. **Cullen, P., A. von Eckardstein, S. Souris, H. Schulte and G. Assmann:** Dyslipidaemia and cardiovascular risk in diabetes. *Diabet. Obes. Metab.* 1: (4), 189-198, 1999.
771. **Cullen, P., J. Söffker, M. Hopfl, C. Bremer, R. Schlaghecken, T. Mehrens, G. Assmann and R.M. Schaefer:** Hypochromic Red Cells and Reticulocyte Haemoglobin Content as Markers of Iron-Deficient Erythropoiesis in Patients Undergoing Chronic Haemodialysis. *Nephrol.Dial. Transplant.* 14: (3), 659-665, 1999.
772. **Daum, U., T.P. Leren, C. Langer, A. Chirazi, P. Cullen, P. Haydn Pritchard, G. Assmann and A. von Eckardstein:** Multiple dysfunctions of two apolipoprotein A-I variants, apoA-I(R160L)^{Oslo} and apoA-I(P165R) that are associated with hypoalphalipoproteinemia in heterozygous carriers. *J. Lipid Res.* 40: 486-494, 1999.
773. **Daum, U., C. Langer, N. Duverger, F. Emmanuel, P. Benoit, P. Denèfle, A. Chirazi, P. Cullen, P. Haydn Pritchard, E. Bruckert, G. Assmann and A. von Eckardstein:** Apolipoprotein A-I (R151C)^{Paris} is defective in activation of lecithin:cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux. *J. Mol. Med.* 77: 614-622, 1999.
774. **Ellinghaus, P., C. Wolfrum, G. Assmann, F. Spener and U. Seedorf:** Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPAR alpha) in sterol carrier protein 2-sterol carrier protein x-deficient mice. *J. Biol. Chem.* 274: 2766-2772, 1999.
775. **Erren, M., M. Arlt, P. Willeke, B. Schlüter, R. Junker, M. Deng, G. Assmann, H.D. Dietl and N. Senninger:** Predictive value of CD45RO positive T-helper lymphocyte subset for acute cellular rejection during the early phase after kidney transplantation. *Transplant. Proc.* 31: 319-321, 1999.
776. **Erren, M., H. Reinecke, R. Junker, M. Fobker, H. Schulte, J.O. Schurek, J. Kropf, S. Kerber, G. Breithardt, G. Assmann and P. Cullen:** Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. *Arterioscler. Thromb. Vasc. Biol.*, 19: 2355-2363, 1999.
777. **Funke, H. and G. Assmann:** Strategies for the assessment of genetic coronary artery disease risk. *Curr. Opin. Lipidol.* 10: 285-291, 1999.

778. **Hergenç, G., H. Schulte, G. Assmann and A. von Eckardstein:** Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. *Atherosclerosis* 145: 147-156, 1999.
779. **Jatzke, C., H.J. Hinz, U. Seedorf and G. Assmann:** Stability and binding properties of wild-type and c17s mutated human sterol carrier protein-2. *Biochim. Biophys. Acta.* 1432: 265-274, 1999.
780. **Junker, R., B. Brandt, A. Semjonow, M. Erren, C. Zechel and G. Assmann:** The biologic lower detection limit of six ultrasensitive PSA assays. *Anticanc. Res.* 19: 2625-2628, 1999.
781. **Kannenberg, F., P. Ellinghaus, G. Assmann and U. Seedorf:** Aberrant oxidation of the cholesterol side-chain in bile acid synthesis of sterol carrier protein-2/sterol carrier protein-x-knockout mice. *J. Biol. Chem.* 274: 35455-35469, 1999.
782. **Kleemann, A., S. Eckert, A. von Eckardstein, W. Lepper, U. Schernikau, U. Gleichmann, P. Hanrath, E. Fleck, A. Neiss, S. Kerber, G. Assmann and G. Breithardt:** Effects of lovastatin on progression of non-dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA Trial (CLAPT) *Eur. Heart J.*, 20: 1393-1406, 1999.
783. **a. Kratz, M., P. Cullen, A. Kassner, M. Fobker, P.M. Abuja, H. Schulte, G. Assmann and U. Wahrburg:** The impact of dietary fatty acids on susceptibility of low density lipoprotein to oxidation. *Atherosclerosis* 144:129-129, 1999.
- b. Assmann, G., P. Cullen and A. M. Gotto Jr:** Treatment of elevated low density lipoprotein cholesterol: the role of LDL apheresis. *Medical Science Publications. Inc.*, Osaka, Japan, 1999
784. **Lee, M., A. von Eckardstein, L. Lindstedt, G. Assmann and P.T. Kovanen:** Depletion of pre β_1 LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma. *Arterioscler. Thromb. Vasc. Biol.* 19: 1066-1074, 1999.
785. **Mayatepek, E., U. Seedorf, H. Wiebusch, H. Lenhartz and G. Assmann:** Fatal genetic defect causing Wolman disease. *J. Inherit. Metab. Dis.* 22: 93-94, 1999.
786. **Nofer, J.R., E. Pulawski, R. Junker, U. Seedorf, G. Assmann, W. Zidek and M. Tepel:** Na⁺/Ca²⁺ exchange inhibitors modulate thapsigargin-induced Ca²⁺ and Na⁺ influx in human lymphocytes. *Int. J. Clin. Lab. Res.* 29: 89-92, 1999.
787. **Nofer, J.R., G. Hobbel, R. Junker, M. Fobker, E. Pawlus, M. Walter and G. Assmann:** HDL3-induced phosphatidylinositol-specific phospholipase C (PI-PLC) activation: Involvement in cell proliferation but not cholesterol efflux. *Atherosclerosis* 144: 5, 1999.
788. **Nowak-Göttl, U., R. Junker, M. Hartmeier, H.G. Koch, N. Münchow, G. Assmann and A. von Eckardstein:** Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. *Circulation* 100: 743-748, 1999.
789. **Orth, M., W. Weng, H. Funke, A. Steinmetz, G. Assmann, M. Nauck, J. Dierkes, A. Ambrosch, K.H. Weisgraber, R.W. Mahley, H. Wieland and C. Luley:** Effects of a frequent apolipoprotein E isoform, apoE4_{Freiburg} (Leu28→Pro), on lipoproteins and the prevalence of coronary artery disease in whites. *Arterioscler. Thromb. Vasc. Biol.* 19: 1306-1315, 1999.
790. **Remaley, A.T., S. Rust, M. Rosier, C. Knapper, L. Naudin, C. Broccardo, K.M. Peterson, C. Koch, I. Arnould, C. Prades, N. Duverger, H. Funke, G. Assmann, M. Dinger, M. Dean, G. Chimini, S. Santamarina-Fojo, D.S. Fredrickson, P. Deneffe and H.B. Brewer Jr.:** Human ATP-binding cassette transporter 1 (ABC1): Genomic organization and identification of the genetic defect in the original Tangier disease kindred. *Proc. Natl. Acad. Sci* 22: 12685-12690, 1999.

791. **Rust, S., M. Rosier, H. Funke, J. Real, Z. Amoura, J-C. Piette, J.-F Deleuze, H.B. Brewer, N. Duverger, P. Denèfle and G. Assmann:** Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. *Nat. Gen.*22: 352-355, 1999.
792. **Saku, K., A. von Eckardstein, B. Zhang, R. Liu, S. Jimi, J. Ou, T. Ohta, G. Assmann and K. Arakawa:** In vivo kinetics of human apolipoprotein A-I variants in rabbits. *Eur. J. Clin. Invest.* 29: 196-203, 1999.
793. **Schulte, H., P. Cullen and G. Assmann:** Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM). *Atherosclerosis* 144: 199-209, 1999.
794. **Schulze-Bahr, E., H. Wedekind, W. Haverkamp, M. Borggrefe, G. Assmann, G. Breithardt and H. Funke:** The LQT syndromes – current status of molecular mechanisms. *Z. Kardiol.* 88: 245-254, 1999.
795. **Seedorf, U., O. Guardamagna, W. Strobl, E. Mayatepek, G. Assmann and H. Funke:** Mutation report: Wolman disease. *Hum. Genet.* 105: 337, 1999.
796. **Tataru, M.C., J. Heinrich, R. Junker, H. Schulte, A. von Eckardstein, R. Schönfeld, G. Assmann and E. Köhler:** D-Dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. *Eur.Heart J.* 20: 1493-1502, 1999.
797. **von Eckardstein, A., H. Schulte and G. Assmann:** Increased risk of myocardial infarction in men both with hypertriglyceridemia and elevated HDL-cholesterol. *Circulation* 99: 1922d-1926, 1999.
798. **Wahrburg, U., and G. Assmann.** Cholesterin. Wozu wir es brauchen und wann es krank macht. *Beck'sche Reihe* C.H. Beck Wissen. Verlag C.H. Beck, München, 1999.
799. **Wahrburg, U. and G. Assmann:** Hyperlipoproteinämien; Arteriosklerose und koronare Herzkrankheit. In: Biesalski H.K., Fürst, P., Kasper, H., Kluthe R., Pölerl, W., Puchstein, C., Stähelin, H. (Hrsg.): *Ernährungsmedizin.* Georg Thieme Verlag, Stuttgart, 2. Auflage, 376-395, 1999.
800. **Wolfrum, C., P. Ellinghaus, M. Fobker, U. Seedorf, G. Assmann, T. Borchers and F. Spener:** Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. *Lipid Res.* 40: 708-714, 1999.
801. **Assmann, G. and U. Seedorf:** Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. In Scriver, Beaudet, Sly, Valle, (eds.): *The Metabolic and Molecular Bases of Inherited Disease.* 8th ed., McGraw-Hill, 2000.
802. **Bolibar, I., A. von Eckardstein, G. Assmann and S. Thompson:** Short-term prognostic value of lipid measurements in patients with angina pectoris. *Thromb. Haemost.* 84: 955-960, 2000.
803. **Cullen, P. and G. Assmann:** Primäre und sekundäre Prävention der koronaren Herzkrankheit. *Dt. Med. Wschr.* 125: 881-887, 2000.
804. **Cullen, P. and G. Assmann:** Primary prevention of coronary heart disease: From controversy to consensus. *Nutr. Metab. Cardiovasc. Dis.* 10: 143-153, 2000.
805. **Cullen, P., A. von Eckardstein, E. Barrett-Connor, B. Lewis M. Mancini, W. Riesen, O. Schober, J.-C. Fruchart, P. Schwandt and G. Assmann:** for the International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease in post-menopausal women. *Nutr. Metab. Cardiovasc. Dis.* 10: 267-274, 2000.
806. **Cullen, P., H. Schulte and G. Assmann:** Evidence that triglycerides are an independent coronary heart disease risk factor. *Am. J. Cardiol.* 86: 943-949, 2000.

807. **Eckel, F., C. Lersch, G. Assmann and E. Schulte-Frohlinde:** Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer. *Ann. Oncol.* 11: 762 – 763, 2000.
808. **Eckel, F., C. Lersch, F. Lippl, G. Assmann and E. Schulte-Frohlinde:** Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer. *J. Exp. & Clin. Canc. Res.* 19: 295-300, 2000.
809. **Fischbach, R.M., E.M. Fallenberg, B.M. Ohnesorge, K.U. Jürgens, G. Assmann and W.L. Heindel.:** Simultated interexamination variability of Agatston score and 3D Ca-scoring methods using ECG gated multi-slice spiral CT for quantification of coronary calcium in asymptomatic high risk persons. *Radiology* 217: 589-590, 2000.
810. **Gotto, A.M. Jr., G. Assmann, R. Carmena, J. Davignon, A. Fernández-Cruz, J.C. Fruchart, J.J.P. Kastelein and R. Paoletti:** The ILIB Lipid Handbook for Clinical Practice, Blood Lipids and Coronary Heart Disease, 2nd Edition, International Lipid Information Bureau, New York, USA, 2000.
811. **Langer, C., Y. Huang, P. Cullen, B. Wiesenhütter, R.W. Mahley, G. Assmann and A. von Eckardstein:** Endogenous apolipoprotein E modulates cholesterol efflux and cholesterol ester hydrolysis mediated by high density lipoprotein3 and lipid-free apolipoproteins in mouse peritoneal macrophages. *J. Mol. Med.*78: 217-227, 2000.
812. **Lersch, C., F. Eckel, G. Assmann, H. Adelsberger, S. Quasthoff, E. Schulte-Frohlinde, B. Marstaller and J. Grosskreutz:** Prevention of peripheral sensory neuropathy (PSN) by carbamazepine in patients with advanced colorectal cancers (ACRC) treated with oxaliplatin. A pilot study. *Gastroenterology* 118: A522-A522 2776 Part 1 Suppl. 2, 2000
813. **Lorkowski, S., P. Ellinghaus, E.A. Galinski, G. Assmann and P. Cullen:** Use of Longer Extension Phases to Improve Yield of High Molecular Weight Products in Differential Display PCR. *Clin. Chim. Acta* 299: 199-204, 2000.
814. **Lorkowski, S., K. Tegelkamp, EA. Galinski, G. Assmann and P. Cullen:** Identifizierung differentiell exprimierter Gene während der Schaumzellbildung humaner Makrophagen. In: Determinanten und Beeinflussung der Plaqueentwicklung. Hrsg. Heinle, H., Schulte, H., Hanefeld, M. Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, 138-142, 2000.
815. **Moennig, G., H. Wiebusch, A. Enbergs, A. Dorszewski, S. Kerber, H. Schulte, C. Vielhauer, W. Haverkamp, G. Assmann, G. Breithardt and H. Funke:** Detection of missense mutations in the genes for lipoprotein lipase and hepatic triglyceride lipase in patients with dyslipidemia undergoing coronary angiography. *Atherosclerosis* 149: 395-401, 2000.
816. **Neufeld, M., J.R. Nofer, P. Becker, C. Langer, G. Assmann and R. Junker:** High density lipoproteins inhibit fibrinogen binding on adenosine diphosphate activated monocytes. *Blood Coagul.Fibrinol.* 11: 505-509, 2000.
817. **Nofer, J.R., R. Junker, M. Walter, U. Seedorf, G. Assmann, W. Zidek and M. Tepel:** Phospholipase A(2) is involved in thapsigargin-induced sodium influx in human lymphocytes. *Arch. Biochem. Biophys.* 374: 213-221, 2000.
818. **Nofer, J.R., R. Junker, U. Seedorf, G. Assmann, W. Zidek and M. Tepel:** D609 phosphatidylcholine-specific phospholipase C inhibitor attenuates thapsigargin-induced sodium influx in human lymphocytes. *Cell Signal* 12: 289-296, 2000.
819. **Nofer, J.R., M. Fobker, G. Hobbel, R. Voss, M. Tepel, W. Zidek, G. Assmann and M. Walter:** Lysosulfatide (LSF) and sphingosylphosphorylcholine (SPC) are agonists exerting the mitogenic activity of high density lipoproteins (HDL). *Circulation* 102: 1770, 2000.

820. **Nofer, J.R., M. Fobker, G. Hoebbel, R. Voss, I. Wolinska, M. Tepel, W. Zidek, R. Junker, U. Seedorf, A. von Eckardstein, G. Assmann and M. Walter:** Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipids. Involvement in mitogenesis but not in cholesterol efflux. *Biochemistry* 39: 15199-15207, 2000.
821. **Pieke, B., A. von Eckardstein, E. Gülbahçe, A. Chirazi, H. Schulte, G. Assmann and U. Wahrburg:** Treatment of hypertriglyceridemia by two diets rich either in unsaturated fatty acids or in carbohydrates: Effects on lipoprotein subclasses, lipolytic enzymes, lipid transfer proteins, insulin and leptin. *Int. J. Obes.* 24: 1286-1296, 2000.
822. **Reinecke, H., M. Erren, J.O. Schurek, J. Kropf, S. Kerber, G. Breithardt, G. Assmann and P. Cullen:** Transforming growth factor beta and coronary artery disease. *Nutr. Metab. Cardiovasc. Dis.* 10, 101-102, 2000.
823. **Schuler-Lüttmann, S., G. Mönnig, A. Enbergs, H. Schulte, G. Breithardt, G. Assmann, S. Kerber and A. von Eckardstein:** Insulin-like growth factor-binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 20: e10-e15, 2000.
824. a. **Schuler-Lüttmann, S., Y. Zhu, M. Hoffmann, W. März, G. Feussner, H. Wieland, G. Assmann and A. von Eckardstein:** Cholesterol efflux from normal and Tangier disease fibroblasts into normal, HDL-deficient, and apoE-deficient plasmas. *Metabolism* 49: 770-777, 2000.
- b. **Schuler-Lüttmann, S., G. Mönnig, A. Enbergs, H. Schulte, G. Breithardt, G. Assmann, S. Kerber and A. von Eckardstein:** Insulin-like growth factor-binding protein-3 is associated with the presence and extend of coronary arteriosclerosis. *Arterioscler Thromb Vasc Biol.* 20(4): e10-e15, 2000
825. **Schlüter, B., H. Schotte, M. Erren, P. Willeke, W. Domschke, G. Assmann and M. Gaubitz:** The tumor necrosis factor alpha promoter polymorphism (-308 G/A) is associated with disease susceptibility and autoantibody production in German patients with systemic lupus erythematosus. *Arthritis Rheumatism* 43: Suppl. S, 1754, 2000.
826. **Schulze-Bahr, E., W. Haverkamp, M. Borggreffe, H. Wedekind, G. Moennig, J. Mergenthaler, G. Assmann, H. Funke and G. Breithardt:** Molecular genetics of arrhythmias – a new paradigm. *Z. Kardiol.* 89: IV12-22, 2000.
827. **Shih, D.Q., H.M. Dansky, M. Fleisher, G. Assmann, St.S. Fajans and M. Stoffel:** Genotype/Phenotype relationships in HNF-4 α /MODY1 - Haploinsufficiency is associated with reduced apolipoprotein AII, apolipoprotein CIII, lipoprotein (a), and triglyceride levels. *Diabetes* 49: 832-837, 2000.
828. **Tataru, M.C., J. Heinrich, R. Junker, H. Schulte, A. von Eckardstein, G. Assmann and E. Köhler:** C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. *Eur. Heart J.* 21: 1000-1008, 2000.
829. **von Eckardstein, A. and G. Assmann:** Prevention of coronary heart disease by raising of HDL cholesterol? *Curr. Opin. Lipidol.*, 11: 627-637, 2000.
830. **von Eckardstein, A. and G. Assmann:** Homocystein and Atherogenese. In Hiddemann, W.: *Medizin im Brennpunkt.* Springer Verlag Berlin, Heidelberg, pp. 201-207, 2000.
831. **von Eckardstein, A. and G. Assmann:** Kardiovaskuläre Wirkungen und Einfluß auf den Lipidstoffwechsel von substitutiven Steroiden. In F.H. Fischl, J.H. Huber: *Menopause – Andropause: Die Hormonsubstitution im Wandel der Zeit.* Krause & Pachernegg GmbH, Gablitz, pp. 119-132, 2000.

832. a. **von Eckardstein, A. and G. Assmann:** Prävention kardiovaskulärer Erkrankungen bei der Frau. In Beller, F.K. (Hrsg). *Der Frauenarzt als Hausarzt der Frau*, Band 2, Pro Kongressverlag Gertrud Lulinski GmbH, Hofstetten, 57-82, 2000.
- b. **Assmann, G., W. Braendle, W. Elermann, J. Hanker, T. von Holst, H.W. Minne, O. Ortman, E. Rütter and A. Teichmann:** Tibolon von A bis Z. *Georg Thieme Verlag Stuttgart – New York*, 2000
833. **von Eckardstein, A., H. Funke and G. Assmann:** Störungen im Stoffwechsel der High Density Lipoproteine. In P. Schwandt, P. & Richter, W.O. (Hrsg.) *Fettstoffwechselstörungen*. Schattauer Verlag Stuttgart, 2. Auflage, 140-175, 2000.
834. **von Eckardstein, A., J.R. Nofer and G. Assmann:** Acceleration of reverse cholesterol transport. *Curr. Opin. Cardiol.*, 15: 348-354, 2000.
835. **von Eckardstein, A., H. Schulte and G. Assmann:** Risk for diabetes mellitus in middle-aged caucasian male participants of the PROCAM study. Implications for the definition of impaired fasting glucose by the American Diabetes Association. *J. Clin. Endocrinol. Metab.*, 85: 3101-3108, 2000.
836. **Walter, M., M. Tepel, J.R. Nofer, M. Neusser, G. Assmann and W. Zidek:** Involvement of phospholipase D in store-operated calcium influx in vascular smooth muscle cells. *FEBS Lett.*, 479: 51-56, 2000.
837. **Weltermann, B.M., A. Rogalewski, J. Homann, K. Berger, H. Schulte, G. Assmann and E.B. Ringelstein:** Wissen über Schlaganfall in der deutschen Bevölkerung. *Dt. Med. Wochenschr.* 125: 416-420, 2000.
838. **Assmann, G.:** Pro and Con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. *Am. J. Cardiol.* 87: 2B-7B (suppl), 2001.
839. **Assmann, G., J.R. Nofer, H. Schulte and A. von Eckardstein:** High density lipoprotein cholesterol, reverse cholesterol transport and coronary heart disease. In Schwartz, C.J., Born, G.V.R., (eds.): *Occlusive Arterial Disease*. 145-157, Schattauer Verlag, Stuttgart,
840. **Assmann, G., A. von Eckardstein and HB Brewer:** Familial anaphalipoproteinemia: Tangier disease. In: Scriver, Beaudet, Sly, Valle, (eds.): *The Metabolic and Molecular Bases of Inherited Disease*, 8th ed., McGraw-Hill, New York, 2937-2960, 2001.
841. **Berendes, E., H. Van Aken, C. Raufhake, C. Schmidt, G. Assmann and M. Walter:** Differential secretion of atrial and brain natriuretic peptide in critically ill patients. *Anesth. Analg.* 93: 676-682, 2001.
842. **Engel, T., S. Lorkowski, A. Lueken, S. Rust, B. Schlüter, G. Berger, P. Cullen and G. Assmann:** The human abcg4 gene is regulated by oxysterols and retinoids in monocyte-derived macrophages. *Biochem. Biophys. Res. Commun.* 288: 483-488, 2001.
843. **Erren, M., B. Schlüter, M. Fobker, G. Plenz, H. Baba, P. Willeke, R. Kwiotek, R. Junker, G. Assmann, H.H. Scheld and M.C. Deng:** Immunologic effects of implantation of left ventricular assist devices. *Transplant. Proc.* 33: 1965-1968, 2001.
844. **Fobker, M., R. Voss, H. Reinecke, C. Crone, G. Assmann and M. Walter:** Accumulation of cardiolipin and lysocardiolipin in fibroblasts from Tangier disease subjects. *FEBS Lett.* 500: 157-162, 2001.
845. **Junker, R., M. Kratz, M. Neufeld, M. Erren, J.R. Nofer, H. Schulte, U. Nowak-Göttl, G. Assmann and U. Wahrburg:** Effects of Diets Containing Olive Oil, Sunflower Oil, or Rapeseed Oil on the Hemostatic System. *Thromb. Haemost.* 85: 280-286, 2001.

846. **Junker, R., B. Pieke, H. Schulte, J.R. Nofer, M. Neufeld, G. Assmann and U. Wahrburg:** Changes in Hemostasis During Treatment of Hypertriglyceridemia With a Diet Rich in Monounsaturated and *n*-3 Polyunsaturated Fatty Acids in Comparison With a Low-Fat Diet *Thromb. Res.* 101: 355-366, 2001.
847. **Lorkowski, S., S. Rust, T. Engel, E. Jung, K. Tegelkamp, E.A. Galinski, G. Assmann and P. Cullen:** Genomic sequence and structure of the human ABCG1 (ABC8) gene. *Biochem. Biophys. Res. Commun.* 280: 121-131, 2001.
848. **Lorkowski, S., R. Schmidt, M. Fobker, M. Kratz, B. Brennhäusen, E.A. Galinski, G. Assmann and P. Cullen:** Expression of the ATP-binding cassette transporter gene ABCG1 (ABC8) in Tangier disease. *Biochem. Biophys. Res. Commun.* 283: 821-830, 2001.
849. **Lorkowski, S., S. Rust, T. Engel, E. Jung, EA. Galinski, G. Assmann and P. Cullen:** Identifizierung der genomischen Sequenz und Struktur des humanen ABCG1-Gens. In: *Die Prävention atherosklerotischer Prozesse.* Heinle, H., Schulte, H. and M. Hanefeld, eds. Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, 210-215, 2001.
850. **Lorkowski, S., M. Kratz, C. Wenner, R. Schmidt, B. Weitkamp, M. Fobker, J. Reinhardt, J. Rauterberg, EA. Galinski, G. Assmann and P. Cullen:** Tangierkrankheit und Expression des ATP-Bindungskassettentransporters G1 (ABCG1). In: *Die Prävention atherosklerotischer Prozesse.* Heinle, H., Schulte, H. and M. Hanefeld, eds. Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen, 216-221, 2001.
851. **Moennig, G., E. Schulze-Bahr, H. Wedekind, M. Borggrefe, H. Funke, M. Toelle, P. Kirchhof, L. Eckardt, G. Assmann, G. Breithardt and W. Haverkamp:** Clinical value of electrocardiographic parameters in genotyped individuals with familial long QT syndrome. *Pacing Clin. Electrophysiol.* 24: 406-415, 2001.
852. **Neufeld, M., J.R. Nofer, P. Becker, C. Langer, G. Assmann, and R. Junker.** High-density lipoproteins inhibit fibrinogen binding on adenosine diphosphate-activated monocytes. *Blood Coagul. Fibrinolysis* 11: 505-509, 2001.
853. **Nofer, J.R., R. Junker, E. Pulawski, M. Fobker, B. Levkau, A. von Eckardstein, U. Seedorf, G. Assmann, and M. Walter.** High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway. *Thromb. Haemost.* 85: 730-735, 2001.
854. **Nofer, J.R., B. Levkau, I. Wolinska, R. Junker, M. Fobker, A. von Eckardstein, U. Seedorf and G. Assmann.** Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. *J. Biol. Chem.* 276: 34480-34485, 2001.
855. **Schotte, H., B. Schlüter, S. Rust, G. Assmann, W. Domschke and M. Gaubitz.** Interleukin-6 promoter polymorphism (--174 G/C) in Caucasian German patients with systemic lupus erythematosus. *Rheumatol.* 40: 393-400, 2001.
856. **Schulte, H., A. von Eckardstein, P. Cullen and G. Assmann.** Übergewicht und kardiovaskuläres Risiko. *Herz* 26: (3) 170-177, 2001.
857. **Seedorf, U., and G. Assmann.** The role of PPAR α in obesity. *Nutr. Metab. Cardiovasc. Dis.* 11: 189-194, 2001.
858. **Tataru, M.C., H. Schulte, A. von Eckardstein, J. Heinrich, G. Assmann and E. Koehler.** Plasma fibrinogen in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. *Coronary Artery Disease* 12: 157-165, 2001.

859. **Utech, M., G. Hoebbel, S. Rust, H. Reinecke, G. Assmann and M. Walter:** Accumulation of RhoA, RhoB, RhoG, and Rac1 in fibroblasts from Tangier disease subjects suggests a regulatory role of Rho family proteins in cholesterol efflux. *Biochem. Biophys. Res. Commun.* 280: 229-236, 2001.
860. **von Dehn, G., O. von Dehn, W. Völker, C. Langer, G.F. Weinbauer, H.M. Behre, E. Nieschlag, G. Assman and A. von Eckardstein:** Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. *Horm. Metab. Res.* 33: 110-114, 2001.
861. **von Eckardstein, A. and G. Assmann:** Clinical implications of elevated lipoprotein (a). *Curr. Atheroscler. Rep.* 3: 267-270, 2001.
862. **von Eckardstein, A., C. Langer, T. Engel, I. Schaukal, A. Cignarella, J. Reinhardt, S. Lorkowski, Z. Li, X. Zhou, P. Cullen and G. Assmann:** ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyte-derived macrophages. *FASEB J.* 15: 1555-1561, 2001.
863. **von Eckardstein, A., J.R. Nofer and G. Assmann:** High Density Lipoproteins and Arteriosclerosis – Role of Cholesterol Efflux and Reverse Cholesterol Transport. *Arterioscler. Thromb. Vasc. Biol.* 21: 13-27, 2001.
864. **von Eckardstein, A., H. Schulte, P. Cullen and G. Assmann:** Lipoprotein (a) further increases the risk of coronary events in men with high global cardiovascular risk. *J. Am. Coll. Cardiol.* 37: 434-439, 2001.
865. **von Eckardstein, A., P. Cullen and G. Assmann:** Problems in the measurement of Lp(a) (millimoles per liter versus milligrams percent): Reply. *J. Am. Coll. Cardiol.* 38: 1584-1585, 2001.
866. **von Eckardstein, A. and G. Assmann:** Prävention kardiovaskulärer Erkrankungen bei der Frau. In: Beller, F.K. *Brevier des Frauenarztes als Hausarzt der Frau* Band 2: Gynäkologische Grenzgebiete, Herausgeber: Berufsverband der Frauenärzte e.V., pro Kongressverlag Gertrud Lulinski GmbH, Hofstetten, 57-82, 2001.
867. **von Eckardstein, A., F. Fischer, H. Schulte, M. Tataru, E. Kohler and G. Assmann:** Association of serum apolipoprotein A-I (but not high-density lipoprotein cholesterol) with healed myocardial infarction in men independent of serum insulin and C-peptide. *Am. J. Cardiol.* 88: (7), 723-726, 2001.
868. **von Eckardstein, A., K. Schmiedem, A. Hövels, E. Gülbahce, S. Schuler-Lüttmann, J. Elbers, F. Helmond, HJT. Coelingh Bennink and G. Assmann:** Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. *Atherosclerosis* 159: 433-439, 2001.
869. **Wahrburg, U. and G. Assmann:** Properties of olive oil. *Lancet* 357: 1626, 2001.
870. **Assmann, G., P. Cullen and H. Schulte:** Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study. *Circulation* 105: 310-315, 2002.
871. **Assmann, G., F. Sacks, A. Awad, A. Ascherio, A. Bonanome, B. Berra, F.M. Booyse, R. Carmena, W. Dahlan, M. DeLorgeril, E.R. De Oliveria, R.C. Ellison, J. Foreyt, G. Galli, A. Garg, A. Giacosa, H. Hauner, E. Helsing, F. Hu, F.P. Jimenez, U. Keil, P.M. Kris-Etherton, L. Kushi, P. Mata, M. Mancini, J. Mancini, M.E. Mazzei, K. McManus, M. Nestle, J.M. Ordovas, R. Paoletti, G. Riccardi, S. Renaud, J.T. Salonen, T. Sanders, Y. Seyama, T. Sorensen, R. Stanton, A. Trichopoulou, B. Watzl and J. Yudkin:** Dietary Fat Consensus Statements. *Am. J. Med.* 113: Suppl. 5-8, 2002.

872. **Benze, G., J. Heinrich, H. Schulte, S. Rust, U. Nowak-Göttl, M. Tataru, E. Köhler, G. Assmann and R. Junker:** Association of the GPIa C(807)T and GPIIa PI(A1/A2)polymorphisms with premature myocardial infarction in men. *Eur. Heart J.* 23: 325-330, 2002.
873. **Clarke R., R. Collins, S. Lewington, A. Donald, G. Alftan, J. Tuomilehto, E. Arnesen, K. Bonna, J. Blacher, G.H.J. Boers, A. Bostom, M.L. Bots, D.E. Grobee, L. Brattstrom, M.M.B. Breteler, A. Hofman, J.C. Chambers, J.S. Kooner, B.M. Coull, R.W. Evans, L.H. Kuller, S. Evers, A.R. Folsom, G. Freyburger, F. Parrot, J. Genst, K. Dalery, I.M. Graham, L. Daly, E.K. Hoogeveen, P.J. Kostense, C.D.A. Stehouwer, P.N. Hopknis, P. Jacques, J. Selhub, F.C. Luft, P. Jungers, A. Lindgren, Y.I. Lolin, F. Loehrer, B. Fowler, M.A. Mansoor, M.R. Malinow, P. Ducimetiere, O. Nygard, H. Refsum, S.E. Vollset, P.M. Ueland, G.S. Omenn, S.A.A. Beresford, J.M. Roseman, H.H. Parving, M.A. Gall, I.J. Perry, S.B. Ebrahim, A.G. Shaper, K. Robinson, D.W. Jacobsen, S.M. Schwartz, D.S. Siscovick, M.J. Stamper, C.H. Henekens, E.J.M. Feskens, D. Kromhout, J. Ubbink, P. Elwood, J. Pickering, P. Verhoef, A. von Eckardstein, H. Schulte, G. Assmann, N. Wald, M.R. Law, P.H. Whincup, D.E.L. Wilcken, P. Sherliker, P. Linksted, G.D. Smith, J.C.M. Witteman, B. Israelsson, G. Sexton, L.L. Wu, R. Joubbran, B. Norrving, B. Hultberg, A. Andersson, B.B. Johansson C. Bergmark, A.M. Svardal A.E. Evans, N. Pancharuniti, C. A. Lewis, R. Holman, I. Stratton, C. Johnston and J. Morris:** Homocysteine and risk of ischemic heart disease and stroke. *JAMA* 288: 2015-2022, 2002.
874. **Eckel, F., C. Lersch, G. Assmann and E. Schulte-Frohlinde:** Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: A pilot study. *Cancer Invest.* 20: 180-185, 2002.
875. **Funke, H., H. Schulte and G. Assmann:** Hochrisikopatienten für Herzinfarkt und Schlaganfall: genetische Prädisposition und andere Faktoren. In Rosenthal, Wahn, Wolf (eds.): *Einfluss von Genomprojekt und Pharmacogenetics auf die medizinische Entwicklung*. Schattauer Verlag, Stuttgart, 89-100, 2002.
876. **Horter, M.J., S. Sondermann, H. Reinecke, J. Bogdanski, A. Woltering, S. Kerber, G. Breithardt, G. Assmann and A. von Eckardstein:** Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women. *Acta Physiol Scand* 176: 123-130, 2002
877. **Idel, S., P. Ellinghaus, C. Wolfrum, J.R. Nofer, J. Gloerich, G. Assmann, F. Spener and U. Seedorf:** Branched-chain fatty acids induce nitric oxide-dependent apoptosis in vascular smooth muscle cells. *J. Biol. Chem.* 277: 49319-49325, 2002.
878. **Kratz, M., P. Cullen, F. Kannenberg, A. Kassner, M. Fobker, P.M. Abuja, G. Assmann and U. Wahrburg:** Effects of dietary fatty acids on the composition and oxidizability of low-density lipoprotein. *Eur. J. Clin. Nutr.* 56: 72-81, 2002.
879. **Kratz, M., E. Gülbahce, A. von Eckardstein, P. Cullen, A. Cignarella, G. Assmann and U. Wahrburg:** Dietary mono- and polyunsaturated fatty acids have similar effects on LDL size in healthy human subjects of both sexes. *J. Nutr.* 132: 715-718, 2002.
880. **Kratz, M., A. von Eckardstein, M. Fobker, A. Buyken, N. Posny, H. Schulte, G. Assmann and U. Wahrburg:** The impact of dietary fat composition on serum leptin concentrations in healthy non-obese men and women. *J. Clin. Endocrinol. Metab.* 87: 5008-5014, 2002.
881. **Langer, C., B. Gansz, C. Goepfert, T. Engel Y. Uehara, G. von Dehn, H. Jansen, G. Assmann and A. von Eckardstein:** Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. *Biochem. Biophys. Res. Commun.* 296: (5) 1051-1057, 2002.
882. **Moennig, G., E. Schulze-Bahr, H. Wedekind, L. Eckardt, P. Kirchhof, H. Funke, S. Kotthoff, J. Vogt, G. Assmann, G. Breithardt, and W. Haverkamp:** Clinical aspects and molecular genetics of the Jervell- and Lange-Nielsen Syndrome. *Z. Kardiol.* 91: 380-388, 2002.

883. **Nofer, JR., B. Kehrel, M. Fobker, B. Levkau, G. Assmann and A. von Eckardstein:** HDL and arteriosclerosis: Beyond reverse cholesterol transport. *Atherosclerosis* 161: 1–16, 2002.
884. **Prospective Studies Collaboration:** Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 360: 1903-1913, 2002.
885. **Reinecke, H., J. Bogdanski, A. Woltering, G. Breithardt, G. Assmann, S. Kerber and A. von Eckardstein:** Relation of Levels of Sex-Hormone-Binding-Globulin to Coronary Heart Disease in Postmenopausal Women. *Am. J. Cardiol.* 90: 364-368, 2002.
886. **Sacks, F.M., G. Assmann, C.M. Ballantyne, P. Barter et al.:** The role of HDL cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. *Am. J. Cardiol.* 90: 139-143, 2002 .
887. **Schlüter, B., C. Raufhake, M. Erren, H. Schotte, F. Kipp, S. Rust, H. van Aken, G. Assmann and E. Berendes:** Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. *Crit. Care. Med.* 30: 32-37, 2002
888. **Schlüter, B., M. Erren, H. Schotte, R. Junker, S. Rust and G. Assmann:** The mutagenically separated polymerase chain reaction is a rapid and reliable method for genotyping of the tumor necrosis factor-alpha promoter polymorphism (- 308 G/A). *Clin. Chim. Acta.* 320: 135-138, 2002.
889. **Schulte, H., A. von Eckardstein, P. Cullen, and G. Assmann:** Übergewicht und kardiovaskuläres Risiko. *Herz- Cardiovascular Diseases* 26: 170-177, 2002.
890. **Uehara, Y., T. Engel, Z. Li, C. Goepfert, S. Rust, X. Zhou, C. Langer, C. Schachtrup, J. Wiekowski, S. Lorkowski, G. Assmann and A. von Eckardstein:** Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. *Diabetes* 51: 2922-2928, 2002
891. **von Eckardstein, A., H. Schulte and G. Assmann:** Abschätzung des Herzinfarkttrisikos – Über die praktische Bedeutung verschiedener Risikofaktoren (Teil 1). *Ars Medici* 11: 504-512, 2002.
892. **von Eckardstein, A., H. Schulte and G. Assmann:** Abschätzung des Herzinfarkttrisikos –Über die praktische Bedeutung verschiedener Risikofaktoren (Teil 2). *Ars Medici* 12: 549-556, 2002.
893. **Voss, R., P. Cullen, H. Schulte and G. Assmann:** Prediction of risk of coronary events in middle-aged men in the PROCAM study using neural networks. *Int. J. Epidemiol.* 31: 1253-1262, 2002.
894. **Zhou, X., T. Engel, C. Goepfert, M. Erren., G. Assmann and A. von Eckardstein:** The ATP binding cassette transporter A1 contributes to the secretion of interleukin 1 β from macrophages but not from monocytes. *Biophys. Biochem. Res. Commun* 291: 598-604, 2002.
895. **Assmann, G. and A. Buyken:** Den Herzinfarkt vermeiden – erste gemeinsame europäisch-amerikanische Empfehlungen. *Herz* 28: 473-474, 2003.
896. **Assmann, G., and JR. Nofer:** Atheroprotective effects of high-density lipoproteins. *Annu. Rev. Med.* 54: 321-341, 2003.
897. **Assmann, G., P. Cullen and H. Schulte:** Methods to identify increased risk of coronary disease in the general population – Conclusion is oversimplification. *BMJ* 327: 619, 2003.
898. **Assmann, G., P. Cullen and H. Schulte:** “Polypill” to fight cardiovascular disease. Interpretation of trial data is optimistic. *BMJ* 327: 808, 2003.

899. **Assmann, G., P. Cullen, H.W. Hense, and H. Schulte:** Response to Conroy et al. SCORE Project. *Eur. Heart J.* 24: 2070-2071, 2003.
900. **Assmann, G., J. Barth, K. von Bergmann, M. Gottwik G.M. Haas et al.:** Evaluation des kardiovaskulären Risikos. In Schwandt, Haas (eds.): *Prävention von Herzinfarkt und Schlaganfall – Therapieoptionen, Konzepte, Programme.* Arteriosklerose-Präventions-Institut (API), München 38-40, 2003.
901. **Cullen, P., S Lorkowski, H. Schulte, U. Seedorf and G. Assmann:** Inflammation in atherosclerosis, not yet time for a paradigm shift? *Curr. Opin. Lipidol.* 14: 325-328, 2003.
902. **Hense, H.W., H. Schulte, H. Löwel, G. Assmann and U. Keil:** Framingham risk function overestimates risk of coronary heart disease in men and women from Germany – results from the MONICA Augsburg and the PROCAM cohorts. *Eur. Heart. J.* 24: 937-45, 2003.
903. **Kratz, M., U. Wahrburg, A. von Eckardstein, B. Ezeh, G. Assmann and F. Kronenberg:** Dietary mono- and polyunsaturated fatty acids similarly increase plasma apolipoprotein A-IV concentrations in healthy men and women. *J. Nutr.* 133: 1821-1825, 2003.
904. **Naghavi, M., P. Libby, E. Falk, SW. Casscells, S. Litovsky, J. Rumberger, JJ. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, Z. Fayad, PH. Stone, S. Waxman, P. Raggi, M. Madjid, A. Zarrabi, A. Burke, C. Yuan, PJ. Fitzgerald, DS Siscovick, CL de Korte, M. Aikawa, KE. Juhani Airaksinen, G. Assmann, CR. Becker, JH. Chesebro, A. Farb, ZS. Galis, C. Jackson, IK. Jang, W. Koenig, RA Lodder, K. March, J. Demirovic, M. Navab, SG. Priori, MD. Rekhter, R. Bahr, SM. Grundy, R. Mehran, A. Colombo, E. Boerwinkle, C. Ballantyne, W. Jr. Insull, RS Schwartz, R. Vogel, PW. Serruys, GK. Hansson, DP. Faxon, S. Kaul, H. Drexler, P. Greenland, JE. Muller, R. Virmani, PM. Ridker, DP. Zipes, PK. Shah and JT. Willerson:** From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. *Circulation* 108: 1664-1672, 2003.
905. **Naghavi, M., P. Libby, E. Falk, SW. Casscells, S. Litovsky, J. Rumberger, JJ. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, Z. Fayad, PH. Stone, S. Waxman, P. Raggi, M. Madjid, A. Zarrabi, A. Burke, C. Yuan, PJ. Fitzgerald, DS Siscovick, CL de Korte, M. Aikawa, KE. Juhani Airaksinen, G. Assmann, CR. Becker, JH. Chesebro, A. Farb, ZS. Galis, C. Jackson, IK. Jang, W. Koenig, RA Lodder, K. March, J. Demirovic, M. Navab, SG. Priori, MD. Rekhter, R. Bahr, SM. Grundy, R. Mehran, A. Colombo, E. Boerwinkle, C. Ballantyne, W. Jr. Insull, RS Schwartz, R. Vogel, PW. Serruys, GK. Hansson, DP. Faxon, S. Kaul, H. Drexler, P. Greenland, JE. Muller, R. Virmani, PM. Ridker, DP. Zipes, PK. Shah and JT. Willerson:** From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. *Circulation* 108: 1772-1778, 2003.
906. **Nofer, JR., R. Feuerborn, B. Levkau, A. Sokoll, U. Seedorf and G. Assmann:** Involvement of Cdc42 signaling in apo A-I-induced cholesterol efflux. *J. Biol. Chem.*, 278: 53055-53062, 2003.
907. **Nofer, JR., S. Geigermüller, C. Göpfert, G. Assmann, E. Buddecke and A. Schmidt:** High density lipoprotein-associated lysophospholipids reduce E-selectin expression in human endothelial cells. *Biophys. Biochem. Res. Commun.* 310, 98-103, 2003.
908. **Onat, A., G. Hergenç, V. Sansoy, M. Fobker, K. Ceyhan, S. Toprak and G. Assmann:** Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. *Atherosclerosis* 168: 81-89, 2003.
909. **Schotte, W., P. Willeke, S. Rust, G. Assmann, W. Domschke, M. Gaubitz and B. Schlüter:** The transforming growth factor-beta 1 gene polymorphism (G915C) is not associated with systemic lupus erythematosus. *Lupus* 12: 86-92, 2003.

910. **von Eckardstein, A., D. Crook, J. Elbers, J. Ragoobir, B. Ezeh, F. Helmond, N. Miller, H. Dieplinger, H. Coelingh Bennink, and G. Assmann:** Tibolone lowers HDL cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. *Clin. Endocrinol.* 58: 49-58, 2003.
911. **von Eckardstein, A., H. Schulte and G. Assmann:** Die Erkennung des Hochrisikopatienten für den Herzinfarkt. *Praxis (Schweiz. Rundsch. Med.)* .92: 441-447, 2003.
912. **Assmann, G., A. Corsini, J. Davignon, S.M. Grundy, P. Libby, W. März, R. P. Mason, S.E. Nissen, T.R. Pedersen, P.M. Ridker, W. Riesen, E.J. Schäfer and D. Waters:** Cholesterol-lowering with statins: Are they all the same? Summary of the expert symposium at the 53rd annual scientific sessions of the American College of Cardiology. *Drugs of Today* 40 (6): 555-561, 2004.
913. **Assmann, G. and J.R. Nofer:** The Protective Role of HDL Part 3. In: Lectures in Clinical Atherosclerosis and Dyslipidaemia, *Science Press, Astra Zeneca Cardiovascular*, 2004.
914. **Assmann, G.:** Symposium introduction. *Br. J. Cardiol.* 11: (suppl 2) 1-2, 2004.
915. **Assmann, G., P. Cullen and H. Schulte:** Risk assessment of myocardial infarction and stroke. *International Congress Series* 1262, 30-38, 2004.
916. **Assmann, G., P. Cullen and M. Stoll:** Individual risk stratification in myocardial infarction and stroke. *Dade Behring Journal* 2: Nr. 2, 7-12, 2004.
917. **Assmann, G., and A.M. Gotto:** HDL cholesterol and protective factors in atherosclerosis. *Circulation* 109: III-8 - III-14, 2004.
918. **Assmann, G., JR. Nofer and H. Schulte:** Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. *Endocrinol. Metab. Clin. North. Am.* 33: 377-392, 2004.
919. **Chapman, M.J., G. Assmann, J.C. Fruchart, J. Shepherd and C. Sirtori:** Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C. *Curr. Med. Res. and Opin.* 20: 1253-1268, 2004.
920. **Engel, T., A. Lueken, G. Bode, U. Hobohm, S. Lorkowski, B. Schlueter, S. Rust, P. Cullen, M. Pech, G. Assmann and U. Seedorf:** ADP-ribosylation factor (ARF)-like 7 (ARL7) is induced by cholesterol loading and participates in apolipoprotein AI-dependent cholesterol export. *FEBS Lett.* 566: 241-246, 2004.
921. **Fischer, F., H. Schulte, S. Mohan, M.C. Tataru, E. Köhler, G. Assmann and A. von Eckardstein:** Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. *Clin. Endocrinol.* 61: 595-602, 2004.
922. **Jacobs, B., G. De Angelis-Schierbaum, S. Egert, G. Assmann and M. Kratz:** Individual serum triglyceride responses to high-fat and low-fat diets differ in men with modest and severe hypertriglyceridemia. *J. Nutr.* 134: 1400-1405, 2004.
923. **Kockx, M., KA. Rye, K. Gaus, CM. Quinn, J. Wright, T. Sloane, D. Sviridov, Y. Fu, D. Sullivan, JR. Burnett, S. Rust, G. Assmann, G. Anantharamaiah, MN. Palgunachari, S. Lund-Katz, MC. Phillips, RT. Dean, W. Jessup and L. Kritharides:** Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux. *J. Biol. Chem.* 279: 25966-25977, 2004.

924. **Kostis, J.B., A.C. Wilson, A.R. Folsom, L. Chambless, K. Wu, M. Benderly, U. Goldbourt, J. Willeit, S. Kiechl, J.W.G. Yarnell, P.M. Sweetam, P.C. Elwood, M. Cushman, B.M. Psaty, A. Tybjaerg-Hansen, F. Haverkat, M.P.M. Maat, S.G. Thompson, F.G.R. Fowkes, A.J. Lee, F.B. Smith, V. Salomaa, V. Rasi, E. Vahtera, P. Jousilahti, J. Pekkanen, R. D'Agostino, W.B. Kannel, D. Levy, P.W.F. Wilson, C.L. Arocha-Pinango, A. Rodriguez-Larralde, E. Nagy, M. Mijares, R. Espinosa, E. Roa, E. Ryder, M.P. Diez-Ewald, G. Campos, V. Fernandez, E. Torres, R. Marchioli, F. Valagussa, A. Rosengren, L. Wilhelmsen, G. Lappas, H. Eriksson, P. Cremer, D. Nagel, J.D. Curb, B. Rodriguez, K. Yano, J.T. Salonen, K. Nyysönen, T.P. Tuomainen, B. Hedblad, P. Lind, H. Loewel, H.W. Hense, W. Koenig, T.W. Meade, J.A. Cooper, B. De Stavola, K. Garrow, C. Knottenbelt, G.J. Miller, J.A. Cooper, K.A. Bauer, R.D. Rosenberg, S. Sato, A. Kitamura, Y. Naito, H. Iso, V. Salomaa, V. Rasi, E. Vahtera, P. Jousilahti, T. Palosuo, P. Ducimetiere, P. Amouyel, D. Arveiler, A.E. Evans, J. Ferrieres, I. Juhan-Vague, H. Schulte, G. Assmann, B. Cantin, B. Lamarche, J.P. Despres, G.R. Dagenais, H. Tunstall-Pedoe, G.D.O. Lowe, R. Collins, J. Danesh, A. Dickinson, S. Lewington, G.D.O. Lowe, A. Memon, S. Thompson, M. Walker, J. Wheeler, Y. Ben-Shlomo, G.D. Smith, V. Palmieri, J.L. Yeh, T.W. Meade, A. Rudnicka, P. Brennan, C. Knottenbelt, J. Cooper, F. Rodeghiero, A. Toso, J. Shepherd, I. Ford, J. Norrie, E. Brunner, M. Shipley, E.J.M. Feskens and D. Kromhout:** A locus for autosomal dominant sinus node disease is mapped on chromosome. *Eur. J. Cardiovasc. Prev. Rehabil.* 11: 9-17, 2004.
925. **Mönnig, G., J. Wiekowski, P. Kirchhof, J. Stypmann, G. Plenz, L. Fabritz, H.J. Bruns, L. Eckardt, G. Assmann, W. Haverkamp, G. Breithardt and U. Seedorf:** Phytanic acid accumulation is associated with conduction delay and sudden cardiac death in sterol carrier protein-2/sterol carrier protein-x deficient mice. *J. Cardiovasc. Electrophysiol.* 15: 1-7, 2004.
926. **Nofer, JR., M. van der Giet, M. Tölle, I. Wolinska, K. von Wnuck Lipinski, HA.Baba, UJ. Tietge, A. Gödecke, I. Ishii, B. Kleuser, M. Schäfers, M. Fobker, W. Zidek, G. Assmann, J. Chun and B. Levkau:** HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. *J. Clin. Invest.* 113: 569-581, 2004.
927. **Nofer, JR., G. Herminghaus, M. Brodde, E. Morgenstern, S. Rust, T. Engel, U. Seedorf, G. Assmann, H. Bluethmann and B.E. Kehrel:** Impaired platelet activation in familial high density lipoprotein deficiency (Tangier disease). *J. Biol. Chem.* 279: 34032-34037, 2004.
928. **Schotte, H., M. Gaubitz, P. Willeke, N. Tidow, G. Assmann, W. Domschke and B. Schlüter:** Interleukin-10 promoter microsatellite polymorphisms in systemic lupus erythematosus: Association with the anti-Sm immune response. *Rheumatol.* 43: 1357-1363, 2004.
929. **Schotte, H., B. Schlüter, S. Drynda, P. Willeke, N. Tidow, G. Assmann, W. Domschke, J. Kekow and M. Gaubitz:** Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. *Ann. Rheum. Dis.* 64: 575-581, 2004.
930. **Seedorf, U., T. Engel, A. Lueken, G. Bode, S. Lorkowski and G. Assmann:** Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages. *Biochem. Biophys. Res. Commun.* 320: 1337-1341, 2004.
931. **Assmann, G.:** Calculating global risk: the key to intervention. *Eur. Heart J. Suppl.* 7: Supplement F, F9-F14, 2005.
932. **Assmann, G.:** Kardiovaskuläre Risikoabschätzung – PROCAM und neue Algorithmen der Stratifizierung. *Biomed. Technik* 50: 227-232, 2005.
933. **Assmann, G.:** Beyond statin therapy: Why we need new thinking. *Curr. Med. Res. Opin.* 21: Suppl. 6, S3-S8, 2005.

934. **Assmann, G.:** Cardiovascular risk factors – where do these come from? Interview by Nicola von Lutterotti. *Dt. Med. Wochenschr. Suppl.* 1: 33-34, 2005
935. **Assmann, G., P. Cullen, T. Evers, D. Petzinna and H. Schulte:** Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. *Eur. Heart J.* 26: 2120 – 2126, 2005.
936. **Assmann, G., P. Cullen, J.-C. Fruchart, H. Greten, M. Naruszewicz, A. Olsson, R. Paoletti, W. Riesen, M. Stoll, M. Tikkanen and A. von Eckardstein:** Implications of emerging risk factors for therapeutic intervention. *Nutr. Metab. Cardiovasc. Dis.* 15: 373-381, 2005.
937. **Assmann, G., P. Cullen and H. Schulte.** Epidemiologie kardiovaskulärer Erkrankungen und Bedeutung einer differenzierten Risikoabschätzung für die Prävention. In: *Fortschritt und Fortbildung in der Medizin* Bd.: 29 (2005/2006), Deutscher Ärzte-Verlag Köln, 2005.
938. **Assmann, G., J. Chapman and J. Shepherd:** Proceedings of the international Merck symposium on HDL raising beyond LDL-C reduction: New paradigms in the reduction of cardiovascular risk. *Eur. Heart J. Suppl.* 7(F): F3, 2005.
939. **Cignarella, A., T. Engel, A. von Eckardstein, M. Kratz, S. Lorkowski, A. Lueken, G. Assmann and P. Cullen:** Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors. *Atherosclerosis* 179: 229-236, 2005.
940. **Cullen, P., H. Schulte and G. Assmann:** Lipidstoffwechsel und Herzinfarkttrisiko – neue Erkenntnisse und therapeutische Implikationen. *Dt. Med. Wochenschr.* 130: 2220-2225, 2005.
941. **Cullen, P., H. Schulte and G. Assmann:** Use of risk factors in determining individual coronary risk. *Z. Kardiol.* 94: 65-69, 2005.
942. **Danesh, J., S. Lewington, S.G. Thompson, G.D. Lowe, R. Collins, J.B. Kostis, A.C. Wilson, A.R. Folsom, K. Wu, M. Benderly, U. Goldbourt, J. Willeit, S. Kiechl, J.W. Yarnell, P.M. Sweetnam, P.C. Elwood, M. Cushman, B.M. Psaty, R.P. Tracy, A. Tybjaerg-Hansen, F. Haverkate, M.P. de Maat, F.G. Fowkes, A.J. Lee, F.B. Smith, V. Salomaa, K. Harald, R. Rasi, E. Vahtera, P. Jousilahti, J. Pekkanen, R. D’Agostino, W.B. Kannel, P.W. Wilson, G. Tofler, C.L. Arocha-Pinango, A. Rodriguez-Larralde, E. Nagy, M. Mijares, R. Espinosa, E. Rodriguez-Roa, E. Ryder, M.P. Diez-Ewald, G. Campos, V. Fernandez, E. Torres, R. Marchioli, F. Valagussa, A. Rosengren, L. Wilhelmsen, G. Lappas, H. Eriksson, P. Cremer, D. Nagel, J.D. Curb, B. Rodriguez, K. Yano, J.T. Salonen, K. Nyssönen, T.P. Tuomainen, B. Hedblad, P. Lind, H. Loewel, W. Koenig, T.W. Meade, J.A. Cooper, B. De Stavola, C. Knottenbelt, G.J. Miller, J.A. Cooper, K.A. Bauer, R.D. Rosenberg, S. Sato, A. Kitamura, Y. Naito, T. Palosuo, P. Ducimetiere, P. Amouyel, D. Arveiler, A.E. Evans, J. Ferrieres, I. Juhan-Vague, A. Bingham, H. Schulte, G. Assmann, B. Cantin, B. Lamarche, J.P. Després, G.R. Dagenais, H. Tunstall-Pedoe, M. Woodward, Y. Ben-Shlomo, G. Davey Smitz, V. Palmieri, J.L. Yeh, A. Rudnicka, P. Ridker, F. Rodeghiero, A. Tosetto, J. Shepherd, I. Ford, M. Roertson, E. Brunner, M. Shipley, E.J. Feskens, D. Kromhout, A. Dickinson, B. Ireland, K. Juzwishin, S. Kaptoge, S. Lewington, A. Memon, N. Sarwar, M. Walker, J. Wheeler, I. White and A. Wood:** Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. *JAMA* 294: 1799-809, 2005.
943. **Hersberger, M., J. Muntwyler, H. Funke, J. Marti-Jaun, H. Schulte, G. Assmann, T.F. Lüscher and A. von Eckardstein:** The CAG repeat polymorphism in the androgen receptor gene is associated with HDL-cholesterol but not with coronary atherosclerosis or myocardial infarction. *Clin. Chem.* 51: 1110-1115, 2005.
944. **Nofer, J.R. and G. Assmann:** Atheroprotective effects of high density lipoprotein (HDL)-associated lysophingolipids. *Trends. Cardiovasc. Med.* 15: 265-271, 2005.

945. **Nofer, J.R., M. Walter and G. Assmann:** Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence. *Expert. Rev. Cardiovasc. Ther.* 6:1071-1086, 2005.
946. **Schlüter, B. and G. Assmann:** Sepsis und Genetik. Zwei Welten treffen sich! *Chir. Praxis* 65, 227 – 231, 2005.
947. **Schotte, H., B. Schlüter, S. Drynda, P. Willeke, N. Tidow, G. Assmann, W. Domschke, J. Kekow and M. Gaubitz:** Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. *Ann. Rheum. Dis.* 64: 575-581, 2005.
948. **Schotte, H., P. Willeke, N. Tidow, W. Domschke, G. Assmann, M. Gaubitz and B. Schlüter:** Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3. *Scand. J. Rheumatol.* 34: 114-121, 2005.
949. **von Eckardstein, A., H. Schulte and G. Assmann:** Comparison of international recommendations for the recognition of asymptomatic high risk patients for a heart attack in Germany. *Z. Kardiol.* 94: 52-60, 2005.
950. **Assmann, G.:** Dyslipidaemia and global cardiovascular risk: clinical issues. *Eur. Heart J. Suppl.* 8: F 40 – F46, 2006.
951. **Assmann, G., H. Benecke, A. Neiss, P. Cullen, H. Schulte and K. Bestehorn:** Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events including Physicians' Experience and Evaluation). *Eur. J. Cardiovasc. Prev. Rehabil.* 13: 776-783, 2006.
952. **Assmann, G., P. Cullen, J. Erbey, D. Ramey, F. Kannenberg and H. Schulte:** Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: Results of a nested case-control analysis of the Prospective Cardiovascular Münster (PROCAM) Study. *Nutr. Metab. Cardiovasc. Dis.* 16: 13-21, 2006.
953. **Assmann, G., P. Cullen, F. Kannenberg and H. Schulte:** Relationship between phytosterol levels and components of the metabolic syndrome in the PROCAM study. *Eur. J. of Cardiovasc. Prev. and Rehabil.*, 14: 208-214, 2007
954. **Assmann, G., P. Cullen and H. Schulte:** Risikoabschätzung – Defizitäre Daten. *Deutsches Ärzteblatt*, 103B, B221-B222, 2006.
955. **Barlera, Simona, C. Specchia, M. Farrall, B. D. Chiodini, M. G. Franzosi, S. Rust, F. Green, E.B. Nicolis, J. Peden, G. Assmann, R. Collins, A. Hamsten, G. Tognoni and H. Watkins:** On behalf of the PROCARDIS Consortium. Multiple QTL influence the serum Lp(a) concentration: a genome-wide linkage screen in the PROCARDIS study. *Eur J Hum Genet. Feb;15(2):221-7*, 2007.
956. **Buyken, A.E., A. von Eckardstein, H. Schulte, P. Cullen and G. Assmann:** Type 2 diabetes mellitus and risk of coronary heart disease – results of the 10-year follow-up of the PROCAM study. *Eur. J. of Cardiovasc. Prev. and Rehabil.*, 14: 230-236, 2007.
957. **Deindl, E., M.M. Zaruba, S. Brunner, B. Huber, U. Mehl, G. Assmann, I.E. Hoefler, J. Müller-Höcker and W.M. Franz:** G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. *FASEB J.* 20: 956-958, 2006.
958. **Engel, T., G. Bode, A. Lueken, M. Knop, F. Kannenberg, J.R. Nofer, G. Assmann and U. Seedorf:** Expression and functional characterization of ABCG1 splice variant ABCG1 (666). *FEBS Letters* 580: 4551-4559, 2006.

959. **Farrall, M., F.R. Green, J.F. Peden, P.G. Olsson, R. Clarke, H.L. Hellenius, S. Rust, J. Lagercrantz, M.G. Franzosi, H. Schulte, A. Carey, G. Olsson, G. Assmann, G. Tognoni, R. Collins, A. Hamsten and H. Watkins:** Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. *Atherosclerosis* 186: (2), S4, 2006.
960. **Gigante, M., E. Ranieri, G. Cerullo, L. Calabresi, A. Iolascon, G. Assmann, L. Morrone, L. Pisciotta, F.P. Schena and L. Gesualdo:** LCAT deficiency: molecular and phenotypic characterization of an Italian family. *J. Nephrol.* 19: 375-381, 2006.
961. **Mönnig, G., L. Eckardt, H. Wedekind, W. Haverkamp, J. Gerss, P. Milberg, K. Wasmer, P. Kirchhof, G. Assmann, G. Breithardt and E. Schulze Bahr:** Electrocardiographic risk stratification in families with congenital long QT syndrome. *Eur. Heart J.* 27: 2074-2080, 2006.
962. **Nofer, J.R., C. Noll, R. Feuerborn, G. Assmann and M. Tepel:** Low Density lipoproteins inhibit the Na⁺/H⁺ antiport in human platelets via activation of p38 (MAP) kinase. *Biochem. Biophys. Res. Commun.* 340: 751-757, 2006.
963. **Nofer, J.R., A.T. Remaley, R. Feuerborn, I. Wolinska, T. Engel, A. von Eckardstein and G. Assmann:** Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. *J. Lipid Res.* 47: 794-803, 2006.
964. **Nofer, J.R., M. Brodde, G. Herminghaus, U. Seedorf, G. Assmann and B.E. Kehrel:** Normal platelet reactivity in apolipoprotein E (apo E)-deficient mouse. *Platelets* 17: 498-500, 2006.
965. **Pedersen, T.R., G. Assmann, J.P. Bassand, M.J. Chapman, R. Erbel and C. Sirtori:** Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment. *Diabetes Vasc. Dis. Res.* 3 (suppl 2), S1-S12, 2006.
966. **von Eckardstein, A. and G. Assmann:** Störungen im Stoffwechsel der High-density-Lipoproteine. In Schwandt, Parhofer (eds.): *Handbuch der Fettstoffwechselstörungen*, Schattauer Verlag, Stuttgart, 3. Aufl. 112-126, 2006.
967. **von Otte S., J-R. Paletta, S. Becker, S. König, M. Fobker, R.R. Greb, L. Kiesel, G. Assmann, K. Diedrich and J.R. Nofer:** Follicular fluid high density lipoprotein-associated sphingosine 1-phosphate is a novel mediator of ovarian angiogenesis. *J. Biol. Chem.* 281: 5398-5405, 2006.
968. **Wronska-Nofer, T., J.R. Nofer, J. Stetkiewicz, M. Wierzbicka, H. Bolinska, M. Fobker, H. Schulte, G. Assmann and A. von Eckardstein:** Evidence for oxidative stress at elevated plasma thiol levels in chronic exposure to carbon disulfide (CS₂) and coronary heart disease. *Nutr. Metab. Cardiovasc. Dis.*, 2006.
969. **Xie, Q., T. Engel, M. Schnoor, J. Niehaus, O. Hofnagel, I. Buers, P. Cullen, U. Seedorf, G. Assmann and S. Lorkowski:** Cell Surface Localization of ABCG1 does not require LXR activation. *Arterioscler. Thromb. Vasc. Biol.* 26: e143-e144, 2006.
970. **Assmann, G., R. Guerra, G. Fox, P. Cullen, H. Schulte, W. DuWayne and S. M. Grundy:** Harmonizing the Definition of the Metabolic Syndrome: Comparison of the Criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European Populations. *Am. J. Cardiol.*, 99: 541-548, 2007.
971. **Assmann, G., H. Schulte, P. Cullen, A. Neiss and K. Bestehorn:** Treatment of Hyperlipidemia in Primary Practice in Germany: Sub-group Analyses from the 4E-registry with Particular Emphasis on Men and Women with Diabetes Mellitus. *Exp. Clin. Endocrinol. Diabetes.* 115: 85-91, 2007.

972. **Barlera, S., C. Specchia, M. Farrall, B. D. Chiodini, M. F. Green, E.B. Nicolis, J. Peden, G. Assmann, R. Collins, A. Ham and H. Watkins:** On behalf of the PROCARDIS Consortium. Multiple QTL influence the serum Lp(a) concentration: a genome-w. PROCARDIS study. *Eur. J. of Hum. Gen.*, 15: 221-227, 2007.
973. **Berger, K., F. Stögbauer, M. Stoll, J. Wellmann, A. Hüge, S. Cheng, C. Kessler, U. John, G. Assmann, E. Ringelstein and H. Funke:** The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. *Hum. Genet.* 121: 169-178, 2007.
974. **Engel, T., F. Kannenberg, M. Fobker, J.R. Nofer, G. Bode, A. Lueken, G. Assmann and U. Seedorf:** Expression of ATP binding cassette-transporter ABCG1 prevents cell death by transporting cytotoxic 7 β -hydroxycholesterol. *FEBS Letters*, Apr. 17; 581 (8): 1673-1680, 2007.
975. **Kratz, M., F. Kannenberg, E. Gramenz, B. Berning, E. Trautwein, G. Assmann and S. Rust:** Similar serum plant sterol responses of human subjects heterozygous for a mutation causing sitosterolemia and controls to diets enriched in plant sterols or stanols. *Eur. J. Clin. Nutr.* 61 (7): 896-905, 2007.
976. **Muntoni, S., H. Wiebusch, M. Jansen-Rust, S. Rust, U. Seedorf, H. Schulte, K. Berger, H. Funke and G. Assmann:** Cholesterol Ester Storage Disease is an Underdiagnosed Disorder. *Arterioscler. Thromb. Vasc. Biol.*, 27: 1866-1868, 2007.
977. **Nofer, J.R., M. Bot, M. Brodde, P.J. Taylor, P. Salm, V. Brinkmann, T. van Berkel, G. Assmann and E.A.L. Biessen:** FTY720, a Synthetic Sphingosine 1 Phosphate Analogue, Inhibits Development of Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. *Circulation* 115: 501-508, 2007.
978. **Schlüter, B. and G. Assmann:** Sepsis und Genetik. Zwei Welten treffen sich. In: *Tägliche Praxis*, Marseille Verlag, München, Jahrgang 48, Heft 1, 3 – 7, 2007.
979. **Tikkanen, M. J., G. Jackson, T. Tammela, G. Assmann, A. Palomäki, M. Kupari and A. Olsson:** Erectile Dysfunction as a Risk Factor for Coronary Heart Disease: Implications for Prevention. *Int. J. Clin. Pract.* 61: 265-268, 2007.
980. **Uehara, Y., S. Miura, A. von Eckardstein, S. Abe, A. Fujii, Y. Matsuo, S. Rust, S. Lorkowski, G. Assmann, T. Yamada and K. Saku:** Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. *Atherosclerosis* 191: 11-21, 2007.
981. **von Eckardstein, A., H. Schult, and G. Assmann:** Das kardiovaskuläre Gesamtrisiko. In Battegay, E., Nosedá, G., Riesen W.F. (eds.): *Atheroskleroseprävention: Diagnostik und Therapie von Risikofaktoren*, Verlag Huber Hogrefe, 2007.
982. **Birjmohun, R.S., Kastelein, J.J.P., Poldermans, D., Stroes, E.S.G., Hostalek, U. and Assmann, G.:** Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. *Curr. Med. Res. Opinion*, 23: 7, 1707-1713, 2007.
983. **Assmann, G. and Seedorf, U.:** Genetik und kardiovaskuläres Risiko. *Arzt & Prävention*, Ausg. 3, 30-31, 2007.
984. **Muntoni, S., Wiebusch, H., Jansen-Rust, M., Rust, S., Seedorf, U., Schulte, H., Berger, K., Funke, H. and Assmann, G.:** Prevalence of Cholesteryl Ester Storage Disease. *Arterioscler. Thromb. Vasc. Biol.* 27: 1866-1868, 2007.
985. **Cullen, P., Schulte, H. and Assmann, G.:** Die Ermittlung des individuellen koronaren Risikos – Prävention der koronaren Herzkrankheit. *J. Preventive Med.* Vol. 3, No 3+4: 300-308, 2007.

986. **Assmann, G., Schulte, H., Cullen, P. and Seedorf, U.:** Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. *Eur. J. Clin. Invest.* 37, 12, 925-932, 2007.
987. **Assmann, G.:** Herzinfarkt und Schlaganfall: Risikopatienten, Frühtherapie, Perspektiven. *Jahrbuch 2006 der Deutschen Akademie der Naturforscher Leopoldina* (R. 3) 52, 361-387, 2007.
988. **Schulte, H. and Assmann, G.:** The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of Cardiovascular diseases – PROCAM. *Eur. J. Epidemiol.* 22: 839-869, 2007.
989. **Assmann, G., Schulte, H. and Seedorf, U.:** The role of genetic predisposition and biomarkers in atherosclerosis. *Int. Congress Series* 1303, 95 – 102, 2007.
990. **Assmann, G., Kanneberg, F., Ramey, D.R., Musliner, T.A., Gutkin, S.W. and Veltri, E.P.:** Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. *Curr. Med. Res. Opinion*, 24: 1, 249-259, 2008.
991. **Ria, M., Bengtsson, O., Eriksson, P., Farrall, M., Green, F.R., Peden, J.F., Assmann, G., Tognoni, G., Collins, R., Watkins, H., Hamsten, A. and Lagercrantz, J.:** A trio family analysis of the role of TNFSF4 in coronary artery disease (PROCARDIS). 2008.
992. **Mueller OM, Chang E, Deng D, Franz T, Jing D, Kincaid R, Konigshofer Y, Kratzmeier M, McNulty M, Qian H, Schneider J, Schulte H, Seedorf U, Tian X, Van Cleve M, Yang D, Assmann G.:** PROCAM Study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. *Clin Chem Lab Med.* 46:490-8, 2008. doi: 10.1515/CCLM.2008.117.
993. **Assmann, G., Kastelein, J.J., Tonkin, A., Amarenco, P., Carmena, R., Davignon, J., Fruchart, J.-C., Gotto, A.M. and Paoletti, R.:** Risk Assessment and Patient Communication. *ILIB Mini-handbook series, 1. Ed.*, 2008
994. **Gotto, A.M., Tonkin, A., Amarenco, P., Assmann, G., Carmena, R., Davignon, J., Fruchart, J.-C., Kastelein, J.J. and Paoletti, R.:** Implications of Recent Trials of Lipid-Modifying Therapy for Clinical Practice. *ILIB Mini-handbook series, 1. Ed.*, 2008
995. **Amarenco, P., Assmann, G., Carmena, R., Davignon, J., Fruchart, J.-C., Gotto, A.M., Kastelein, J.J., Paoletti, R. and Tonkin, A.:** Stroke and Lipids. *ILIB Mini-handbook series, 1. Ed.*, 2008
996. **Carmena, R., Davignon, J., Fruchart, Amarenco, P., Assmann, G., Gotto, A.M., Kastelein, J.J., Paoletti, R. and Tonkin, A.:** The Metabolic Syndrome. *ILIB Mini-handbook series, 1. Ed.*, 2008
997. **Tölle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S, Keul P, Assmann G, Chun J, Levkau B, van der Giet M, Nofer JR.:** HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production.. *Arterioscler Thromb Vasc Biol.* 28:1542-8, 2008. doi: 10.1161/ATVBAHA.107.161042. Epub 2008 May 15.
998. **a. Assmann, G., Schulte, H. and Seedorf, U.:** Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Münster (PROCAM) Study. *Int. J. Obesity* 32: S11-S16, 2008.
- b. Assmann, G. and U. Seedorf:** High density lipoprotein mutations. *Clinical Lipidology: Companion to Braunwald's Heart Disease*, 85-92, 2008
999. **Gerits, A., Müller, G., Trompetter, T., Schulte H. und Assmann, G.:** Risikofaktorenrechner für die Risikoprüfung in der Lebensversicherung auf Basis der PROCAM-Studie. *Versicherungsmedizin* 60: 2, 74 – 77, 2008.

1000. **Fruchart, J.-C., Sacks, F.M., Hermans, M.P., Assmann, G., Brown, V.W., Ceska, R., Chapman, M.J., Dodson, P.M., Fioretto, Ginsberg, H.N., Kadowaki, T., Lablanche, J.-M., Marx, N., Plutzky, J., Reiner, Z., Rosenson, R.S., Staels, B., Stock, J.K., Sy, R., Wanner, C., Zambon, A., Zimmet, P.:** The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. A condensed position paper by the Residual Risk Reduction Initiative (R3i). *Diabetes & Vascular Disease Research* 5, 4, November 2008
[Fruchart, J.C., Sacks, F., Hermans, M., Assmann, G., Brown, W., Ceska, R., Chapman, M., Dodson, P., Fioretto, P., Ginsberg, H., Kadowaki, T., Lablanche, J.-M., Marx, N., Plutzky, J., Reiner, Z., Rosenson, R.S., Staels, B., Stock, J.K., Sy, R., Wanner, C. and Zimmet, P.: The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. *Am. J. Cardiol.* 102: 10, 1K – 34K, 2008]
1001. **Prospective Studies Collaboration:** Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet.* 373:1083-96, 2009.
1002. **Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J.** Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet.* 375:2215-22, 2010. doi: 10.1016/S0140-6736(10)60484-9.
1003. **Assmann, G., Cullen, P., Schulte, H.:** Non-LDL-related dyslipidaemia and coronary risk: a case-control study. *Diab Vasc Dis Res.* 7:204-12, 2010. Epub 2010 Jul 19.
1004. **Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J.** Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet.* 375:1634-9, 2010. doi: 10.1016/S0140-6736(10)60545-4.
1005. **Fruchart JC, Sacks FM, Hermans MP; International Steering Committee of R(3)i.** Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). *Curr Med Res Opin.* 26:1793-7, 2010. doi: 10.1185/03007995.2010.489341.
1006. **Assmann G, Carmena R, Davignon J:** Consumption of potatoes and cardiovascular disease risk factors, *Cahiers de nutrition et diététique.* 45: S68-S73, 2010.
1007. **Bestehorn K, Smolka W, Pittrow D, Schulte H, Assmann G.** Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. *Curr Med Res Opin.* 26:2833-9, 2010. doi: 10.1185/03007995.2010.532088. Epub 2010 Nov 8.
1008. **Assmann, G. and Seedorf, U.** Phytosterols, Plasma Lipids and CVD Risk, in *Nutritional and Metabolic Bases of Cardiovascular Disease* (eds M. Mancini, J. M. Ordovas, G. Riccardi, P. Rubba and P. Strazzullo), Wiley-Blackwell, Oxford, UK, 2011. doi: 10.1002/9781444318456.ch29
1009. **Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J.** Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med.* 364:829-41, 2011. doi: 10.1056/NEJMoa1008862.

1010. **Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundström J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D'Agostino RB Sr, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, Gómez-de-la-Cámara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J.** Lipid-related markers and cardiovascular disease prediction. *JAMA*. 23; 307:2499-506, 2012. doi: 10.1001/jama.2012.6571.
1011. **Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jørgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J.** C-reactive protein, fibrinogen, and cardiovascular disease prediction. *N Engl J Med*. 367; 14:1310-20, 2012. doi: 10.1056/NEJMoa1107477.
1012. **Emerging Risk Factors Collaboration.** Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. *Int J Epidemiol*. 41:1419-33, 2012. doi: 10.1093/ije/dys086. Epub 2012 Jul 23.
1013. **Muntoni, S., Wiebusch, H., Jansen-Rust, M., Rust, S., Schulte, H., Berger, K., Pisciotta, L., Bertolini, S., Funke, H., Seedorf, U., Assmann, G.:** Heterozygosity for Lysosomal Acid Lipase E8SJM Mutation and Serum lipids Concentration. *Nutr Metab Cardiovasc Dis*. 23:732-736, 2013. doi: 10.1016/j.numecd.2012.05.009. Epub 2012 Jul 12.
1014. a. **The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects), Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G.** Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. *Lancet*. 383:(9921):970-83, 2014. doi: 10.1016/S0140-6736(13)61836-X. Epub 2013 Nov 22.
- b. **Assmann, G., P. Buono, A. Daniele, E. della Valle, E. Farinaro, G. Ferns, V. Krogh, D. Kromhout, L. Masana, J. Merino, G. Misciagna, S. Panico, G. Riccardi, A. A. Rivellese, F. Rozza, F. Salvatore, V. Salvatore, S. Stranges, M. Trevisan, B. Trimarco, C. Vetrani.** Functional foods and cardiometabolic diseases * International Task Force for Prevention of Cardiometabolic Diseases. *Nutr Metab Cardiovasc Dis*. 12:1272-300, 2014 doi: 10.1016/j.numecd.2014.10.010
1015. **Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, AtorvastaAM Jr, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoğlu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P; Residual Risk Reduction Initiative (R3i).** Residual macrovascular risk in 2013: what have we learned? *Cardiovasc Diabetol*. 13: 26, 2014. doi: 10.1186/1475-2840-13-26.

1016. **Hermans, M.P., Fruchart, J.-C., Davignon, J., Al-Rubeaan, K., Amarengo, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., Chapman, M. J., Cuevas, A., Farnier, M., Ferrannini, E., Fioretto, P., Genest, J., Ginsberg, H. N., Gotto, A. M. Jr; Hu, D., Kadowaki, T., Kodama, T., Krempf, M., Matsuzawa, Y., Núñez-Cortés, J. M., Calvo Monfil, C., Ogawa, H., Plutzky, J., Rader, D. J., Reiner, Z., Sadikot, S., Santos, R. D., Shlyakhto, E., Sritara, P., Sy, R., Tall, A., Tan, C.-E., Tokgözoğlu, L., Toth, P. P., Valensi, P., Wannner, C., Zambon, A., Zhu, J., Zimmet, P.;** Residual Risk Reduction Initiative (R3i). Residual Microvascular Risk in Type 2 Diabetes in 2014: Is it Time for a Re-Think? *J Diabetes Metab* 5: 8. 2014. doi:10.4172/2155-6156.1000413
1017. **Müller-Wieland D, Assmann G, Carmena R, Davignon J, von Eckardstein A, Farinaro E, Greten H, Olsson AG, Riesen WF, Shlyakhto E.** Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk. *Eur J Prev Cardiol.* 23(3):275-81, 2016. doi: 10.1177/2047487314567001. Epub 2015 Jan 16.
1018. **The Emerging Risk Factors Collaboration. Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, O’Keeffe LM, Gao P, Wood AM, Burgess S, Freitag DF, Pennells L, Peters SA, Hart CL, Håheim LL, Gillum RF, Nordestgaard BG, Psaty BM, Yeap BB, Knuiman MW, Nietert PJ, Kauhanen J, Salonen JT, Kuller LH, Simons LA, van der Schouw YT, Barrett-Connor E, Selmer R, Crespo CJ, Rodriguez B, Verschuren WM, Salomaa V, Svärdsudd K, van der Harst P, Björkelund C, Wilhelmsen L, Wallace RB, Brenner H, Amouyel P, Barr EL, Iso H, Onat A, Trevisan M, D’Agostino RB Sr, Cooper C, Kavousi M, Welin L, Roussel R, Hu FB, Sato S, Davidson KW, Howard BV, Leening M, Rosengren A, Dörr M, Deeg DJ, Kiechl S, Stehouwer CD, Nissinen A, Giampaoli S, Donfrancesco C, Kromhout D, Price JF, Peters A, Meade TW, Casiglia E, Lawlor DA, Gallacher J, Nagel D, Franco OH, Assmann G, Dagenais GR, Jukema JW, Sundström J, Woodward M, Brunner EJ, Khaw KT, Wareham NJ, Whitsel EA, Njølstad I, Hedblad B, Wassertheil-Smoller S, Engström G, Rosamond WD, Selvin E, Sattar N, Thompson SG, Danesh J.** Association of Cardiometabolic Multimorbidity With Mortality. *JAMA.* 314(1):52-60, 2015. doi: 10.1001/jama.2015.7008.
1019. **The Emerging Risk Factors Collaboration. Paige, E., Barrett, J., Pennelis, L., Sweeting, M., Willeit, P., Di Angelantonio, E., Gudnason, V., Nordestgaard, B. G., Psaty, B. M., Goldbourt, U., Best, L. G., Assmann, G., Salonen, J. T., Nietert, P. J., Verschuren, W. M. M., Brunner, E. J., Kronmal, R. A., Salomaa, V., Bakker, S. J. L., Dagenais, G. R., Sato, S., Jansson, J.-H., Willeit, J., Onat, A., Gómez de la Cámara, A., Roussel, R., Völzke, H., Dankner, R., Tipping, R. W., Meade, T. W., Donfrancesco, C., Kuller, L. H., Peters, A., Gallacher, J., Kromhout, D., Iso, H., Knuiman, M., Casiglia, E., Kavousi, M., Palmieri, L., Sundström, J.; Davis, B. R., Njølstad, I., Couper, D., Danesh, J., Thompson, S. G. and Wood, A.** Use of Repeated Blood Pressure and Cholesterol Measurements to Improve Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis. *American Journal of Epidemiology* 186(8):899–907, 2017.
1020. **Olsson, A. G., Angelin, B., Assmann, G., Binder, C. J., Björkhem, I., Cedazo-Minguez, A., Cohen, J., von Eckardstein, A., Farinaro, E., Müller-Wieland, D., Parhofer, K. G., Parini, P., Rosenson, R. S., Starup-Linde, J., Tikkanen, M. J., Yvan-Charvet, L.** Can LDL cholesterol be too low? Possible risks of extremely low levels. *Journal of Internal Medicine.* 281(6):534-553, 2017. doi: 10.1111/joim.12614.

1021. Wood, A. M., Kaptoge, S., Butterworth, A. S., Willeit, P., Warnakula, S., Bolton, T., Paige, E., Paul, D. S., Sweeting, M., Burgess, S., Bell, S., Astle, W., Stevens, D., Koulman, A., Selmer, R. M., Verschuren, M., Sato, S., Njølstad, I., Woodward, M., Salomaa, V., Nordestgaard, B. G., Yeap, B. B., Fletcher, A., Melander, O., Kuller, L. H., Balkau, B., Marmot, M., Koenig, W., Casiglia, E., Cooper, C., Arndt, V., Franco, O. H., Wennberg, P., Gallacher, J., Gómez de la Cámara, A., Völzke, H., Dahm, C. C., Dale, C. E., Bergmann, M., Crespo, C., van der Schouw, Y. T., Kaaks, R., Simons, L. A., Lagiou, P., Schoufour, J. D., Boer, J. M. A., Key, T. J., Rodriguez, B., Moreno-Iribas, C., Davidson, K. W., Taylor, J. O., Sacerdote, C., Wallace, R. B., Quiros, J. R., Tumino, R., Blazer II, D. G., Linneberg, A., Daimon, M., Panico, S., Howard, B., Skeie, G., Strandberg, T., Weiderpass, E., Nietert, P. J., Psaty, B. M., Kromhout, D., Salamanca-Fernandez, E., Kiechl, S., Krumholz, H. M., Grioni, S., Palli, D., Huerta, J. M., Price, J., Sundström, J., Arriola, L., Arima, H., Travis, R. C., Panagiotakos, D. B., Karakatsani, A., Trichopoulou, A., Kühn, T., Grobbee, D. E., Barrett-Connor, E., van Schoor, N., Boeing, H., Overvad, K., Kauhanen, J., Wareham, N., Langenberg, C., Forouhi, N., Wennberg, M., Després, J.-P., Cushman, M., Cooper, J. A., Rodriguez, C. J., Sakurai, M., Shaw, J. E., Knuiman, M., Voortman, T., Meisinger, C., Tjønneland, A., Brenner, H., Palmieri, L., Dallongeville, J.-P., Brunner, E. J., Assmann, G., Trevisan, M., Gillum, R. F., Ford, I., Sattar, N., Lazo, M., Thompson, S. G., Ferrari, P., Leon, D. A., Davey Smith, G., Peto, R., Jackson, R., Banks, E., Di Angelantonio, E., Danesh, J. for the Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group* Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. *The Lancet*, 391, 1513–1523, 2018
1022. Gregson, J.; Kaptoge, S.; Bolton, T.; Pennells, L.; Willeit, P.; Burgess, S.; Bell, S.; Sweeting, M.; Rimm, E. B.; Kabrhel, C.; Zöller, B.; Assmann, G.; Gudnason, V.; Folsom, A.R.; Arndt, V.; Fletcher, A.; Norman, P. E.; Nordestgaard, B. G.; Kitamura, A.; Mahmoodi, B. K.; Whincup, P. H.; Knuiman, M.; Salomaa, V.; Meisinger, C.; Koenig, W.; Kavousi, M.; Völzke, H.; Cooper, J. A.; Ninomiya, T.; Casiglia, E.; Rodriguez, B.; Ben-Shlomo, Y.; Després, J.-P.; Simons, L.; Barrett-Connor, E.; Björkelund, C.; Notdurfter, M.; Kromhout, D.; Price, J.; Sutherland, S. E.; Sundström, J.; Kauhanen, J.; Gallacher, J.; Beulens, J. W. J.; Dankner, R.; Cooper, C.; Giampaoli, S.; Deen, J. F.; Gómez de la Cámara, A.; Kuller, L. H.; Rosengren, A.; Svensson, P. J.; Nagel, D.; Crespo, C. J.; Brenner, H.; Albertorio-Diaz, J. R.; Atkins, R.; Brunner, R. J.; Shipley, M.; Njølstad, I.; Lawlor, D. A.; van der Schouw, Y.T.; Selmer, R. M.; Trevisan, M.; Verschuren, W. M. M.; Greenland, P.; Wassertheil-Smoller, S.; Lowe, G. D. O.; Wood, A. M.; Butterworth, A. S.; Thompson, S. G.; Danesh, J.; Di Angelantonio, E.; Meade, T.; for the Emerging Risk Factors Collaboration. Cardiovascular Risk Factors Associated With Venous Thromboembolism. *JAMA Cardiol.* 4(2):163-173, 2019.